var title_f12_10_12448="SCLC pos PET";
var content_f12_10_12448=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT negative PET positive Paraneoplastic disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 71-year-old man presented with a polyneuropathy thought secondary to a paraneoplastic syndrome as he had a high PQ type calcium channel antibody present in serum. PET-CT showing intense metabolic activity in a normal sized left hilar node after CT was negative. Ultrasound guided bronchoscopy sampling revealed small cell lung cancer in this hilar node.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12448=[""].join("\n");
var outline_f12_10_12448=null;
var title_f12_10_12449="Acanthosis nigricans on neck close view";
var content_f12_10_12449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A mildly hyperpigmented,&nbsp;velvety plaque with small papillary projections&nbsp;is present on the neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12449=[""].join("\n");
var outline_f12_10_12449=null;
var title_f12_10_12450="Inguinal lymph nodes vulvectomy";
var content_f12_10_12450=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50585&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radical vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 351px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFfAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxZeMVJjvSR9cYqULk9K4nI7ERMuaqXUOQfWtMIcZxUFwo2n1ojPUUlc5e7g65rOXdBIHXseRW5fKcnisacdeK64u6OVqx02lXIkRcGugtGz1rgtIuvJmCE4B6V29g+9QRXJiY21OmhLoayAHoeK0bOM4A7VnKQqZHWr+nMXUE9a82Z6EXobtjHn8K6Gwt0OGbBx61zCSiIdeat2184OAxIrFlKDkdjHGAPlAVR6U/zUj6sCfSsmzvzIu3ODVr7O0pySMio1J5bbjby5boo4PpWBKZXcjBPP5V1S2mIhu5zVK6thCC+OKRUGkYL6fIwDL39azNWtx5ADj51Oa3Lq+2OFU8eo7Vn3h89Dnmndo05H1MO1gB4J61pWsJiHGTUVtGuzIP8XNbdrChC8jJpuQJtLUr2qyK4Mgyp/StzT4o42ElQtCVUAAfWr1smIx647VncmUtAumM67V6ViatbFVIOct0rownAOOBVG4QSSHzBn0poyTtsckljtRt569qxtVtFaN0xx1z712k8BLZKjArBvYgZGXtWkZtMG77nBywEE84NMaPAGetbOqWxilJAwCazZR8ua9CFTmRg1bQqyJ8uKjs12TL6E1OyHj065pka4lBx0IreMtDFq5tRp7VIAB2NPgTK5xU4QdhXO3YS1Kqj5sVJs+lTGPPamhDnoam5aRF5f0pjIKtCPnIP4UNFk5xSuUmU3jwc014t64yattHyBjigJweOKLjIUX92FNL5WOQam20hBFBNiBkB68mscWU6XrSBh5ZPQ+lbpXOc03YABVxqcorGZLbRsPmUGqv2GMZ8tmQ+xrVnTnOKiKj8apVJLYlxTMp7aZeVcMPcVVcyoSHTj25rcKjGMVFJGpHIraFZmTpJmGdk2OBuqcIOOTmpJUHm8LinomRitXO+oQhyiouBxTgABk0KpVsHpRJ1FZ7my2IZWwDzVCU73Cr3NWbl+tVrJd8zORwOK1irK5jJ3ZeijwoqQ8LSgY4pr8cVF9TRIfD0qynIqnATirkQzUz0HEkxgVBNHnNWgpI6UCPjmoTsU0Yl3bhl5rn72LaSBXX3SEZGKwr+HIJrppzuYVIW1ObIKPletdjoF55kSZPOOa5W6jKsal0u8NrOP7hPNa1Ic0bGUJcruekh8KMHj3q5ZyOr9se1YlpdB4lB5zzWlDLjbXkVIWep69GV0a5ldnIJyKt2z7jiMVlxNvOc1et9wZfL5Oelc0lY6oxOi0ofOC5OQa6y1ZDGPcVylngANIR744rWtbwFhjkD07VGhE4X1N5ysceR0qjJIs6MMZFPVxMM/pSrFsBbt6VDM1E5yawYXQKgFM8/Sqd8gtwW6p6V0zIWycH61lajCoxuA2n2qWzqhq0mcyu0SFlPyOe3Y1sWcYmnjfJygwPes+4syhLIfkNXNJbB57daLlTio6o6Hyi8Z55xxTIJWV1XGB0JNRrcsBwQFHWq805MyYcJ3x61KMFBvRm/nC4qhcbieR+NPguNyBWdMfrU7E4BRNyjnmrRg007GRdxqsYy5yTiuYvlljmZQ2QeRgV180YnkJYBfQVjXtltYh3BzwPamtyouxzF2hmhO8DOawLpMEgjpXaS2WEJbGB0965/UrYj94B0relUs7Gco9TAdiSFIpmMOAKszDb2xUCKVLseldqaJ5Opu2ZLIKtj5RwKq6Ud0CZHatTyty9BWcnqYpWIAAaGXipPKdfTFLtY8Y4qG7FcpCFHpzSbDu9qs+VSlCO+aSlcRVI55HNRkEHGPl9atkYHNMIB7U27CK+PQ0pGe1TbMZNNwSeRQO5AYx1ppXr6VYK4GaZnPvTJKzpkcmq8sY7VanIjBZzhfWo2xj1yKdwsUsAc9qgnI2k5/Grci46jiqN0RtwO5rWG5LRTyDyasQpnHFQKuXPpV1fkQ1rJ6WBIryY8w4NQyNgVKT1YnmqNxLjNXBCloVLyQDJzzVqxj2QLnqeTWWCZ7xI+ozk1uKMDmtZaKxjDV3Hg8UxzS54qN87vas0jcfApU4IOa0IRgciu4n0mEnL2y8elEei2rIGVBtP6VwPGRktjueBktmciqginhfUCuwXRbVVOAMGmTaFEE3rwfTNT9ZiwWEmcZcRDBJFYl/FuU4rv5tNi3KHG3PcVDJ4et5Mghh7g1pDFxixzwU2rHkWoptzwazh19q9Yu/B0EzY8xgD7ViXvw/uIzutZldfQ8V3QxtF7s4amArR1sYOh32NsTk5HSurs5N7DPIrlb7w1qli25rdio53JzWr4fvGY+XMCsi9jU1oxqR5oahRlKnLlmrHYWtv5pJz8orYtyIwqhenesywmVvbFa9pt35IryZnpwndWZpW8RbBc8VpWUG7ITpVW3AXDdq19NbJAUfpWa0KdTQs28HlLhs59a0BjyTkf/Xp0ZUjHcdOKkiUvndjGelSyVrqVYlxHtZePWs3UbVpMkdq23wgqCQbwSehqGaKVnc5OeMJIVxkY5BrMQmCdh/C1dHLb+bce1Z2rWflRExLuIPIzUpm7s7D7BBIDk9OtWms45OZB04FVtKIDhm4I4NajyqrsG+6eRRexhPfQSytkQsv3cfhVk5ZXXzGNRWUiXEjhTjB4z6VpPFAgx8vmAce9O5jNGNejKLHGxEuOAKhFg0ke64PzYxj0rQitQVLNjfknNNkibYzBi2P1q7kPRaHP3NmIiUHK+tY89vujZTjHpXVz27bNz5z6Vj3Nu+4bUIA60oslXb1OGu7bynZSKy7l/uwj77t09q63xBauLSSaFAZFGcetc94b0yW7uPtEwzg55rvoSTjzMUtDf0u12wrkHOK0BEMkYIq3DAVUDAGKl8oHnFZyld3MkrlBoWP0qpqEptYN6qCSQOTgVtiIZ61Wv7SKeLZMRtPNTcqMVfUzNOuPtSkMu11OGAq00YA5FT2lhBbIVgwAeSfWpni4yBmi4ppX93YzjGD9ajeI9BitFoR6UwxfgB0qjMzWQgc1Gcg8CtB4TjsaqyR4HTmquFiuQc896ZtOakYFajLc96sVhjrkEEVCy4JGOBVjIAwRSEA0xFKRMise9XZMoPQ1vOrDg9Ko3tsJYsHhuxq4PUTMtNoOTzRLPlT6VWllaByk3yketQS3CHOHH510qDeonJE0knBz+FZV7OAD6064uh0Q7jUUNs9w4Z84Ht0reMeXcwlO+hPo8GN0r/eatfHHFVrZQiY6VYWs6juzSCshMcVEwJHWpj1qE/e68UomjPbYi8k7RSREEd8VKUjiQ/LjNaYcDkr171FIgY7gARXzlz3767GcsG84RD7VbayHljIOa0LdQMYAq2WULyKpMJT7HLzWKzBo3QgDo1UFsWibaNzD3rsdqFulNkgjK5AANVdAqjWhzMliCgI6/SnJbKFwcVeu/3eQTgVmPcAShCevQ1N2NJyCS1TkEAg1zuqaHZTT5aII56OvBrpGdSoDEZ+tZWplQhy3I6VUKkovRjhSjJ2kjn5tPuNO5U+ZD6jt9a0bGbeq54qaxu1OAxBDcHPeq+oReTKJYgPIzggDpW3PzaM56tD2Tsjds3BkGcha2oG8pgc8HvXM2bh4+v0rbsJxLDskPK9al6GCR0NvMQx3c4rStXUkDbwa56DKN1+U1t2O0kAg7z3qDXk0LjW6tISScVFPCqoccDFXBhVzjODUc6mVcccdxSZMUZMsCrGWGM1iXLk5GMjNdFPGQhGcn6VgzIVuvLbJHWsjrpxuVGiEbq4Hyt1q+0QlgCgknHUUwoGUxt+FMtJWikMbdRQZVItAIJIl3KvzpyM1PDf/aTG/kEfX1qSZ2KbGAKev9KjtpYIkeNhtdTlB3I7VSZzyRok7R5jAYPOBVd2E0uEIHes+e4f7QGdjtJCkDpWvFDj5gBk96CXTaV2V5oG24PFVZbcEEnPPrWwyjGD1qlccjHai4JHM6nAPKYYGKqaLboY2RBhkPIHcVr6imfese3ZrbUI3BAVjtb6VpTnYc6d4mwLcDls014Ru4rVkiIGSMimKq+n51scsTMa3AUVXuYVK4GD7VueSpOMVHNag9qLlJnNLbKH6kZ7VMsbofatj7GCDVSe0O3ITJHTmkW3zaEPlkrnjHtUToOm2r0dq2wEAintEeBtqkzBxszJMYweMCq0sALcCtmWD2qtLCOoHNWpWJsY0kHXiqstuR92tiSJhkgVVkTPXiqTCxjvEV55qEuy9a1ZY88Dk1Ulg45FWhNFQuG+9xTJQCMg8U6WEgZFQHcgx1FUiSle2yXCFZAD6VgT6MVY7OV966d3U9sGq82K3hUcVYzlC+5gwaYcjIq80Ihh4AzirqkdqrXhyAAav2jk9SOW2xUUHpjipkx36mkVcdaRvlPFXuWnYc688VXfgZNSM5zUM74U5ppWCT0Pop1wDjpUaRkg46VIG+XnmhHAzjrXzlj2+ew+3PO1uCKstyvBFZ24mTNXFcbeOfrSK5uo1xt5zSCUAc1FJIDkdD2qNyCvWi5d76Mp6mwaNwvWuctBKZWE6jCcK3rW/OMnBPFVLiMBOOlUmbwlyqxzF7LNHfrtkyM9Kl1JvMgG4845xS3luWm8wHkVQu5mKFSOScVpa9i5z0VipZeYJuAdg71vQsk8DRt/EMGqUKhIFXHJpbCTkqexqpLUzm/armY/SptkrQt1U45roLHcspLdGrjbi4Fvq5APUA11WlTiUDJ60TVtTiS1OhgbO0Ejk1uWODtXI49K59FO1SQCB6Vu6bHukB5zWN9ToslG50NtA7H5fmU9OKmNj5a7SOD61Ppj7UAyNtW7iZSnaqdjmvJM568g2gDtWHe22xjIe4rpbo739ay79Q6MG71kdNNtbnM3G6RQ1uQTVd3LxpIRtkHDVtW9qEXCjgdqx9RjMMzcHa36UjaVnoi3ZSlhhsEUpKtcqPudgx71m2U7F9oPSteaSP7KTIB05Pp701oc0oivp6yyEB8Dqa0PMS2ty8rKI1HLHoK52DUUN2baJnZgevatLUAt3prwynBOAfpmncbpyVucvb0lXerAj2NVZWDEjHNIBiBUj4A6U1Ux96kJwXQp3sWUJrl74kOUA78V2Fwy7MYrk9X2ifPbNVB3FHXRnUaLJJcadCztvOME/StQWwcHOM+lZHg1g1jMmRhZM/mP/rV0Sgg9M10Jnnyi09Ci1t82MUNAAOa0W+nWmlOOgp3I1Mr7OD0JGaY9mwOQ2fY1pcCkLevNAamcIyvBWopowR0NabAE0zCEnI/OgVupgvFIGJBBB9aY0e44ZTW1NCMcAEGqrxEfSmg5jHltwBkVRmi5OVzW5NFkcdapyoyj5lJHrVoVzEliwflFVzGTnI5rbmhVhnGKryRLjFVdjZhSxYzwM1UkhJ7VuywDnAqjPFsOcVaYlZmJNb5zxzVN4mUnvW9JHkZx+NVJocjIxVqRLRiE4J4qvL8zj2rVntgc5rMntZFYlefatotNmbQw8VHMcL2oyRww5pk3zDito7kjT69qp3L4U81ZkfC47Vk304C4HJraKuZylofTDKwHB4qIOVaoHvOMVAbnnOa+YPbV+pdWYbiTjAqRbj0NZhk+Uk9KbHcfOBnFBZqPIDzmmF89BkVRnnwvJ5qSF9yjJpAn1JJgq8g1SvSBFnPFSXUwDAZrK1KZhFQaQ1KFxIMEZ4rHc+ZeBSeAc1ZnlwmQecVnWvMjlj16VtBGj1Rp3DsAGPToMU7T15Zu/vVKOTBAJPlr0J7mnz3yW0ErtgccCqSdzRxajY5nxDqATxEVB4AAzXV+GdRB2gtnNeXahLJdXklwedzZrpvDNySsZJ6GvSrYdKiu6PHpYjmrSi9me16fKsigce1dBZNtPXHavP8AS7wmNWU11+n3e5F/veteNJWPTtpodLFNsXg4qdZiwznpWOlxkbT1qcOccVNyeUuTSqPrisyYtITUrZNR+ZsB3dalsq1iNl8sd6ytUAIPHOK0pZcg4rD1SQg4zj1oW5SMWFyl5ljwTit9QJIChb5WHOK5a/cxuNo6HOav2WpxyDZvG5eoqmhyi3qjbt7SNNnlKu5R1x1q05CqQwye4qnDcj5Rnk96mkmUAgHnuTSsZ8zbuy5BgoM4FR3TIgyDzWbJe+WvXmsy/vyq8tmp5Wx2bL93cqVI3Vyurzgvx60lxfHk5rKuJjJIOeprenTtuLlsztfA853TL2IB/Wu2hkGDxXnXhBzHcED+Ou+tXAx147Yq5tJmEqd9i5gMvHFH8OM1IjKy/L2quxIf7pHPeg5uTWwx4vmz/Kk27fepVRyd3UelNlXDA5BoK5RqbTxxmgxKT0zSgAc45qxGgYbv0qkzOSsU5LcHuRULwZ4zWjJEcnnFVnjbzMDoKoyaM57deePxqrJDjtxWq8LZzUTwEE5OapMmxhTxKM4qi0RI5rfuLYEk9KoSxEHkAj1qkwTMWaP0JFU5I+Du5xW1Ko5qpLHgHIrRaCMaSLjiqskXbFbDxd8CqkqEHBHFMLmU8IIxVOaHFa80OR6VVeNs8iqTEzGkt0k6j8az7mzdc7DkVvSR81Ay8kYBFbRqNEtXOPvGeFW3gjHtWVGhuJQzZCg13F3FE64lVSvvWXJawEFIGCHPQiuqFZGMqMt0erG4z3pBON3XislZwe9KLgBuvFfNn0PszUmucrtUmlhY4yTzWfC29gc1NLNxhaAUS28pkkwDwKueZtj4PSsu3YZ5qS6udqkA0XDlbdguLkvLxVHUJsqAetIknVmNU55UaUncDQkaKLRUvnMcDn261h/a8Lwea2tSZXhIz2rkLy5jtjz94nAFd2Hhz6WIlUVJc0tjUbUT5IQdKytRvzIwRiWj74OM1TE7PkbSM802cP8ALuQ4HJAHUetejTwyi7s4MTj+eNqZBcyxhWWPO3PGRz9KfpWpmxmyy5jbqB2qm4/eEHOwngHrUcmS2ByPpXW4pqzPJU3F3R61oGqpcRK0Z4I4rutLuAyLg8mvIfB8qrbxgsNw4Ir0vTp18tdpAr5/FUlCbSPocPU54JnY27fJnJq0kwXr096xdOucL83NW5X3Ln0ria6G3U05bpQnygZrNlutxNV2lIGDnFMfLDIpJGiVkTtKXHHAFZ92vm8Z5qZSR8oNIyYPNUjNmDqFuzZxjpXM28Rj1JmwAQc5rvbiNSrAHHFcNrG+01BWP3X4rWGrsVGo1sdFDdDap3cj3qc32UGTk1yjkyPvErLgY2jvU8czYxmjkG4q1zXubsYyOo7ZrJurkkZyeKHY7TkZqlcZIPpVQiCfQbNMSOtQxvmXPpUEzfLmmwvjknGe9bJCUTrNEnKXFuysVYOBwM/p3r0WxlW5Cg5SYDPHceo9a8k0+U4RlbB3cEdq9C02QmCEkk57jsaykrESvFnQYMLjbnrxnvV+J0uEwwww7HrWf55kjXcd4HJI6ipkMYYNvwfyrNOxM4qSv1Le1kHUBT2IqGSMZ+blT6VaXDx8tkd6YoBLRj5vWrOaxVkTaAACR2qWBjs6EH3q0sLKeu5T6jmlcAHLDp0oM5O+hXYuTyPyNB5ANTHb1bge9Qnyy/OR9KtbGTVyPIbIxjFV5UHOKuqiuSM/jUckGCSMiqIaS0MySLK8c1RlUDIYVqyxurHaFK+5qvIgzkinqJIxJYA7ZBxWfNBJu6hh710E8Q5KrWfOvPPFNMZjyxnHHB96rSRnnIrVkQ8nGarOu4Zq1Jk2Mh4xjHSq0iYPIrTmi55OB6iqskWM5OapSEZcqdSKqsmO3NaLrgkAcVCyAnNUmK5h39u7gbB07VlfZpmONh/GupdBnGKrtFzmtIz5S+Z2sQf2rEPunNL/AGmueFcj6V28Hh2w4dYFXPbFbNpodngDykx9K851KfY9xwktzzuLU1CcJIT7KaSPULh5Pkt5X/CvUDolsvKxL+ApF0mONw6IOvPFZ+0hfVCR58lxeqQGspgT/smrY0zVrz5kt/LX/aNez6LYWk8SrIq1pTeGFCl7bbtPai8XrFEOuouz0PC4/DF9L8skxX2Xirtr4KUHMrOx9zXpt7pYifkbWqBMxMA65HqBU+2ZrzOS0ZxH/CG2jLhk/Wqtx8ONMuMF423diDXo7Im3IHNRgMfugVSrzXwsiUObSWp5Lf8AwwXDmzuCDjo4zXJan4T1bSo2e4gaROm9PmGK+iGA646deKguYxKnCjBHQ1tHH1Ybu5jPCU30sfJ2oIFbAGMUy3i3Luwcn1r2nx34Ht7tHvbCEJcqMsg4D/T3rzSex2joUZeoxXq0MbCrHzOB5bNybWxT0mVrW7Cg/KTXomj3JO05rz+LbC3QOxHcYxW7oF8QwRjyKyxcPaLmR0YaLpe5I9OtJ+Bt61sxHcoI71x+n3ahlHeuntLqPYDk/SvIkrHeTMr7iMUAsFwFwad9piHIPWnrKhqAbdtiAHDdOac53cgfhRI3dR0ojJx8w600K3Uo3EhwSOvSsTX9Oa608lADKp3iuoktwPmC4FZNxKUc5+6fWqjo9AWq0OGtmycHORwc1bKtnINUpIbibxFNHEoCyNvTPHHetg2rxPtYEMOoIrabtY6FRly8wioWjGarXKcHFaixDywTVWcKq5yMntSizntqc3OrZKk8VWlk2gKOvSrl8+Hc4rMhPmT5PQV1RV0bRWptWsvlLGCe4r0HTncadCykFW5x615JfXPkyg5xjmtXwl43ez/0XVFaS0J4cfeT/EUPDylHmijjxM1GaTep63ZXh83C/dA5BFaEU8W4eau6Enrj7h7GuaiaKeBLiwk86A4ZZExke1XbO9yuy6+R3OFcfdb/AD6VySiWmmdZYPgnvG3Ru30q8hUMSV2Dpg1hWcwRPkHyD7yDn/gQ9q03uMQnaQcc8c5FIxnG70NJCAcA544prAcMQMHrVW2uUdQTg8VYVlYghjnHTNOLMJxaYyVOx4FReWCMDgdjVjywrbgPxpH3IR8mQT2rQxI1jAXa2GqKUMnTOKnlBb/Vn5vcVEWbaA680EtFOXaW+bIJqGaIelWDiVzjOV7YqCZGJ+Ung9KZLRnyrJGS27cpqrIFdGBUGr80ipgOMelVbiBXTjIOc5HFNCuZssShcLkD61RmjYdCCPatWSIhPlBNU7lHXBA49xTuK5mSnYvz9DVSVcjcpxWrIofIIwapTQiMfLz7U7AZsqcjODmqspAOOlaEqEHgYqqw3H5gM+1UnbYRTZe5qFl4OKsPkZzkj1qFsDkHg9qq7W4HqiW69KkRQjYBxU6x91pWiOCT1ryLn0cpJl+KJXiFMeLYfSpbIEKKnnXcvSlc53IbZExONuAK6rSL/awRuQa5BHAl25q/DKUkUgng01Jx1RnUSkrM6PxLbxy2jSqAGx+dcpaRlwQ4+td/EsV1pBZgCdvftXCGT7PfvGQQDWldWal3MKFTRw7DXt9pPHBpIoMdat3JJHA4quX2pjvWSdjbnZDOiJz396rZ3txUdzMzuEByxrV0rTmbDTAj2qopzZMqlkZc9uSvzDjFeVePtDktpmubNQsMx/eL2zXuN9CiZ9K47xRZLc6fNCw6g49jVRm6c7o0w9WzTZ4Dd2LAgp0GAWPbNF3HHZ3Eclrv+zsNoZyMsR948ds1uXVkeEj4buCTyc1l6ugMqYXCqgXgV61OrzKx6ksIpvmRvaNdrKignn6112mTbwqelee+Ho9yjaTkV22nhkIK9a5K0EnoctuVuJuPEWcDGKcisrAc/TNS20glBLg5psyktlK5yo66FlWGMNViHaycYyKzFHGWbmrULCNcqR9KDOULFi4LBSO3esXUovN+6OK2XZZE9B3xVSQxscDHFCM72KOj2kaarYTy8/Z3LLGRkNnGc/lVnxxZq9tNc2KsTEd656lR1BqvdyGEoyjBU1Zv9XjGlS8g7kIx+Fc9apJSS6HXQu0mtzkLG+S6hBUjp61HdjjjHFY+nabcxSztBIqiNTJtfI3AdgfWrC3n2gFSNrDqDXfyW1WxpVwzWpmak/3gPWqEGQxAFX7uJnctg4qmreVG7MOa6VpEmMNdSheL590qE9uat6lFbPYQJBbCKSEfO55Zz/hWfppa81iOMsEErgbz0Ueprt4PB8+pXtxHHqFsdiyCIAkmcoMnAHQEdzgV0tyg1E5F7GspVGcv4d8QXWgzgwt5lux+eFjwfp6GvWNH1K01+yMlhIrnAMsDcMv+fWvH77T2imZCuGFQaddXWm3iS2sjxTKeCp6/WlOlGqrx0Zz1aM6L1Wh7zZ372sgR95jB4bPzJ7H/ABrajucRllK7GGcr29wP5ivM9I8WLqkaR3oEF2OA38L/AOfSugs9Ue2YAqMdduePqK8+cXF2Zpyye51sdz9nIJHykc4/n9K2rSVZACBwa42K+SRQ0RDJ12gcr6/hWvYXG0qVOF6gf0qLWFOCaOo45CEbjzg07h0xyDVKKRJHUkcjnNWA24/MOveqWpwSjYSQSBSMAn2NRMrsoIGR6HqKmYMMbTnsKYWcJhxtIpmditu+XD8e9VmAbo2RnqKtkqxO04PpTAoPRefQUxMglhQpggEEVnzQP5u2FgV9D1zWs0IMZ2nHp7VSJKMd4APYiqTMjHkSSMsCpIz1FQTpuxg84zWldPgdSD6isu4LEHpx3pha+pQuFKkn17VVcpIPp6Vekb5QWGWPUVTfauSBgmqApuqnPJrOuYWXDJ61pyAEnHWqsgYZB5Ge9NOwrmY5O3DjBqu464ORWhOg55GKquAOQKcikz2LIHGaVgGXrVRZc9TSiYbsCvKsz2OZmnafLGATUzyALg4qis4Ce9RyybkyKCRv2hWnYjgrxUi3DBkLMcVntLtfgdetK9ym0YPzA0NaFtp7HqOh3AOjuevFcXqj51AOOOa0tKv/ACdJYE8kVzs9z50zyA8A8U6krpI46atJs6VUV4QScHFZ1yPLVmz06VYt5s2oJ9KxtRuWWGVegwaiSshptuxHpRNxftIegPFdkknk25P3jiuc8NwrHEGIycZqfxDrMdhZs2RvbhB71vFezgZSbnOyI7/UFaUxj7w5PtWDrE4ZTk9qz7O4dt00pJ3HJNUtTvlWKVyflUE5rJwZ1KNjgr+5kbU52diYlcxq2eB7Vn6pLFNK5XDHAUMFC8Aeg71npei7nmKttd2Jx2PNXYrRbpW8mVVkRCzCRgoOPT1Pt1r1PZOFrnr4TH0qis3rsQ6U0iTsV/ACu40eRpNpxxXIeHLmKHUxFc4Af5Rn1r0XSrWIR7gQOazrGGJfLUehdhido8jge1TeWVHBNSWuFOCeKlmjLj5DzXIzJSM/yC7H5/wp7QbQCGOanW38rGc5NJ5oK8duKDSUuwxEdVPUmq8kBDhufpVsXAUnf07VBLOGJYngUGWtylejdEc1wMt1Ob/7M75jDHC5x09a7yZ90TY5HWua0nR/7V1xoltknd3ACsSMn0yOlXCKb1R2YN8rbexPZ6q1jDMLd2SeQYZlxgp/dOax40R9R3ngtywrW13RG0pJWTekgfa9vJyY/wAe4rHucW8InYkKFyW7YrZWSsj1r050rxLUtskp2RDJrkfEMgine1jIZx97HapLzxNIoaPTSVJ4Mp6/hWRaRPJKWIZ2Y5J6kmu2lRcFzzPAqV1Vn7Kjq317DreJkwyZDDkEVsw6xMkkRnG3AxvXg1s6FpP2spCkTvcSYVEC8k1meINMmtHkVoJBsOG46GolVVSXvI7aOG9h7sCyupWt1J5JXzN2BnHP4U/UNN05jM1q1zFKg3qs6dAOqNgdT2PQd65lYrmCaKbypI/lEqEjGVJwGHtnvXoNtJPemW7n2S3NyjCRpFDE7hyfr70TSo2fRkxk8TdPSxxpmS2kDIu9WB3I/wAwx6j0rT0zxCF/dXW7y8/K3Ur+NWD4dWJWLklvQ1k3GmJ5gjAK7jgcgUlOnU0ZNTDy3idbZ6u1vIs0L7vcdCPeum0zxDaqQ00qRRdwxxtPt7V48rXFi4yxCHkZOa1LB4r1iLhQz/w+1RKhbVbHPGPtfctZns1v4x0hcIt00ueB5cbNWlbeLtKRmW4uXiHYyRMo/E4xXiaZt5DGeB2xUizz27q0MrKD78VmoJuxz4rCSpR5k7n0Da39rqEPnafdQzL1IRg2PqKtZGf3nKn07V4/4UujdainnxAscASIoG0/h2+ld0+rRaWuNTmlgAHE2DNC31x86f8Aj1HJra548qltGjp3hXZlQvHOe9QuuDlDh+wI4NVdN1W1ntlktp47hHH34XEyj645X8QKs/aUlBZWDdiQcj60uVoSlzbCYzEfl2MTng5/Cs2eVCCsjbXHPPetGYh1+UgP7d6yrknO2RRQK5SuZRghvlPrWdOcscD/AIEOlXp5EAIYj0Gaz50AyV4+lNFaIp3CsyY7+1UpTsxuOVqzPKYjhskeoquzhzggVSQrlVypGRUDyZODUtwMDK/lVR3GORWiVyGQSBmJ6Yqudyk/Nn2qWaSPq0iLj3qvkvkxAuPVQWH6VXK3okHNbc9S8wH2qCR/LkDButVpJ8HGaryzYOTzXlnss1luemTStMSv3jWQk28ZPFTeeOFU5p2Jk+xohgAxJ6VnXBaSdSrYXuKR7pQhGeaq29yGmz70gpyadzqV1AW+nOzdAv61S052ktN7j77ZrC1e93CO2Q/eOTW9pgP2RFI6VnJX1IceU7C1jVdPVj6Vy+ryquenJq3qWsra2Qj3fNjAArlri5eaRNx5Zs0pNNihB6tnX2t4tvZ5J2gDk+lcJquoSavqm4Z8lDhR/WpNc1XdH9kgbn+Mj+VZlrPFaLvcqMeprW+ppSpNK/U27icR24QHHFcX4o1TbD9lhyXf7xAyAKt6nqrSoxgxz39K5S4YtIxc5JPeumjTvJSkFRqMWluU7fTofOEsk6wKDkgZZj9AKuXMtk90BZWz28YHLsctIf7zdvyqqV5yDzTdxByRXpObktTzVS5HeLNG9gabTYoYFhRo5DKHC4diccFvTjgV0Ol6mxthG7ESDGawLKRWCoG5PY1pG3AcOo6Vy1VdWPQo4rS0ztdIkMoJDZrobaIlQa5nw4YXUbWIbutdXE6xpgGuGUbGsqvM9AuI0CjnnvWHeSBGYCtG7uOD0rnb53mkPlnkCpRtRi29SOSZzNtLfJjmmozPIVXJAFOtbU5Jk5J6k1NKwjG2NQKDolJLREU3yxFF696Z4Y1qfSnvba3KAzMjvuQE/KcjBqS2RpH5HFaelaVaXeoQwTGNN2W3bcMfbd/Si7WzNMMoXaqK6M7XLubxDrDG3Kec6s8oyAMdSOaj1HwxZXekm3W8YTSoVA28D0rqD4at7aOK4Yg7HKuRyQwP8qh8V2VulrHNZStk/M+0bQD9e9Q6nLotz0IShK0Kei22Pnl9NltL+W0mUCWJijCvQPB3h9WCyyqfUZqlZ6NNda7KW3SGR9wc969T0qxW2tUUrgba9KriJTS1OehhYYa6iiqNPjSIFVGfUDmoZrCCWFsgbiMMp71vCMBlPI4zior2JXRcLhicFhziuS7O+DR5Xr/htIY5WtgUjY7sds+hrP0jXLezXyrxzFInHK8fhivUr6yG+WDeLmE8AqOo9a8q8X+HJbe8Z4gWjbnkciuiDVT3ZhVheHNSWv5ktz4jtpHZYX3HrWRLq8RkKvGSG71hTWUkZO5WU/SptL0+4uiwU5RD39a7I4ejFc1zwZYvFc/s/Z2ZLc3KTE7VO7NJpspW6Vc4JPGa0dQ8N39jZxXc9vMkEudkhQhXx6HvWIUfcvXP5VrTUJKyObE1K9OSqNL5HXXTboyG4lTuOc0un7bh1EnO49axdOum3BXOcnGDWxpYCXRjxkq4I+hrjnBwOmpV9tR5keneGbey0+3fGGlfBDZ+6O4rB8Zaz9onFsrKo6cnAz71PLp9/aahJE7qjeXvBLcFcZBFchNa3d5d5dPM80/LnvU0qfNK8j5utJLbqNsb9dPvPNw0dwh4eJijD6EVv23xE1KOZRJBBfIDyZ8rIR6eYmD+eaxZ/D10sXmPEyrnAGDmqg0y4jYlVXK/w9zXZyRepzRt1PVNH8baBcoDqCavp023koUuYy3t0bFGoeK9JVwtnqRnQn/lpZyKR+RNee2tihX9/MkbEdCasrZWwHyzISeh3CsOSLeprJpLQ6mTX7UgN9utiCen2eXj9KiOr2s2dt7zngR2Uhz+ZFY9pbKBhjFj8DXX6P8AYlMYlntoFXBLEKf50+SCMnUkjPs1trthtk1WYn+GGxUZ/FmNdFbeD3nhR49H11wRyZZooQf0NdJY6v4YtEU3PibHYxQYXH/fIqW98SeCXQfvtUvdvZWc1rFJ7Izc5GE/giKGEPcaXbRgd7nVyf0UCmnw7o0SgSP4Wt/mDZbzJ2GOe7c1onX/AAqwza+FNSu+uN0bHP5mof8AhKLsHGjfDpiuMAtByD+VWqc+i/AV2+pTudA0G4lFx/bdlFIOFWx0pQO+eoPrWpC9tFALeHV/E08A4KW1qsQ/QVAmsfEu8YR6b4ahso8ZyY1XH4nFSnRPiheoVlazt933iXUn+Zq/Z1H0E1c83mvPLmCkE570159x4OarTsH5GKZGMZ/nXgNH1F0XGlIAx1pqzlDnmq+Tu4NPbaBjIJ70ieUe8rOcgHNOtg6K0j8Ac5qKNyemAB3pLq6iEYR3GO4Heob7FqyG2W+71DzMcZwPpXT3GoLaxCNMNJjp6Vydtqccfywo2akfUCDlUyfU1Li9hWu7mpueWXzbhs/WqWpamkWREwBxjd6Vl3N3cTjBbavoKoG3LMScn61cKVtyluPa+AJ8pdxz1NZupNPcR/OxC+grUitQR0ov7ZYrZmbgAZraLinoVdt6nO6dqe1GWcAAHGatyqJV3Lg5rjbpZQ7YZhkk1d0y8mjBQscehr1pYf3edM4vbRnU9mlY2WUg9KjPJp0dxHNjBAbuKRhg1EW+pFWm0JGSG46iuj0m8W4XyJyEc9GrmmbavA5qS3kYc96Jw5lc50jsZIbm0PmRscr0KmrNn4kkVhHdZB7ms3R9ZKbIrk7k6bvSr+rWFvdxebbYWXGcDo3vXJKCekjeE7O5tG8E8YeJtwNOh2oMuev51xOn3s1nciJ2YIDyD2rureO3mtBM11GARnlgK55U3E7o4hWsRxy5dhk4PQU6RFbpx61TlvbWBytuTM/+yM1Vf7bc9jGh7VDRurN3uXrzVLTTIGd8u4HCL1NQeCdZ/wCEg1aQOqxlOEiB52/Wqz6XG8LI7ZOOc1kWuj3WnXKXWns6zK2VCDquM80uWM4tPc9HCRim2tz1uSTymaHy2iAOQp9fcGn6qgvrVUkgSJTgkgbd2K41vF7Xah7pJPtYADMBkGtQa0s8URXcwxwM1xSpzjds7fq07RlbUq2sKRa7Nablj4Dxr2yfSuqt4PNth2IOK5i80x5J4tQZwTNtUYP3a2bS58tSkkm4nhgP5iuyk7pJhNcyvF6kudshAG5QME0Srk5Tke1SiM+XhcEfzptmqfaArFo2PryK2FdJXQG1k8kOY8n1XrWXqVnFcQslwu8N/EPvKa7VDsVNjIQOCMdaydWtmnLz+XnPZRtx+FFmtjGjinzWZ5bquitDnKLLCeFcDg+x96wLG3FreTLtCg/Mo/pXqaRjccMFfPKkfe/CuU8QW8VvqH2hIwA3Vc9DWik2rHo6T2Wpmapq8N1ZWenXsssFtCGO9SXJJ/2SQB+Fed3iLHKjq6OHGRg8jnofQ16Ncafo92lvLePejLgTNGi4VO+0Hq31wK4rxJZQW9wBYqoRBs3KpAkwfvnJzk9668NKK0bPBx1OdrU46GVna4dCfeuhsZD9shfP34xXNRkyvg/LW7ZttaybrgFa1rrTU4MNJSUrHoMOoyTPbvPh1WLYM9gB0rpPA6W19r+jreqghkTyQFHLHPt0OcfgK43S8SWTpn5lBqpoOrSabfiaJmjeN+GABxiuemtHY8TEK07dD65k8I6NLGFa0A4xkHmsWX4a+GVYFonVv9pxz+deX3XxdufslukU2ZRkOckfhisn/hY19cuUnlcoDnrnFdXt420gczpSXU9S1D4b+B2dTeYGDjHm4z7cVRXwJ8PrZlCylhknAYvz+VeeN4jW8nKxS3EsjkERquST9K1UsvEDoZU025t7c87p2EI/8exTjWdtImLi7m1f+G/h5DcgCG9crnIQ7R+uKVNG8BxuPs/h6S4bHWSX/wCua5x4ntwskt/YKzHJ8vdOy/XAx+tTx6n5ap/p17Lg8iOBYwfoSf6VLxLuUqU+x22nR6LbEDT/AAhZjsreUW/Uit21v71FItvD9nbg9/kX+teVXnia4WNkhS4ZT93zLoAj8Av9apDxbqEZJENtyOFeWV8e/UUfWZdyvq9Q9jOr68CFWLTYeOnmj+gqrDqOvTud+p6fEB15z/hXj1z431wKViTS4gT1FpuI+hYmsHXPEGvapcQzXOpqrxcIYbdI8fkKPbt/aD6vM91utWktZXa78WRwEgHCKCv4ZJqNr+O9V5bbWdZvUVcs0HCgfgMV86XcupXCqLvVr2ZFGFVn4H0xVRYZgrqb6+2MMFRcOFP1GaXtX1kP6vK25uwjjJP4mnTzxxLjINUXkZsAcCoXKqwyc149j3+Yle7dQdowOtZzXE0042u3XtUk8gIISktljt13OQWq0ktxPUvZcoFd2z3pPJyeTVUXYDkk059RiUZLAfjU8r6GiRbiRYzk4pzsHbA6Vh3OsxZIDjj3qr/b0cfO7P0q1QnLZA2ludTsXjnmpEiBFcefEZzxExpR4iuz9yEY9yabw1TsVFxezO0CqgycAe9cr4m1UXGbe3bKA4Zh39qo3d/qV6NjFlQ/woMZqG30u6bBKED3rWjQUXzTZTuVYVRjhwDWi2mW08DSbmjZFJQr03e/tVj+x2ABPFTW8MkRMT/dPBNdLq63TJUE9zF0SCCe5f7RxEsbHcDg5xxj8ccVELsxbVlGexIq7eK9iHg+ZYHIP1xWffFJmQRRKgVccEnd7n3rSMlLc6atG8Pd1JyQ+GQginLJjOBg1jrI0Mm4lic9BV2DUY7hmV4zGR37GtXTaWh4/NHm5NmaCTMO+K2NP1OSHaFwy+hrn1BIyvI9akjcqehzWEoqRoqMo9DqbpYNRTzI/lkHUVmJI0FyvnglR1DHrVWC7KkFSR2NXpZYrmLEhwQKxcbaPY0jodbo+o2uzFrbljV13uZ1xtEY9AK83t7u40u6WWBzgH8CPeurPi5GtgzKEYdQK56lJ77m8IO/u6mvKI7VFM7gM5C9e5rpIbK1s/D9xDduGnZlkh2n7oI+bPsRivMDdjVt0925WNT8kecEmtBbu4uLURtM2VGMDjI96x5XE9zD4e8VzOxbgEdzK7wkBSSpqOeCe1lYRttI7E9Kl06wUxKYmKcEvjuP8au3unfatOiGmgidSRIzN98HpgdsUKx6ymlsVmvbqG1t1uJWMb/Mqkda6DTvMNsJmOeO3euIeG6t59lyr7l4wa6TS7wW7RRSXHlxdBkcZPrScWrOJnUT0aO70S6gvLd4GIDj7p9akNqi3Tbn4yCVzyfWuJspHhu5PPJT5sgjvnuK6e0mjQrKG8wMeWJzWpzVsPyNyg9zblC7d0YIH1rLvLq5QkrIVUdiauvdAQsCABglSO9YF/cmSNixUKBk0bswoQbeqG3OrExBWi3hTkEdvesXUnt7xDJISAOkeOppxl3DCgnPQCpo9L85jIzbI0G5n7D2qHUWx32hS20MW/tt9r5oVQo+XHcfhXEakjsHAUMQce+K7/W5w8oiaSNgiBFdAF4Hr6n3rjrlMySgg8t1FXRaTFbni7nGMjJcjsCeBitUt5cNsRnIY1d1ixUETRDdt5wRWddKwtYCRjqa9BVPaWR4FbD+w55LZnR6fqSwMuWwDwT6VDrF7aTTbrdCvvWDA7u4QKzMeABXeeH/AAG0jWN14puv7I0+5b92pQvNMB12qOn1NUoRg7tnzla0mYOg6JqWvX6W2l2stzM38MYycep9B7mvcPD3wm03RbWO68ZXpeTGRZWzHr7sOT+GB711+hnTvDunCy8L2C2dtj5p3G6WU+rGoLmN52LzOWduSWOSaqWIpwXu6v8AAxjSk3rp+ZTN/FpitH4Z0y00uI8b0jDSsPUsaw7xLjUJzLeXEk8ncyNuroFt4kUg8/Wo2hQAhFx/WuGVWdTWTOhRjDZHLvZruIBx7CoJLHaOQRXSSQEnJTafSqkqZJDdKgZzFxaDGVJBqi9uyn7oJrpriJTyp49KybklJduzjsaLjTMKdSDhlGKozo3bFbs6BzgYrOuYQPY1VxGRKpGcnFUnU5yDxWnMmeCMmqbrtOMYq1LuJo5yXxHaxg7XLH2FZ1x4jdv9TH+JNc8qcdBU6p0wOa9GODpR6XOV4upLRaGi2tXjdCoqE3945yZTUSpz0qVY8HPer5KcdkVGVWW7Dz7huTK5oCu3JZj9TUqR57Cr1rYSTsAFrKdWMdkd1LDSl8TM5IctxV230ySQjapwa6vS/DZfBZc11+meHBgfu+veuOeKfQ7Y0acNTz2z8OvJjINdFpvhtRgMufwr0az8PiMj5OD7VqQaNHGc4wR7VzSrSZpzq2hxFp4ajKj5ccelaI0FTFggbh3rtEss4PXI6io7qx+QbR8w61m5vcjVs4S50gRx4CZI9utZN/pamIEAhhXoZt1clJRjuM1h39k4kYjJ7EU1NlcrRxL2YZULoGTODkVzvibQjZy/a7IZt2xuQfw16F9nCyvC/CSDg+9C2pMEkTAhhlAR71tCo4u5UZNO55DBZ7n3KDgnIrQutGSLTY5mZBI7MpXdhlwAcken+FX703/h3WilkjoImBikkQMR6HpjrUF1JqOt3by3hy0hzI+AC1dEpvR3PWpUKctYowkRoyDbzFvXI4z6VcjusriZdp9e1aMyKb2CJ1BXcFyowBXSXGmaUWuoEikkVWzA5YKcH+8P1rOdVfaKeGS0scgkQYbkcZPbNIwkjbDAimXdm1reyC1f5FP1FWoZJZEJnhY443AZp82l0c8sFF7FcYlYg5xTjbvGQSCV9RVhFQt8pH49q2NMiErIpKH60OotjN4dwd0Z9tPGm1pYw4U5DjgippLuKOYtczsTJ93yxnJrZvPDZCeZACpI5wcg1hLHdaVfx3K28cpjbIWRdynHqKytGT1OmlVcY6bnX6NMPsytt+UDuK66wSDy1lhXBIBxXlc+voZHNpF5byNuMRBAQ9wB6Vq6f4pmhkRJAwwOwrkqYeerR6NNqrFa2Z3uqW8UxDkKG7EisexitIdTRr2FZYuVOD09x71SfXluwoUlnPHFKEnupIkgGWZsKvTJqKMZQepvGj7lpM7vTdMi1PUI2Vo/JRSRIRtGAM/nVHVHij3CGFCWOAw69aprL5CG0lRoblPfgH0P+NN1GXZAFJyzLkYPStJtpp9TkjSkp3k7rp/mWrK5d3CPnCDp7Vk6rIpmIJAQNyM9RRpmpqJoZ26D5XHr2qj4kikjv1QNmOYZQjuDWyZ0cnLOxBHOtvKxicMT8oU8kCtnTrq+Fq0To72jq0ixkZ+bGN2fauX+w3RkEsZZ5BwsapktW5pWpGa12ea8cIHzBByD7is53i+aJNZc0bWuVtYtYmsfPnjEUhJCsefMz7DpiuIkBhk2FyXY8qOStdzrsu+yBaYSyvgqoYHac9+ODmi0+HmoR2A1J4xPKrHzYyNwQjqMZ+bHfFaU9U20YSrQpq9SVrnK6pFbwxnyZjOmACzLtzx6Vhiyl1B1jiwkSffdjhRWhraxxT7HAjROXAPH0FbfhPTJNalj81fKsUOVj6bvc1tTdvfPLzCvZezjq+pa8FaJCJ47i2Rgkf3pnALOf9kHoK9DuhmeJ2QuyAbTJ8x/Emr9nYxW8aRwIFAHGB2qc22+XfJluwFP2sW7s8BUuV83UdYTXEzqZGxGB9KvOX/hP/16jSPaRtUYFLNEWJ52j2rGUk3oNxHKWYDkbh2zTfMAOHAwe9RRq0eSuTnsTxUj8g7xkUrkSQsrJ5dUJVjUnpk+9WS6qpAU+2arSheDIQAemaFsQZl5GEVnXkj0rMkAl54I9xW3csoiztOO3HWs+eMdQKYrmFeJsGVAx6VnThiDzz9K2rlQzYIxWZcKVJwBTGY9wnIK5qqy8HoTWpOq4561mTRkHKUId7nksPzCrUacVUhBRsHpWhCpIBFe9N2R59GPMOUVPDGZGAAJNSW8DSEACum0fSc4d1rz61dRPYo0UldlPS9HaXG4Gu30bQwu0bMn1xWno+lbgu1OMV22k6UFAYqQRXmyqOb1Opzsijo+iAKNyY49K37fTI0I9T2xWraW23AxVpbZjIBjH1qU7mHPfcqQWqqMYGPcVIlsgyxUbvStaK3UfKRz60ptwp56UcrZPtEZItOuFwOoqvPCQhxGCRW1dW+FDLkY9KovG3LD5vTBpPQ1hNPU5qQfOUmTA6qe/wBKyNTt2jfKNle9dfewqybtvPXNYd6NyEEA+pIqVodcXfU47UIgTlcjup9DUtsBJNFJgYcbSPQ1Z1BB9CprPtnZZGQHBB3VqnoHLqWPEOjvqNnJDbs0U0yAMFHEuDlR/wB9CuZ0/S0mzBOxhMfEjFeUPcGvULWNLgQXls+yVBxjsf8A9dcrHaqNZupL9t8kpzHFGQN+f4j6nrn1qnrE78HV5U4r/gnK3WlSbLqXS7cvYKxRZXIy2Peudh0y+nZR54i85iqgtgADqSfQV32twXdtY2kKzqumyTdScEEnBLY7DJ/WmRWlrHeSlp1+zxBY4wvRwW3YJxnnaOcVcWrXPRjJqN9/66+Zx6aKWaKCCWGZ2JXAOCT64Pr2rc03w7KluIwshu3dk8pVyVAHOfx4qbWhCt5dSBSL0zs6OOF2nttxxitbw/PcNpkqpKYyxwxAGdo64PbNTKSRTpz9nzI5ux8Mh7+KK6R1DEMVTAbb3wTxkDnmqGoaVLp7ySW8gkQN8oYYYj1ru7+ENGfLbaGO7AH8/es/7CLuaKGXzChYZEYG459M1i5vRITpc3vy2Ob0/wASSWq7ZYyAePm5FPkvLa7J5HPbtWxd6CtvmGRSGzzkYrNPhmJ7wlQQPQU1UjczdCDd0YWq6VFMC0DKG7YrIsZJLG7VboM6Z4YnOPrXYan4ZkVBLbTFDnlRyKxbrQbjGJJWJPUba2hVTVm9CoYeSd0b+kW8UNwhkQOjHIKnjNddBH5U6y22Y5FwQQ3IP1rjNI0q6s4fLk3QTJghZBjcDW1HqHlAwXcTxyDA3I2c1hKOuh1tKS0LWobZ3d5JSJwec9Saz9Qt9Y+y+fBbiVNucIckD1PtVuWfTQEdJJjKpyc4q9F4lSNFjtI3RpBtlZjkOM9DQo/zDn7TlSpx+85uzimWz82QEMGywxWu863FtCJgC0Z+RzW3FJcxaey26wLDIWDHYGbBGMH2xXOa3pk0VjG0bEPyQPX6Vp6ERq82krabHb+H7eG7CWwaO0d/mN1/EuBwM9hXB6roDNcyO1xNboz/AOsSMnzFzy3HcCpfD/iILCIJ5Nsx+U5711WkXtvBdo15GLmzwQ8THrkYyPQ1hCq4PkmjknCdGUqkdU+nX+vwOK0Xw6s2ozxR33nwIGeJpHA6cjOe/HT1rtvFl9aNpmmiyP2eEwSeYXY7kkB+Y7QeCfcVS1ews7fw5DeLL5V3LOUWFVyWXPJJrJliOu3DDZKkaKBM5bKngDjjOTXWpcqfmc9RKs1Vbdo3372/E5HTdIfWbgX18pFnu2wx/wDPVvX6V6Po1itoiwR4BXBJHYVRj0yc3MflBIbWBVWJQOldLYWO9tzkZYYOD1rOUnLQ8qpZe83ua1ruQDcQyY9Oc1Z3IoyFPNRQxlAFKHK+hqdiW6r+FTc8+Su7jDI2DtUYFMVnYEyY9sU7cuSNpyP1pdynIyB/SkJpIgMknmYXB+tNkdlJLY+lOuIs7CmeD2PWmso9aV7bkuzIGuM4BGBTJWHVQfxFK3yNnbkmopXO75jxVRkZyXYru7ODySBxVGWU5wFP1q67gjC9aqTfdORRzXIaM24I3HHOKy7kZzjg1q3J25Gw/Ws65ZcgZw3piqixXMuVeOSSaoyrwe1akrKSc1RnAYYBxVXC55StjIeNpq5Z2biQIw4Ndzb6C7Hldv4VPP4ekQK6K5I56V9DWpycXY8ihilCormfpOkcAkV22iaQQoDAH0pvhyz+1Rxttx2OfWu/03TRGI/l4HWvmarfNZn0iq3WgaRpipEDt59K6S2tVVRxT7O2wOBWhHHgAMKhIyc7iW8QXJxV6NFYA8UkajGCpqYIFUBV4renTvqYSndjSqqMkUhA604ZJxikdD07+lb8vZE3GyY2dqpSxhl4AH0q2UYLk5Iqu2D8w6d/asai6GkHbYyLy3OPl5HpWDfKNjetddcxhkOOo6Gud1W1zvB+UkZBFYPQ9HDz5tGcTqkf7zeG7YIHpWTuCSq3ocGtjU4h5ToW59feuaE5kkZDnPTP0qondyXR3XhtgbaZGXIU7wfT2/SsPxZEmneLLV4QBFPb7izEZyB2P4nirPhG7P2gRsRtmUxnPUEciue+LlxJHb6dOpIfe0W78K0Su+UMJf2yTZS8V68JLUW8IDLuA3Y7isXRp7t5JDMHMBcBm29CB6+uKn8AaYuoXcl7qc5j0vTcXEpK7gzZG1APVjWy0eqS2ckEcCJbyztd79uCQ/H0HA7VsqPJGx78KqUvYwW2/wDXchkthNEzwRvK7TY3OeVH8IH15zW5DZix09SvmJKwGVJzz3GKueHbFLWSC4l89oVwy7sA7vr6V0DWZnP2uSFhEW/1jLlc/WsJSvokZVcUoSUen9aGBp1o0flfaHSR8ZCnpnsK1NS8m1v7OezUJJHtL7ePmFF06RvFKyh4lck7Rgn6Umrm3Fha3FpLvkkY+Yh6r+FQ4tq6MHN1JxctndeXzMfXJWuLzzEUliMk+9FpGHPz5B9R2ou2CxGTPI6D0qhazyz3S7GKr3A71go6XZ3Qpe5ppY0jbur7VIdCcnPWlntEMi/KCD1zV+AZbYq4x940+dEVQc/MTis3J3Of2zvYzNUs2uoj8xZsAZ71ktDPHZ/ZJURlJyu7+h611VrZytchm5AGCPWtK40u3uVw4w4FKVdwdkQ8VGn7j1R5fdWcsGSgBP8AdpI7aSaLfvhGCAfm6E+36V1+p6JJyI/mjQEs54A+p7Vi6VHZW2oRu4faMkMH3DP/AOuuijU51qjphivaRfs9bE+jzXECGOdt0KkYZGyK1bq2SdAnmZyu5JJMkI3PH06V0ttpNjFHwYma5U7gB/EeQf0rD1ywHhy/jnjlS4tJQPkPIX14+vFbKFnzHAsZCtUstH08zzrX9H8i6wA8c4AyCONw7g0tjrUojaKTiZPlPv712OuzxXscM0bKsyLlMRgq3BGD7YriL2F0uIT5QDScZHf0rSUYyWp30ZyavNGvZTXurXEFrC2XySgPRfUn0HFdnHZRwJHDDxCnJbHLserH+lN8M6eun6b86/6TPjzHHZeyit1YwzAYx2HtWV7nhY3Fe1naPwopBUQ5Y7cdq0LO2EUW7fkk9TVW5txuCPzGcd+fx9qmtzFFKwDvjoB1ApM89u60AXKw3qxsZmLnGdvyjj1rRW4iVNpOf5moWIJHAx703y14JUZpbGTsydJY5Dx09ahkUhu231pd4DY2kfSmF8t1/CkZ2EZx65x2qJ2DY24yPepGKgnA+aqsxZuPu80WJY6Qk8EgVXYL1OTjrSzqdgBOTVbcN2CW3dT6UjO1wmI2nis9nAOckD0NWpGYP8wBXtiqd0N2Tgj8KES7FW4lXGSSc1nyrvJORxUtwjbMVVY7FAIOfatUybFO6UdhmsyQqHIHBHatSV93AOPaqFwVycjmq3EeiW2nAdVz+lasGlBkwiDkd8UyCeSPl4VK+inFa1lqdoBh4pY/cjP8q+lhj8NUXxHy1TAYmH2bmPb6I+mXqTRxZt5B+9CjhT6119rHG0a4wQarPNYXSbWlB3cAHI4pNJdoJmtJirIo3ROGByPQ+4rx8ypU7+0ptPuevl1apb2dVNPobUSBSOxxVpB0J+lLByoyOamCg4zXBCN9j0nIRmKkcVMmWoVVfg08rjGOld0Y2MnIYQVPA+tPYKI9xpecYPNLlcbTWliGyIoGGV5HtVeSEL0AwetWHUBflJH0phw2AeDWco3NItoozLEpwXwT0BrLu7dpN278Aa3JI0yN659OKgu1jjheSU4RFLMT6CuOdK+p006vKeE/FDUpLW8hsrFtkrfNMR2HYfjXJreXUcquoVweoIpde1B9U1y8uiPvudvsOwrPjnk+dT95etChZHt4Oop3idPpmr+RMk0qFSrBvkOcEVU+KOs2WqWNrHZSlysxcqVIIyMc5qhbL0OchhU9zAGgkSNQXZSORnrTTSdz0I4ZRkprc2/DMVsvw9QR7hPNcN5qBuJNjKQMdyAa6G/tdQuNFtRpxSXS4OVQECSN267uh/OuI8BWt408kcshWCzYEoT93fxkfXAr0MS2z35hSTMbgElB6VpUqu9u5vZwd4u7u33t/wAG2xl6cdRE8a3kZWCM/d5IJ7ZI6V16ag0lqbC4aVF8suqdVYgcEVi6zeRxzMttEY8qOFGMke1SaI9zeTRyXo8yUN8hTjPGNvp71jGVnZGeJj7aCqyjYdNJb21ofMm+0xDgJnG0/SuZmuUaci1BXcenpWrIsdtPcwzxL5pz97nFcw0/2RpxjeRyDSnbfqd+EppJy3J9SnWP5Gcs7DGM1d0eFkt1Z0xuPWuctYXupDOxO/PQ9q7zTUT7NEspIkXG7NZyg7GuIn7ONi/bRiOMYBLN1qK48qJcucHOfxq1dXkNtAu1g8hOAuc5qUaW86RTExvdbjujUZVB2Oe5rGFJzd+iPG9pyvmnomO0WQcs6kxMOo61LLrFrHcPFFYXF7IOQoH64Falh4furlUSMYBOS2K0Y9LTS3l+yusl4Vw7FOF9ge9ddPBp+81p3POrYqhzu+r7X/M4PxZa6hcWsIvAYXlAZYIyCqr2JxWUuh2sUljH5kjzuymRs4VRnkY78V1Guz21lazJsE08rDzblySUHYCqaDCrOq9AMHFaySj8J6WGr1FSSWi120v/AF5kN48kWt/Z7WRpLe3bgkcnH86q31pJqEjrKXZEyc9AMnpmtmwMdqjyyhWlboP8at3t0FsRFFGgd/4sYrOU1FO5DrSg0oxv0v8Amzz24tzYQMnJUH5Se/0q/wCF9La5kW7uYyHBPlqeij1p+oRi8njt4kLIG+dvSuntlFtAqhhu71lzX2ZrjcU1TUFux0kaKojjGG71Qv7i5s7CWWFfNmHIGO3fir/mjBP3u+R3qPzlaPMgwfSkjxFdbq5zujXl9capultnaIt99+McenpXWRAPJuVcdiDUVgIkAUPvbOTnrV4EP93IGcU9BVp80tFYVI88sBmlkUKM8GmlSr7txI9Khnn8tgPLc57gVnI57NsXd82NuPQ0xlPLFQP60u2TkrjP0o80IP3hwO9RzDfkRSZIJB9sYqpI7I+FGcdMjNW5MkExmqk3mht3XNUpkiNK+V3BAe/pUM2BIdx/AU2YNwG6emKa04XqAcDHFaLUykrDJRgblIzWe8zOGyoI9zVua5iY8klj2IrPmmVSwweuRkVVuxiVZiuwgn5hxx2qhLIQxGRjuatyyBgXCgH2rOmYybi65JPegCpcJ1ZDz9aoT54Zz09KvSgDgD6CqUwG0ngEVcBXPbmtt2RgUwWnPTitJSpbHGakULWDRqmZX2fb29qcsRBG3j6VoyoAOKaseWzjFTZFBayXCDiVwPrV+O/uYyBuDr7io4YcrxU5gyuR1qNVsyW0adpqEc2AQUb0NacfKVyiAhuRWpZ3jxEI/KngH0rsw+Ls+WZjUpX+E1ypP1phT5uaevK7s05cEV6W5z3sMIxxj86hPUgjFSse/NJgZG4GpauUnYrspPHeua+It09t4TvRH/rJUK8cYXGWP5A11jxkcg1w/wAUYfM8O3zZI8mHAP8AtOwH8s1jONi1PqfOcLpn5+CTnNPmtTnzYHAcfrVO9ykhI6VAt06kbSRV8jktApYp05XRrWt6iuElXY3qOma2dMnjluVjJGT0rAWP7bb/AHQX9RSRWlzbuDDLhsdG5xXPOC2Z9Hh82i1aojS1tp01r7RGSFHykL1IFd34Cu7eSdCjebNMjb/MAbaRzgDtxXnkN9cQTq9xHuI6nrmrKyncLnSbpra7U5AHGTWburHrRxFLEU3TjI9MlgCyyEnJHIzW5awC305ZVLp5nI2sMceteRweL7/T4JG1iLzOOZNv3qt2/jxNbtUsrJZIplGBnqB7VgoTjeQq1FytFyRr6ob261W4GnxmTb8rOx4BPvVCewe0iaWSTdKRhwR0rc0nVvsGmLayxkopLZUDJJ6k981m3RfW7k/ZiqxA8nPHHb3pRcm7dDtw9WV7SVorqZq2eFjdWxXV6Zp9zqbySOriSTAUqMJjGK1vDnhiIxiS6UsAOCw4zXoGnaTElspjTYAR8xxkfSutJyuonnZjnFOn7sN11Od0HwMkKq15IZ5s5C9hXXWWkxpcHygykY257etaVlEXbCHCAYPvVmSOO2tZWLMFzuHPI+ld1HCxtzM+PxWY1q8/fldkMyR21sSzbMjGV+WuLvNVFxN9m05XBckFnPP1q7qd/Je7iS6wDjHrXJ30t8ivBp6RwpKcGQnLY9BWdevFu0djswOD0bm9fwJdWREv7TSbY7ogfOuCRyW7c9/pSahCGXYm3Oe3QU+wtEEO1ZGd4+C57nvTb5jAjy8AAfdPrXHKeup6tJcslFP/AILOUuEmOtGSUsViARFzwxx6VcmubmWRAxUsTt+XjHtVDz2lumkckOx4b0rUs7YkCVVDTHBBbtWU0nuerXkqUU5bpEiae2I38xoyGy2wfe9jWh5YXJZc00blfLLnPtxUsV1EZmifcGHPI61NrHh1Jym7vUqyFy+0qEj9a5DWddZLsw2O0RxnBfOSx+lehNbrJGc7T9elYy6HZQ3fmW9rGHbJdsUKw6VWEX7yH6NM7WSSzRhWPXArRSY78bTg+goitkwmcrjtnAqaaOTb+6C8d6iTOacle43AxkkihuAG+8D2pEaXYBMFB74qUOpGEIPtUNmZDFc7ydqkEHB3CmXAXOSMjvipTggggCoMDGBj8Kl3ZJFI4RfkGQO1RyTLJENoIb0IpJ5Nj425NRzEMoKjaOvSmmRIrzSlQTIPyqAyxsflBXsM8VKzs7YKge9UbscsFA4rSJm33KmoO6knI2g9RVVLhJUIds44Jq0+ShD546VmXNqHkEi7zg546H61rF6ho1ZiTSFTtAGKz7mTJPpVliA+18gjt3rOuJBkghh6VozMiuGBAODge9VJpAVxkY706ZznAIHrnvVaZQQcc4qkkKx7PYpK7481wR71pPFfRAGKTcMZwwqlZt5d6VboTXUxhXTjpiuNao3loc6l/db8SICauQ3sn8cRz7Gp7u1UHcAKltYlZBkc0arQL6DrfVI1wJFYfhV1NStiuQ4ye1VzZoRgqKb9hXsoqdSfdLCzRuw2uo59alunVYd24HHPWqBsx6UC25xjis5K5VkdXp7brdGJzkCrRGDkdK5CMSrwsjr7BqlE10vAmkH416MMYoxSsc8qN3e50+CD65oODwa5oXV5jid8U4XN5/z1JP0q/r0ewewfc6ToMMciuX+IEayeD9QXI3SSxoPfHNTm8vQPv5+oqpqUk9/Y/ZJwNm/zMgYJNUsdT1v2Ilh5dD5t1uyKSMQOM1kRWZfIxXuOseCUvFYwyhH7AjiuXHgXUra4DNGksY67TTp4uD6mEqE1qcPbaLJt8yNmQ+1WSl7bofMAmX0I5/OvdvCPgeC7sz9pbK9sDkUzWvhxModrcKyDnjn9K196cbpXQubldup4Wl3E5Cyq0Z/2h/Wia3iYZTqfSu4vvBd352yS2JwcZA6VSuPBl7bxs8anjtisXys2jXlE5FnnjTy5B5kX91xuFWvD9zBpV208EBiZ/vbDkY+hqzcQzWzFJozx2IquyRPnPytUzp8ysd9LM6kOtzpIL/TNU1VXvI12ldrMuVJPuO9bp8PWrMsmiTKGA3ld3QfSvP1hB4wG9xWtpc11aMHgkD7f4H/x61iqLhseths3h1lyv70exeErS8jPlXb8EfdHIrubS3GUwucDr6V5h4R8bWcZKaj5trMRgMw3L+favVtIvba6s0e1mjmUjrGwOa78JGLep4mZznKbnbR9ti0xitInkc4UDJOOtctPq6av/q9wt1JAHqan1zVIVZkcyqQcYIrjNf8AEVjpS7nk8yRzhIo/vMaeJxTv7OGxODwja55LU29TuvLhZnz5cY+VT39hXI319NqNs1tBGq4O8yA8oenpWZeXGp6m5mvrmKxgP3Ys5bFFmqWjl7a+jlb0auLn1ue1h54eitXeS9bG3AzWNgkMTbmAxz3NZGqXD7c3JJZugB4p5v5I3Ml1GSnqh3CrsGlm9ZbmWMlDyiNxx6mspanbTrUab9pJpmbpFp5uJZo9vOADXRRWa7RhmGO1W7S2Q/LtXjg47VcNsG4U4PoKDzsTipVpXZTiiO4DAC+tQLp8f215+rEbRntWs1uFUZJyKasYOc4A7VDOZTtsUVg4IDEGo5raYjMbAH3q5KWRj5a7setPUF4gzDBPalbqClJakEcQMSiQDPfFKxC8AYIpwhKvuLkgCh2G75SGHeod7GT1ZCXEmVVTgetV3RhJ8i7R61JJcRxk7/lBqCWd9vyEEHpWLY1dbDJg4yeCPSqsu/buXKn2q2zPgZIzjnFV7icooBTINAXZXcb48v8AeHrVaSXC7QeB3qdyrc8g1UnkQDGOfWrRDY2ZgV9c1ms7bjn+dJPK6tw+5B0HpUE0ob7px61pFEsJZeC2386oTTkhscZ7HtTppTGudpb+lUZmJBdTgntitYom2hE79C4/EVWmkVjkAewp8khCH5vlNU5dq/OvGa0iQxksqksGUBj7VUcEqQakmbCZ6kVXkkDDuD6VpHUVz3O7XbOrKMY710Ng4aEfMc1iTR+YvHWtLSWKqBn8K5FodEloacqBlYGq9qpVyD0zVrzMKc9ajixupNkItICx9qmEYpsTKBmpQ449KasZtjfKBFNaH5an3DPFOUrjFHKK7KZgIYHFSJEGByKtOowKiPB4pqNh3bIFtyvSgJ271aiYNkHrTiF3cd6fs1a6HzPqQLHmnNACOgqwFAp4wKapJ7i5jKlts9qhNow7GtgoGcdqsNCuymsLzbCdSxz8KyQyB4pGRx3Xitq01uaPC3aeYo/jUYNRSQKTxxUckA28U6Uq2HfuSInGNT4kdBBcWt6nyFXzyQRzT/sVsVK+RGQeoIrmLdWilDJn/Cui065Mo2ucsOh9a9XC42GIfJUj7xx1KXJrF6HOeIPAOl6orNGnky9sdK8q8UfD660+QnyyyZ4Ycg19D9RTJYkkQrIoZT1BFdNTCRlrHQzVRrc+SbjTJbKTawO6p7NGDAOvFe3eMvDFhApu448Z/h7CvLNQhWOUlVx1FefJOEuWW5pFtlf7MHQMM1CLy401y9tM8DjoY2IqKa5kVNoOKz0gur+5SGFXlkbgKoyTWdjrhWlFWTNC78Waq0LBr24lcDPXNcLrHjM6ddPLJM1zqrDG5juEA9vep/Gd0NEZ7aF917jDYPCmvMXiaSVmfLMTkk966cPhoz96WxVbGVJRUUb134uvrqQvJPPIT1+Y0lrr2qzMFgkdB25qrpulNcMoRc/SvWvAfgFpgtzNGCgIyD3PtV16lGlolqa0adaXvTlZGv8ACjQNQvXW+1m5nkjHKRM3yn3Ir2iCErlSPlxVXS9NS1skEaYCLlQO9bEMZcKxO3jkV5cm5O5tOabujNe3ljkBQrt7gj+tTwxkFSFxj1OavyWfnKM7sA+tI8Ydgithxxx2FTySRDq3Kk8TFxsAI71XeFkdckFM4Oa1FZUY+YcDoDTLmMYyuD3FTyiVS2hmu8blvKw23IIHr6U3Zu6rjjoafcwsqM8Aw3pVO0Z0VhMOc9c9vepbszVaq6JgrBtpTBH61WaMRMzquKtSyKRkn8ap3JLjKsePQ9axmwW5XcpKMlDmq8ixL0ft0qMzgOQW5/u0OEZ85BPvWdzRxsVpQxPyhvY1WmmBi2sxLA8DFW5ZQCAwAXviqcrozcc+9Mm9ys90SgUqQR39aqy3BaPBwCPWrM0i4YoVPt6VRIWVidv61aM211K9xP8AJyn5VnzyNEdyjI64FWZ2K7lLYXHTrWYZM556VshLuLLKW56DqQaoyPw208HvUskmWJzwaozybc7atENkEszBiCc4pjOp7YPvTHfBDFRmoZJFY88VrYzYSOoJOelVJJBlsDIp7MNhxjGarsG5AxitYoTZ9BwS5HWrMNxsPBxWIisOFangS9iDXmObO5qLOkS83Ac1JHdDua5jfcx9FzQLudCC0TY9qTncORM7KK5BHJqUXAznNcjHqeB8+5fqKsxakpP3qOYh0ex1InBPWpll461zcN8G6NV2O6Bxg1SmS6ZtLMcY7U7fkZNZKT9Tnj61Mk2R1qucnksX0cAmpo3BrMMpB61LFL83NUpjcNDUDDFNZgKq+bxSGUHNP2lzPkLKyYNWVdnUYNZW41agkIGDVRrNClDTQnKMT1pHJC4NPV+56U5MMc1dlL4WZ3aGxR9yKt2S+XMGHA70xcAVR1XUUthDaxtm6uXCRqOoGeT+VaUlGnJS7GM7y0R1ANBpq9BUF7N5UTEHBr6KU1GPMzgsYXjCVWtdmRjH515Hq8IBYjrmu/1668xmBPHauH1BA7kZOfavBq1HUm5HXT91WOXktpJ5BGiFnY4AAzk13moPafC3wXJfTrG3iO+UpCp5Mf09h39TxWh4Z06x8O6XL4o19xHBEu6BW6k9iB6nt+dfP3xG8X3fi/XpLyckRD5YYgeI07Af1967aNNUoc8t3sawg60uVbLc5DVZJr27knmJeR2LMT3NO0/SmuH+7x9K1dLsTcuARkV6n4Q8KRzSReYuxOCWAzxWE8Q0uVHoqnCGrOa8FeG2guFeRQUY8givcdDtI7OFECgDtWbBoflNtt9u1TuHHWugsgwWVJFw3B5HSuFycndmtR86TRethI6+X9wBuSO9XYbZxG+5ix7GoLNvmJPKLxj3rQjlAUK33zz7VrThF6yZw1JNOyGhtqCM9evSoUWNJWZWG9hyPWrUijYx745rKkfypPNUbu3Ip1JclrkQXNexYZFdBkDr0qvNLsVh/d9qkluFVUZWDKeeKguGR4yB37+lYTa3RpFdxH+cBjjHtWZexg8Z+UnnHXFWraPyVwWLDtzVa8i5D7yOenSs73NY6MjESmPAJ2iqrqsQIUnH1qSSSRWONu3pVOd1kySfwrnmlc1V7lYoBIWyS1RSEoc8tzTLn944UEoB6GmyYVMZX65rMuTFdo3yGOM+pqlMFUnkKvrinyou7PBP51WlRpQRnIHarRk/IpSyhWxjcp9KpGZg75U49KmmYjK7RwetV5iD90c1tFWE2VJ5WD++O4rOmBLnJ9+KtXWR8xPIqhNJtBJBJ9RWkUS3ZEMzMCQOPeqjyKQc53VNJIr5Jc57E1SlbaCQSR3NaxXczeojS7/kAziqchGSTihnVs9T7VXlZABuyfatYq+hA5z0xx70xnPTPNQGRXJwx+lM3BBlsmtlGxMj6EjHQ1YReMmol4AqfdgZry2rnTccBk0EYPNMEhxkDrUbyDdU8gWZbESuMED8ain0xGGQu0+oqaybLc8g1rxpkAHrVezTQc7icylhOh/dS/g1WEW+iHMO8f7JrYuIAhyKntxuUcCsnFop1dDEXUXiOJoJF+q8VYh1eE/xAfWtZowDyKbJYW0w+eGNvqKTuhqpF9CGK9RxwwINW4ZAeaototqT8ish/wBlsVE2kXCH/R7xgPRxmpux3i+pvJ92njaRx+tVdP0yYRg3F0z+yjFXU05PNA82THpmhJvYzbiuo0AcdKtwqvc0260tXi/cyNHJ2bOagtdOlUfvrlm9gMVo1OEuWxPPCS0ZoOYwvUVWM4TODn6VILaJOxb6mpoQgPCircZzlbYyuku5zera1qXMGkWEs0543v8AKi/j3pPBujXVrqLaprsn2i+bhdpyErp5AMGquWVuOnpTUZ0ZqT1sNyUo8qVjZk1MKPliYn64rPurt5lI8thmoVkb0qVQT1FdM8bVraN6HN7GMdjndQtdxYsrHPQVW0vRLYC41DVXW3021BeV2PBxyRXWPCrocqD9a8e/aK1LVbbRNOtbdki0l2KyohwXkHI3eo6/jV4aUVP978ieTmaSPP8A4s/EGfxdqPkWu6DSLc7beAcZHTcw9SPyri9Ns3mk46Gq9nbtNKAOhPevS/C/h8NGhIFdGIxDZ61GmqUbIm8J+HyWjd149a9X0q2FpiHCLIcDPt61S0fSo4IApHzA4xW0YY45YpsbQCFOP0rz41LvUzqS5nY2hbxxxqgXLEH5j3FZk1wiaj+9wkTLjn1rQ1CRlgGeAOcnkkelYuoo00kMsZBZTnHtWs2lsGHjd+8a0bbVjwSATx/tVf3rvXPJ9jwK5q3upGdSz52rgVoQSG5jkIONpAOKjnfRDqUmtzYDMHYnlCOBVOXHKnpTWkZ0Pz9OnFUp5hndkg1Eqjk7GMYPoNm2IuxAflqOG4DKVdhkcYJ5qrPP/p8Ea7gzZJOeCP8AOKWaNQxYAbumSKVzdLTUsxJs5yefXvUF0mW3senvxSxP+4HJOOM1Uvro+Q4Y7SOhxmlZEq9xlxcADZjk9TnOKoXADKdpwahUgq2ZGwevFV5A6hgrfnXPUeptaw5YzGDu+Zj3JyaquM/eYAimjzd25nJGOgNR3M3lgfICT0qEmDGys/mZ8whfrioLqXAwshzjtSOzvGWOM+mOKo3D7cYB3VtEh7jZHZGBUgn3qlcTNtw2Q3Y1IzuWLOcgfpVS5c9WP0raOpLIHkdC3Q57kVQml6qGOT1OKleV2U7z8o7VSuJcLgDg9+9bIghZyNy7arStnPzAe1ErMoJB69s1UkcgbiOBWiRL0CXPJVgPeqkhzkk81JO+RknP0qpJID1HP8q1itSGxzZByQAabv5IOBUDsRg5yaaXBAwf0rdRuZydz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lymph node bundle is shown entering the femoral canal. The tip of the scissors is placed at the distal end of the femoral canal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of C William Helm, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12450=[""].join("\n");
var outline_f12_10_12450=null;
var title_f12_10_12451="Benzyl alcohol: Pediatric drug information";
var content_f12_10_12451=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benzyl alcohol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?19/61/20435?source=see_link\">",
"    see \"Benzyl alcohol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/50/23332?source=see_link\">",
"    see \"Benzyl alcohol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7897463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ulesfia&reg;;",
"     </li>",
"     <li>",
"      Zilactin&reg;-L [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F9944977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiparasitic Agent, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Pediculocide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Topical Skin Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F9944986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/61/20435?source=see_link\">",
"      see \"Benzyl alcohol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion (Ulesfia&trade;): Treatment of head lice infestation: Children &ge;6 months of age and adults: Apply appropriate volume for hair length to dry hair, saturate the scalp completely, leave on for 10 minutes, rinse thoroughly with water; repeat in 7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length 0-2 inches: 4-6 ounces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length 2-4 inches: 6-8 ounces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length 4-8 inches: 8-12 ounces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length 8-16 inches: 12-24 ounces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length 16-22 inches: 24-32 ounces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length &gt;22 inches: 32-48 ounces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid (topical) [Zilactin&reg;-L (OTC)]: Cold sores/fever blisters: Children &ge;2 years of age and adults: Moisten cotton swab with several drops of liquid; apply to affected area up to 4 times/day; do not use for more than 7 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7897529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zilactin&reg;-L: 10% (5.9 mL) [contains ethanol 80%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ulesfia&reg;: 5% (227 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7897643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9944987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical use only. Do not swallow liquid or lotion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion (Ulesfia&trade;): Apply under adult supervision to dry hair, until entire scalp and hair are saturated. Leave on for 10 minutes then rinse thoroughly. Avoid contact with eyes. Wash hands after application. A lice comb may be used to remove dead lice after both treatments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid (topical) [Zilactin&reg;-L (OTC)]: Apply to affected area only with moistened cotton swab. Allow to dry for 15 seconds. Avoid contact with eyes.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F9944983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid (topical): Store at 15&deg;C to 20&deg;C (59&deg;F to 86&deg;F). Flammable; keep away from fire or flame.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9944978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion: Treatment of head lice infestation (FDA approved in ages &ge;6 months and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid (topical): Temporary relief of pain caused by cold sores/fever blisters (FDA approved in ages &ge;2 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7695205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Benzyl alcohol may be confused with benzoyl peroxide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7897485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Erythema, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Anesthesia, hypoesthesia, irritation, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Ocular irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Dandruff, dermatitis, dryness, excoriation, exfoliation, paresthesia, rash, thermal burn",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9944980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benzyl alcohol or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9944994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; if contact with eyes occurs, flush immediately with water; allergic or irritant dermatitis may occur",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9944981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; the \"gasping syndrome\" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; avoid use in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7899266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7897464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7897465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no well-controlled human studies with topical benzyl alcohol in pregnancy. Use only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9944984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits respiration of lice by obstructing respiratory spiracles causing lice asphyxiation. No ovicidal activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9944985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Quantifiable serum plasma concentrations reported following prolonged exposure (30 minutes) in patients 6 months to 11 years of age",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F9944997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/50/23332?source=see_link\">",
"      see \"Benzyl alcohol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lotion should be used in conjunction with overall lice management program. Dry clean or wash all clothing, hats, bedding, and towels in hot water. Wash all personal care items (eg, combs, brushes, hair clips) in hot water. May use a fine-tooth or special nit comb to remove nits and dead lice. May shampoo hair right after treatment. Keep topical liquid away from fire or flame. Inform physician if swelling, rash, or fever develops or if application site irritation occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13083 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-03DA1CD083-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12451=[""].join("\n");
var outline_f12_10_12451=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897463\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944977\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944986\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897529\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897643\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944987\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944983\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944978\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7695205\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897485\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944980\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944994\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944981\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298848\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7899266\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897464\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897465\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944984\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944985\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944997\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13083\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13083|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/61/20435?source=related_link\">",
"      Benzyl alcohol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/50/23332?source=related_link\">",
"      Benzyl alcohol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_10_12452="Vagal nerve stimulator";
var content_f12_10_12452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vagal nerve stimulator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Physician's Manual for the Model 100 NCP&reg; Pulse Generator. Cyberonics. Copyright &copy; Cyberonics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12452=[""].join("\n");
var outline_f12_10_12452=null;
var title_f12_10_12453="Nicardipine: Patient drug information";
var content_f12_10_12453=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nicardipine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     see \"Nicardipine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"     see \"Nicardipine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cardene&reg; I.V.;",
"     </li>",
"     <li>",
"      Cardene&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nicardipine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart valve problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10906 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12453=[""].join("\n");
var outline_f12_10_12453=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201178\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022928\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022930\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022929\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022934\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022935\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022937\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022932\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022933\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022938\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022939\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=related_link\">",
"      Nicardipine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=related_link\">",
"      Nicardipine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_10_12454="Lateral segmentectomy";
var content_f12_10_12454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral segmentectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 584px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parallelogram partial mastectomy, lateral segment (\"lateral segmentectomy\"), preoperative, and intraoperative images.",
"    <br>",
"     (A) Intraoperative marking with patient in supine position demonstrating the tangential approach of the parallelogram skin marking to the nipple-areolar complex.",
"     <br>",
"      (B) Full-thickness ���������broglandular resection.",
"      <br>",
"       (C) Final skin closure.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Calhoun KE, Anderson BO. Oncoplastic surgery: Segmental resection for lumpectomies. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"       </div>",
"       <div class=\"contractual\">",
"        <br/>",
"        <a href=\"file://www.lww.com\">",
"         file://www.lww.com",
"        </a>",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12454=[""].join("\n");
var outline_f12_10_12454=null;
var title_f12_10_12455="Management of duodenal ulcers in patients infected with Helicobacter pylori";
var content_f12_10_12455=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of duodenal ulcers in patients infected with Helicobacter pylori",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12455/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12455/contributors\">",
"     Sheila E Crowe, MD, FRCPC, FACP, FACG, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12455/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12455/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12455/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12455/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/10/12455/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcer disease continues to be a common problem, although the incidence of duodenal ulcers has declined in recent decades [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/1\">",
"     1",
"    </a>",
"    ]. Different factors have been implicated as etiologies for DUs, including diet, stress, smoking, and overproduction of gastric acid. However, the majority of patients with duodenal ulcers (DU) are infected with",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    (",
"    <em>",
"     H. pylori",
"    </em>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with",
"    <em>",
"     H. pylori",
"    </em>",
"    infection and DU disease will be reviewed here. Other aspects of",
"    <em>",
"     H. pylori",
"    </em>",
"    infection are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ERADICATION OF H. PYLORI",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with duodenal ulcers (DUs) associated with",
"    <em>",
"     H. pylori",
"    </em>",
"    infection should undergo therapy to eradicate the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Treatment regimens for H. pylori'",
"    </a>",
"    below.) This recommendation is based upon overwhelming data showing that cure of",
"    <em>",
"     H. pylori",
"    </em>",
"    infection reduces ulcer recurrence and complications such as bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. In a study of 100 infected patients with DU, eradication of the infection was associated with a higher rate of healing (92 versus 61 percent when",
"    <em>",
"     H. pylori",
"    </em>",
"    persisted after treatment) and a lower rate of recurrence during a 12-month follow-up (21 versus 84 percent). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Disease recurrence'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Empiric treatment versus specific testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In settings where the prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    in DU is greater than 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], empiric therapy for the infection is reasonable for uncomplicated cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    in DU appears to be considerably less than 90 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"     \"Unusual causes of peptic ulcer disease\"",
"    </a>",
"    .) The prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    is also lower in patients with complicated DUs (ie, those complicated by bleeding or perforation) compared with those with uncomplicated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Patients with",
"    <em>",
"     H. pylori",
"    </em>",
"    negative ulcers appear to have a significantly worse outcome especially if treated empirically for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, documenting infection in patients with DU (uncomplicated or complicated) is an appropriate caution prior to initiating antimicrobial therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Uncomplicated duodenal ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uncomplicated DUs should receive anti-",
"    <em>",
"     H. pylori",
"    </em>",
"    therapy if the organism is present. Although, the eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    without concurrent acid suppression therapy is capable of healing DUs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/16\">",
"     16",
"    </a>",
"    ], acid suppression has long been the mainstay of therapy. An intragastric pH &gt;3 for 18 to 20 hours per day will heal nearly all duodenal ulcers within four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/17\">",
"     17",
"    </a>",
"    ]; suppression of nocturnal acid secretion appears to be the most important factor in ulcer healing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/18\">",
"     18",
"    </a>",
"    ]. Acid suppression can be discontinued in patients with uncomplicated DUs after four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Complicated duodenal ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to patients with uncomplicated DUs, those with complicated DUs should receive anti-",
"    <em>",
"     H. pylori",
"    </em>",
"    therapy if the organism is present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether antisecretory medication should be continued after",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication in patients with complicated duodenal ulcers is controversial. While some studies have suggested that elimination of the infection alone is sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/19-21\">",
"     19-21",
"    </a>",
"    ], at least three consensus panels have addressed this issue, and recommended maintenance acid suppression following",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication in patients with a complicated DU [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/2,22,23\">",
"     2,22,23",
"    </a>",
"    ]. This is particularly important if nonsteroidal antiinflammatory drugs (NSAIDs) were implicated as a possible cause, and if they are to be restarted [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/24\">",
"     24",
"    </a>",
"    ]. Most complicated ulcers occur in those using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and NSAIDs and many patients continue to use these medications despite physicians' best efforts at counseling against this. As a result, continuing acid suppression indefinitely makes clinical if not economic sense.",
"   </p>",
"   <p>",
"    There is general agreement that these patients should undergo follow-up testing at least four weeks after the completion of",
"    <em>",
"     H. pylori",
"    </em>",
"    therapy to assess eradication of the infection. Patients can be switched to H2 receptor antagonists (H2RAs) for several weeks prior to noninvasive",
"    <em>",
"     H. pylori",
"    </em>",
"    testing, since maintenance PPIs can affect test results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Factors influencing treatment outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient compliance with treatment is critical to the successful eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    . An illustrative study evaluated the efficacy of triple therapy for",
"    <em>",
"     H. pylori",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/25\">",
"     25",
"    </a>",
"    ]. Compliance was the most important factor predicting success; successful eradication occurred in 96 percent of patients who took more than 60 percent of the prescribed medications versus 69 percent in patients who took less. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"     \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"     \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors other than compliance may also influence treatment outcome. As an example, tobacco smoking may slow DU healing. However, once",
"    <em>",
"     H. pylori",
"    </em>",
"    is eradicated and the ulcer has healed, smoking does not increase the risk of ulcer relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that pretreatment with a proton pump inhibitor could decrease the efficacy of",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication. However, the data clearly show no change in eradication rates or ulcer recurrence at one year in patients treated with proton pump inhibitors prior to anti-",
"    <em>",
"     H. pylori",
"    </em>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disease recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have evaluated the rate of disease recurrence following eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In one meta-analysis, recurrence of DU (as determined endoscopically) occurred in less than 10 percent of patients following",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication versus 65 to 95 percent in those who remained infected [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/6\">",
"     6",
"    </a>",
"    ]. A higher rate of endoscopic recurrence (20 percent within six months of eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    in patients with no evidence of NSAID use) was found in another meta-analysis but the outcome was still better than in patients who remained infected (56 percent recurrence) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/7\">",
"     7",
"    </a>",
"    ]. Some studies have found lower relapse rates (as low as 2 percent per year), particularly outside the United States, or when recurrence was defined symptomatically rather than endoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/7,29\">",
"     7,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ulcer recurrence following eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    is not usually due to recurrent",
"    <em>",
"     H. pylori",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/7,29\">",
"     7,29",
"    </a>",
"    ]. Among the factors that can contribute are NSAID use and continued acid hypersecretion (",
"    <a class=\"graphic graphic_table graphicRef76314 \" href=\"UTD.htm?5/23/5501\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/29\">",
"     29",
"    </a>",
"    ]. Maintenance antisecretory treatment may be necessary to prevent relapse in this subset of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     H. pylori",
"    </em>",
"    infection and nonsteroidal antiinflammatory drugs (NSAIDs) can act synergistically to cause ulcers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .) NSAID users with a history of DU disease should be tested and treated for",
"    <em>",
"     H. pylori",
"    </em>",
"    if they are infected. There are also data suggesting that testing and treating (if positive) all patients for",
"    <em>",
"     H. pylori",
"    </em>",
"    prior to beginning NSAID use may be warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], although this is not currently the standard of care or of confirmed benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients with a duodenal ulcer should avoid NSAIDs whenever possible. However, for those who require NSAIDs, we recommended maintenance PPI treatment as long as the NSAID is continued to reduce recurrent ulcer risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recently bleeding gastric or duodenal ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of various methods to detect",
"    <em>",
"     H. pylori",
"    </em>",
"    may be affected in the presence of recent gastrointestinal bleeding. Recommendations for",
"    <em>",
"     H. pylori",
"    </em>",
"    testing in this setting are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT REGIMENS FOR H. PYLORI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple regimens have been evaluated for",
"    <em>",
"     H. pylori",
"    </em>",
"    therapy (",
"    <a class=\"graphic graphic_table graphicRef65237 \" href=\"UTD.htm?18/49/19228\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Eradication rates with the original",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    triple regimens (bismuth,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , and either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ) are in the range of 75 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The optimal therapeutic regimen has not yet been defined. Treatment should be effective, but considerations such as cost, side effects, and ease of administration must also be taken into account. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TESTING FOR H. PYLORI FOLLOWING ERADICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of testing for",
"    <em>",
"     H. pylori",
"    </em>",
"    following eradication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS OF ERADICATING H. PYLORI",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    at the time of initial ulcer diagnosis facilitates healing. It is the most cost-effective long-term treatment of duodenal ulcer (DU) disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. One report, for example, estimated that the cost for DU management in an individual patient over the course of 15 years is about $1000 for",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/39\">",
"     39",
"    </a>",
"    ]. The estimated costs of intermittent acid-suppression therapy ($10,350), maintenance acid suppression therapy ($11,186), and vagotomy ($17,661) were much higher. A systematic review of 27 randomized controlled trials comparing",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication to no treatment in a total of 2509 patients after DU healing demonstrated an 80 percent decrease in the risk of relapse with",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication (RR 0.2, 95% CI 0.15-0.26) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12455/abstract/41\">",
"     41",
"    </a>",
"    ]. The number needed to treat to prevent one ulcer relapse was only two.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"       \"Patient information: Peptic ulcers (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=see_link\">",
"       \"Patient information: H. pylori infection (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a duodenal ulcer (DU) should be tested for",
"      <em>",
"       Helicobacter pylori",
"      </em>",
"      (",
"      <em>",
"       H. pylori",
"      </em>",
"      ).",
"     </li>",
"     <li>",
"      We recommend patients who test positively should be treated with eradication therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also suggest concomitant treatment with acid suppression for both patients with uncomplicated (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) and complicated (ie, those presenting with bleeding or perforation) ulcers (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"       \"Treatment regimens for Helicobacter pylori\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acid suppression can be discontinued in patients with uncomplicated DU after four weeks. However, maintenance acid suppression (even after successful",
"      <em>",
"       H. pylori",
"      </em>",
"      eradication) may be appropriate in those with complicated DU since cure of infection reduces but does not totally eliminate subsequent complications. The most appropriate acid suppression is a once daily dose of a proton pump inhibitor (PPI) since PPIs are more effective than H2 receptor antagonists (H2RAs) in maintaining pH &gt;3, especially in",
"      <em>",
"       H. pylori",
"      </em>",
"      negative individuals. Maintenance treatment should be continued indefinitely.",
"     </li>",
"     <li>",
"      The accuracy of various methods to detect",
"      <em>",
"       H. pylori",
"      </em>",
"      may be affected in the presence of recent gastrointestinal bleeding. Recommendations for",
"      <em>",
"       H. pylori",
"      </em>",
"      testing in this setting are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"       \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The rate of successful treatment depends largely upon patient compliance. Thus, patients need to be educated and involved in the decision making process. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"      </a>",
"      .) Confirmation of eradication is reasonable because of the availability of accurate, relatively inexpensive noninvasive tests (stool and breath tests). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"       \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a duodenal ulcer should avoid NSAIDs whenever possible. However, for those who require NSAIDs we recommended maintenance PPI treatment as long as the NSAID is continued to reduce recurrent ulcer risk (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12197?source=see_link\">",
"       \"NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Individuals who have frequent recurrence of ulcers or complications especially in the absence of",
"      <em>",
"       H. pylori",
"      </em>",
"      infection or NSAID use should be evaluated for a condition associated with gastric acid hypersecretion such as Zollinger-Ellison syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"       \"Unusual causes of peptic ulcer disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/1\">",
"      Munnangi S, Sonnenberg A. Time trends of physician visits and treatment patterns of peptic ulcer disease in the United States. Arch Intern Med 1997; 157:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/2\">",
"      NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/3\">",
"      Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/4\">",
"      Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/5\">",
"      Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/6\">",
"      Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/7\">",
"      Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/8\">",
"      Sonnenberg A, Olson CA, Zhang J. The effect of antibiotic therapy on bleeding from duodenal ulcer. Am J Gastroenterol 1999; 94:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/9\">",
"      Borody TJ, George LL, Brandl S, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 1991; 86:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/10\">",
"      Tytgat G, Langenberg W, Rauws E, Rietra P. Campylobacter-like organism (CLO) in the human stomach. Gastroenterology 1985; 88:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/11\">",
"      Greenberg PD, Koch J, Cello JP. Clinical utility and cost effectiveness of Helicobacter pylori testing for patients with duodenal and gastric ulcers. Am J Gastroenterol 1996; 91:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/12\">",
"      Reinbach DH, Cruickshank G, McColl KE. Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection. Gut 1993; 34:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/13\">",
"      Laine LA. Helicobacter pylori and complicated ulcer disease. Am J Med 1996; 100:52S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/14\">",
"      Zelickson MS, Bronder CM, Johnson BL, et al. Helicobacter pylori is not the predominant etiology for peptic ulcers requiring operation. Am Surg 2011; 77:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/15\">",
"      Bytzer P, Teglbjaerg PS, Danish Ulcer Study Group. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis--results from a randomized trial with 2-year follow-up. Am J Gastroenterol 2001; 96:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/16\">",
"      Lam SK, Ching CK, Lai KC, et al. Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. Gut 1997; 41:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/17\">",
"      Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/18\">",
"      Jones DB, Howden CW, Burget DW, et al. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987; 28:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/19\">",
"      Graham DY, Hepps KS, Ramirez FC, et al. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993; 28:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/20\">",
"      Labenz J, B&ouml;rsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994; 55:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/21\">",
"      Vergara M, Casellas F, Saperas E, et al. Helicobacter pylori eradication prevents recurrence from peptic ulcer haemorrhage. Eur J Gastroenterol Hepatol 2000; 12:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/22\">",
"      Buckley M, Culhane A, Drumm B, et al. Guidelines for the management of Helicobacter pylori-related upper gastrointestinal diseases. Irish Helicobacter Pylori Study Group. Ir J Med Sci 1996; 165 Suppl 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     Professional Advisory Panel (CRAG) and Scottish Intercollegiate Guidelines Network (SIGN). Helicobacter pylori eradication therapy in dyspeptic disease: A clinical guideline. 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/24\">",
"      Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/25\">",
"      Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/26\">",
"      Chan FK, Sung JJ, Lee YT, et al. Does smoking predispose to peptic ulcer relapse after eradication of Helicobacter pylori? Am J Gastroenterol 1997; 92:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/27\">",
"      Annibale B, D'Ambra G, Luzzi I, et al. Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? Am J Gastroenterol 1997; 92:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/28\">",
"      Adamek RJ, Szymanski C, Pfaffenbach B. Pantoprazole suppresses Helicobacter pylori without affecting cure. Helicobacter 1999; 4:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/29\">",
"      Harris AW, Gummett PA, Phull PS, et al. Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output. Aliment Pharmacol Ther 1997; 11:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/30\">",
"      Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/31\">",
"      Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/32\">",
"      Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/33\">",
"      Laheij RJ, Rossum LG, Jansen JB, et al. Evaluation of treatment regimens to cure Helicobacter pylori infection--a meta-analysis. Aliment Pharmacol Ther 1999; 13:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/34\">",
"      Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001; 36:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/35\">",
"      Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996; 275:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/36\">",
"      Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/37\">",
"      Imperiale TF, Speroff T, Cebul RD, McCullough AJ. A cost analysis of alternative treatments for duodenal ulcer. Ann Intern Med 1995; 123:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/38\">",
"      O'Brien B, Goeree R, Mohamed AH, Hunt R. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995; 155:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/39\">",
"      Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995; 155:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/40\">",
"      Sonnenberg A, Schwartz JS, Cutler AF, et al. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. Arch Intern Med 1998; 158:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12455/abstract/41\">",
"      Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2004; :CD003840.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 21 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12455=[""].join("\n");
var outline_f12_10_12455=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ERADICATION OF H. PYLORI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Empiric treatment versus specific testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Uncomplicated duodenal ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Complicated duodenal ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Factors influencing treatment outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disease recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recently bleeding gastric or duodenal ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT REGIMENS FOR H. PYLORI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TESTING FOR H. PYLORI FOLLOWING ERADICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COST-EFFECTIVENESS OF ERADICATING H. PYLORI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/21\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/21|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/23/5501\" title=\"table 1\">",
"      Causes of refractory or recurrent peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/49/19228\" title=\"table 2\">",
"      ACG first-line H pylori regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=related_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12197?source=related_link\">",
"      NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=related_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=related_link\">",
"      Unusual causes of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_10_12456="External otitis: Treatment";
var content_f12_10_12456=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   External otitis: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12456/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12456/contributors\">",
"     Laura A Goguen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12456/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12456/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12456/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12456/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12456/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12456/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/10/12456/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13312371\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term external otitis (also known as otitis externa or swimmer&rsquo;s ear) refers to inflammation of the external auditory canal or auricle.",
"   </p>",
"   <p>",
"    There are five fundamental steps in the management of external otitis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thoroughly clean the ear canal",
"     </li>",
"     <li>",
"      Treat inflammation and infection",
"     </li>",
"     <li>",
"      Control pain",
"     </li>",
"     <li>",
"      Avoid promoting factors",
"     </li>",
"     <li>",
"      Follow-up and culture recalcitrant cases (as well as consider alternative diagnoses)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of external otitis usually involves topical drug therapy rather than oral antibiotics or surgery, as the disease is limited to the skin of the ear canal.",
"   </p>",
"   <p>",
"    This topic will focus on the management of external otitis. The clinical manifestations and diagnosis of external otitis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H191116177#H191116177\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312378\">",
"    <span class=\"h1\">",
"     CLEANING THE EAR CANAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cleaning out the external canal (aural toilet) is the first step in treatment. The removal of cerumen, desquamated skin, and purulent material from the ear canal greatly facilitates healing and enhances penetration of ear drops into the site of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ear canal cleaning should be performed through an otoscope that allows direct visualization and use of a wire loop or cotton swab to gently remove debris and cerumen. The ear canal may be irrigated with a 1:1 dilution of 3%",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    at body temperature if the tympanic membrane is visible and intact.",
"   </p>",
"   <p>",
"    Patients with a ruptured tympanic membrane (or those in whom the tympanic membrane cannot be clearly seen) should be referred to an otolaryngologist for further management. Otolaryngologists often clean infected ears under a microscope; this provides binocular magnified vision and liberates both hands. The ability to use both hands with magnified vision may also facilitate cleaning when the ear is extremely tender. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=see_link\">",
"     \"Evaluation and management of middle ear trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13050?source=see_link&amp;anchor=H22#H22\">",
"     \"Evaluation of earache in children\", section on 'Traumatic tympanic membrane (TM) perforation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link&amp;anchor=H21#H21\">",
"     \"Acute otitis media in adults (suppurative and serous)\", section on 'Ruptured tympanic membrane'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312385\">",
"    <span class=\"h1\">",
"     TREATMENT OF INFLAMMATION AND INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of inflammation and infection primarily involves use of topical agents. Systemic antibiotics are indicated in patients with deep tissue infection (outside the external canal) and immunocompromised hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279397\">",
"    <span class=\"h2\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapy is highly effective for external otitis, delivering a high concentration of medication to the infected and inflamed tissue with minimal side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312392\">",
"    <span class=\"h3\">",
"     Topical preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several topical agents are available for treating external otitis, including antibiotics, antiseptics, glucocorticoids, and acidifying solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/1\">",
"     1",
"    </a>",
"    ]. They are administered as single agents and combination formulas (",
"    <a class=\"graphic graphic_table graphicRef67418 \" href=\"UTD.htm?8/45/8925\">",
"     table 1",
"    </a>",
"    ). Most are used in a liquid form, although ointments and powders are also available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1295111\">",
"    <span class=\"h4\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical antibiotics are highly effective for treating external otitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/3\">",
"     3",
"    </a>",
"    ]. One systematic review found that topical antibiotics increased absolute clinical cure rate compared to placebo by 46 percent (95% CI 29-63 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/2\">",
"     2",
"    </a>",
"    ]. The review also found no significant difference comparing topical antibiotics to antiseptics, or to combination",
"    <span class=\"nowrap\">",
"     antibiotic/glucocorticoid",
"    </span>",
"    preparations. There was also no difference in cure rates between quinolone and nonquinolone antibiotics.",
"    <br/>",
"   </p>",
"   <p>",
"    Certain factors should be considered when selecting an ototopical antibiotic: coverage of specific pathogens (",
"    <a class=\"graphic graphic_table graphicRef54268 graphicRef70073 \" href=\"UTD.htm?13/13/13535\">",
"     table 2A-B",
"    </a>",
"    ), side effect profile (including ototoxicity and contact dermatitis), and drug resistance.",
"   </p>",
"   <p>",
"    The ideal antibiotic regimen should have specific coverage against the most common pathogens, P. aeruginosa and S. aureus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fluoroquinolones",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       ofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      provide excellent coverage against both pathogens. In two clinical trials, ofloxacin appeared to be as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"       polymyxin B",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      formulation (Corticosporin otic suspension) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Another trial found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16595?source=see_link\">",
"       ciprofloxacin-dexamethasone",
"      </a>",
"      was superior to polymyxin B-neomycin-hydrocortisone in decreasing inflammation, edema, and achieving pain control [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"       Polymyxin B",
"      </a>",
"      (a polypeptide type antimicrobial) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      (an aminoglycoside) are antibiotics combined in many frequently used ototopical medications (eg, Cortisporin, Coly-Mycin, Pediotic). Neomycin is effective against S. aureus, while polymyxin B is effective against P. aeruginosa.",
"     </li>",
"     <li>",
"      The aminoglycosides",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      are also effective against both P. aeruginosa and S. aureus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effect profile can also influence choice of treatment. Ototoxicity is the most important concern with aminoglycoside agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/7\">",
"     7",
"    </a>",
"    ]. Aminoglycosides are a significant potential source for iatrogenic hearing loss and balance dysfunction, particularly in the presence of tympanic membrane perforation. Allergic contact dermatitis is commonly associated with neomycin when used for prolonged courses [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/8\">",
"     8",
"    </a>",
"    ]. Topical fluoroquinolones can cause local irritation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H24#H24\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Contact dermatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concerns have been raised about the development of antibiotic resistance, particularly against P. aeruginosa with chronic use of ototopical fluoroquinolones. However, in vitro, P. aeruginosa sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    remained high (98 percent) in one study despite long-term antibiotic use [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/9\">",
"     9",
"    </a>",
"    ]. Drug resistance may be important in the setting of treatment failure, requiring culture of the ear canal. (See",
"    <a class=\"local\" href=\"#H13312469\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312406\">",
"    <span class=\"h4\">",
"     Antiseptics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiseptics function as bacteriostatic agents, not as bacteriocidal agents like antibiotics. Their precise mechanism of action is not fully understood, but they make the ear canal less habitable for bacteria and may loosen debris in the ear canal. Systemic reviews and meta-analyses, albeit of low-quality trials, suggest that these agents are similarly effective as other topical agents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Available antiseptics are listed in a table (",
"    <a class=\"graphic graphic_table graphicRef67418 \" href=\"UTD.htm?8/45/8925\">",
"     table 1",
"    </a>",
"    ). Alcohol is the most commonly used antiseptic component of many ototopical preparations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312413\">",
"    <span class=\"h4\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical glucocorticoids decrease inflammation, resulting in relief of pruritus and decreased pain. Glucocorticoids used to treat external otitis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef67418 \" href=\"UTD.htm?8/45/8925\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/1\">",
"     1",
"    </a>",
"    ]. These topical agents are well-tolerated.",
"   </p>",
"   <p>",
"    <br/>",
"    A meta-analysis of randomized trials, which included three studies comparing",
"    <span class=\"nowrap\">",
"     antimicrobial/glucocorticoid",
"    </span>",
"    versus antimicrobial alone, found comparable clinical and bacteriologic cure rates at seven days for regimens with and without glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/2\">",
"     2",
"    </a>",
"    ]. The addition of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , however, did decrease time to symptom resolution by one day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312420\">",
"    <span class=\"h4\">",
"     Acidifying solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. aeruginosa and S. aureus readily grow in environments with a pH of 6 to 7, but grow less well at a lower pH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, simply acidifying the ear canal inhibits bacterial growth. Commonly used acidifying solutions are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    , boric acid, hydrochloric acid, and sulfuric acid (",
"    <a class=\"graphic graphic_table graphicRef67418 \" href=\"UTD.htm?8/45/8925\">",
"     table 1",
"    </a>",
"    ). Acidifying solutions are generally safe, but may be associated with local irritation manifested by burning or stinging. In the presence of tympanic membrane perforation, acidifying solutions can be particularly irritating to the mucosa of the middle ear.",
"   </p>",
"   <p>",
"    One meta-analysis found no clinically meaningful differences between acidifying agents and other topical interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/1\">",
"     1",
"    </a>",
"    ]. However, there was one trial of high quality that found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    was less effective than acetic acid plus glucocorticoid and antibiotic plus glucocorticoid drops at two and three week follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312427\">",
"    <span class=\"h4\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several combinations of the above topical agents are available in clinical practice (",
"    <a class=\"graphic graphic_table graphicRef67418 \" href=\"UTD.htm?8/45/8925\">",
"     table 1",
"    </a>",
"    ). The efficacy of several different combination preparations have been examined in meta-analyses of randomized trials, with no specific combination therapy superior over other therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312434\">",
"    <span class=\"h3\">",
"     Choice of topical agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choosing the proper ototopical agent or combination of agents is difficult given the wide array of choices (",
"    <a class=\"graphic graphic_table graphicRef67418 \" href=\"UTD.htm?8/45/8925\">",
"     table 1",
"    </a>",
"    ). The choice frequently becomes a personal one based upon clinical experience. One meta-analysis of nineteen randomized trials found no clinically meaningful differences between various topical interventions, except that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    was less effective than",
"    <span class=\"nowrap\">",
"     antibiotic/glucocorticoid",
"    </span>",
"    drops for patients whose symptoms had not resolved by one week [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/1\">",
"     1",
"    </a>",
"    ]. The overall quality of the studies was low.",
"   </p>",
"   <p>",
"    In our practice, we select therapy based on the severity of external otitis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H277540#H277540\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Clinical features'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For mild external otitis, we use a topical preparation such as VoSol HC, which has an acidifying agent and a glucocorticoid. We prefer not using an antibiotic due to potential adverse effects that are not likely warranted in mild external otitis. (See",
"      <a class=\"local\" href=\"#H1295111\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For moderate and severe disease, we use ototopical medication that is acidic and contains an antibiotic, an antiseptic, and a glucocorticoid. The antibiotic should have good coverage against S. aureus and P. aeruginosa (",
"      <a class=\"graphic graphic_table graphicRef54268 graphicRef70073 \" href=\"UTD.htm?13/13/13535\">",
"       table 2A-B",
"      </a>",
"      ). There should be limited risk of an allergic reaction. Cipro HC and Cortisporin are good first-line agents (",
"      <a class=\"graphic graphic_table graphicRef67418 \" href=\"UTD.htm?8/45/8925\">",
"       table 1",
"      </a>",
"      ). Cipro HC is associated with fewer side effects than Corticosporin but Cipro HC is more costly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral antibiotics should be used for patients with evidence of deeper tissue infection (outside of the external auditory canal). (See",
"    <a class=\"local\" href=\"#H13312448\">",
"     'Oral antibiotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312441\">",
"    <span class=\"h3\">",
"     Installation and duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper installation of ear drops entails tilting the head toward the opposite shoulder, pulling the superior aspect of the auricle upward, and filling the ear canal with drops. Patients should lie on their side for 20 minutes or place a cotton ball in the ear canal for 20 minute to maximize medicine exposure.",
"   </p>",
"   <p>",
"    Most topical preparations should be given three to four times daily. Topical fluoroquinolones can be given two times daily.",
"   </p>",
"   <p>",
"    A common cause of failure for topical treatment is underdosing. Patients should be sure that sufficient medication is placed to adequately coat the entirety of the ear canal.",
"   </p>",
"   <p>",
"    It is reasonable to prescribe an initial seven day course of topical medication with instructions to continue up to a total of two weeks for unresolved symptoms. Patients with symptoms persisting beyond two weeks should be re-evaluated for treatment failure. (See",
"    <a class=\"local\" href=\"#H13312469\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H279471\">",
"    <span class=\"h4\">",
"     Wick placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct application of topical agents to the infected site is a key element in the treatment of external otitis, regardless of severity. Patients with severe disease (completely occluded canal) should also have a wick placed. Wicks are commercially available and are made of compressed cotton. They expand as the ototopical medicine is applied. The wick allows topical medications to reach the medial aspect of the ear canal; they also facilitate longer retention of topical solutions in the affected areas. Wicks should be replaced every one to three days if significant swelling persists. Wicks can be removed once ear canal swelling subsides. Wick placement usually requires referral to an otolaryngologist, but can also be performed by the primary care clinician who has previous experience with wick placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312448\">",
"    <span class=\"h2\">",
"     Oral antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials directly comparing oral antibiotic therapy and topical antibiotic therapy. However, the addition of an oral antibiotic to topical antibiotic therapy does not appear to enhance treatment in uncomplicated external otitis. One randomized trial in Australia of patient with mostly mild to moderate infection found no difference in clinical response score comparing a topical ointment (containing an antifungal, a glucocorticoid, and two antibiotics) plus oral placebo with the same topical ointment plus oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/12\">",
"     12",
"    </a>",
"    ]. These patients were seen in general practice and comprised mostly of mild to moderate cases of external otitis. In comparison to topical therapy, systemic antibiotics may increase rates of infection resistance and recurrence, possibly due to lower antimicrobial concentrations at the site of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic antibiotics, in addition to topical antibiotics, are indicated with deeper tissue infection due to lack of adequate penetration with topical therapy. Combined systemic and topical antibiotics are also indicated in patients who are immunosuppressed (ie, post-transplant, receiving chemotherapy or radiation therapy). Patients with deeper tissue infection and with immunosuppression may be at risk for malignant external otitis and should be referred to an otolaryngologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20216?source=see_link\">",
"     \"Malignant (necrotizing) external otitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When systemic antibiotics are necessary, we recommend a quinolone antibiotic, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    , for coverage of P. aeruginosa and S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/14\">",
"     14",
"    </a>",
"    ]. Strains of community-acquired methicillin resistant S. aureus continue to emerge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/15\">",
"     15",
"    </a>",
"    ] and should be taken into account in patients who fail to respond. Ciprofloxacin can be given at a dose of 500 mg twice daily for 7 to 10 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312455\">",
"    <span class=\"h1\">",
"     PAIN CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain from external otitis can be variable. Most patients with mild to moderate levels of ear pain will have prompt relief from topical therapy. Those with severe pain will generally respond to oral nonsteroidal anti-inflammatory agents (NSAIDs) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , which can be started at the initial visit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Some patients with severe, persistent pain will require opioid analgesics. Care should be exercised to ensure that pain medications are not masking an inadequately-treated case.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312462\">",
"    <span class=\"h1\">",
"     AVOIDING PROMOTING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education regarding proper ear hygiene cannot be overemphasized. The adage \"don't put anything smaller than your elbow in your ear\" to clean the ear canal is valuable advice. Patients should be told that the ear canal is self-cleaning and should not be cleaned with fingers, towels, cotton swabs, or other foreign objects.",
"   </p>",
"   <p>",
"    The ear should be protected from water during recovery from external otitis. This can be accomplished by placing a cotton ball coated with petroleum jelly in the ear canal while bathing. Patients with active external otitis should not swim. Ideally, patients should refrain from water sports for 7 to 10 days. Competitive swimmers may consider return at two to three days if pain has resolved and they wear well-fitted ear plugs. Hearing aids and ear phones should not be worn until pain and discharge have subsided.",
"   </p>",
"   <p>",
"    Prevention should be considered in patients with recurrent external otitis, particularly swimmers, immunocompromised hosts, and patients with a systemic dermatologic condition affecting the ear. Specific preventive measures for those who engage in water sports include use of ear plugs, shaking the ear dry after swimming, and blow drying the ear after water exposure (placing the blow dryer on a low setting 12 inches away from the ears) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/16\">",
"     16",
"    </a>",
"    ]. Drops containing alcohol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    help to dry the ear, prevent skin maceration, and re-acidify the ear canal, but it is unclear if any type of treatment prevents recurrence of external otitis. Hearing aids should be removed nightly and regularly cleaned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13312469\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timeframe for follow-up depends on the severity of external otitis. Patients with mild external otitis can be told to return if symptoms persist or worsen. For patients with moderate disease, follow-up is recommended at one to two weeks. Patients may need to be followed sooner for severe disease.",
"   </p>",
"   <p>",
"    Patients will generally experience some symptom improvement within 36 to 48 hours after treatment is initiated, with full symptom resolution by about six days [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who do not respond to treatment within three days, culture of the ear canal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    referral to an otolaryngologist should be considered. The patient should be questioned regarding compliance, especially water precautions and avoidance of ear manipulation. Patients who do not respond to initial treatment should also be evaluated for other conditions that may mimic, complicate, or underlie external otitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H20#H20\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H569884709\">",
"    <span class=\"h1\">",
"     TREATMENT OF ASSOCIATED CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of other conditions that present similarly to or complicate bacterial external otitis varies based on the underlying etiology. These conditions should be suspect in patients who fail to respond to initial therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H20#H20\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H569884918\">",
"    <span class=\"h2\">",
"     Otomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otomycosis is a fungal infection of the external auditory canal (",
"    <a class=\"graphic graphic_picture graphicRef83226 \" href=\"UTD.htm?13/26/13732\">",
"     picture 1",
"    </a>",
"    ). Otomycosis can occur as the primary infection or can develop along with bacterial external otitis, usually as a result of antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H21#H21\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Otomycosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mainstay of therapy for otomycosis is meticulous cleaning of the ear canal and topical antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/17\">",
"     17",
"    </a>",
"    ]. All debris and visible fungal elements must be removed by the clinician. This should be done under direct vision with a cerumen loop or cotton swab. Binocular magnified vision facilitates removal of debris that is often focused in the medial aspect of the ear canal, coating the tympanic membrane.",
"   </p>",
"   <p>",
"    Several ototopical medications are used adjunctively to treat otomycosis, including antifungals, antiseptics, acidifying solutions, glucocorticoids, and drying agents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/17\">",
"     17",
"    </a>",
"    ]. Topical antifungals are considered first-line pharmacologic treatment (",
"    <a class=\"graphic graphic_table graphicRef75986 \" href=\"UTD.htm?1/34/1581\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/18\">",
"     18",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     Clotrimazole",
"    </a>",
"    has the greatest zone of inhibition for common fungi. Clotrimazole and miconazole also have antibacterial effects against S. aureus but not P. aeruginosa. Some antifungals are available in liquid form, others only as a cream or ointment that is either injected into the ear canal or swabbed in the lateral ear canal and allowed to melt down in the ear canal. We use clotrimazole 1% solution, applied twice daily for 10 to 14 days, and then reassess the ear canal. If fungal elements are identified, the ear canal should again be meticulously cleaned and undergo a further 10 to 14 day course of topical antifungal with reassessment thereafter. Persistent otomycosis should be managed by an otolaryngologist to ensure optimal cleaning of the external canal (usually with microscopic otoscopy). Ear cleaning followed by topical therapy and reassessment in two weeks may be required for several cycles to achieve eradication.",
"   </p>",
"   <p>",
"    Antiseptics such as Cresylate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/5/41042?source=see_link\">",
"     gentian violet",
"    </a>",
"    have been effectively applied by otolaryngologists for resistant cases as a single treatment following ear cleaning (",
"    <a class=\"graphic graphic_table graphicRef80231 \" href=\"UTD.htm?29/16/29963\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/19\">",
"     19",
"    </a>",
"    ]. Cresylate and gentian violet demonstrate strong activity in vitro against all fungi and most bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12456/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral antifungals may be used in refractory cases. Intravenous antifungals are reserved for patients suspected of having invasive otomycosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H569884925\">",
"    <span class=\"h2\">",
"     Contact dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact dermatitis in the external auditory canal can be caused by ototopical medication, cosmetics, or shampoos and thus can mimic or complicate treatment for external otitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H24#H24\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Contact dermatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial treatment of contact dermatitis involves eliminating the causative agent. The ear should be thoroughly cleaned. Acidic solutions such as Domeboro help re-acidify the ear canal, dry weeping lesions, and debride crust. Topical glucocorticoids can be used in combination to control the inflammatory response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63949079\">",
"    <span class=\"h2\">",
"     Carcinoma of the ear canal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the aggressive nature of cancer of the ear canal, management generally combines surgery and radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63949169\">",
"    <span class=\"h2\">",
"     Periauricular cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periauricular cellulitis without evidence of deep tissue infection is generally treated with oral antibiotics (",
"    <a class=\"graphic graphic_table graphicRef64128 \" href=\"UTD.htm?23/12/23756\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link&amp;anchor=H6#H6\">",
"     \"Cellulitis and erysipelas\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63949176\">",
"    <span class=\"h2\">",
"     Malignant external otitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant (necrotizing) external otitis is a severe, potentially fatal complication of acute bacterial external otitis when the infection spreads from the skin to the skull base (soft tissue, cartilage, and bone of the temporal region). Patients with malignant external otitis should be promptly started on antipseudomonal antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    750 mg orally twice daily) and referred to an otolaryngologist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20216?source=see_link&amp;anchor=H13#H13\">",
"     \"Malignant (necrotizing) external otitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/2/15394?source=see_link\">",
"       \"Patient information: Outer ear infection (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/57/10130?source=see_link\">",
"       \"Patient information: Removing objects stuck in the ear (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26816?source=see_link\">",
"       \"Patient information: External otitis (including swimmer's ear) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158769004\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are five fundamental steps in the management of external otitis (see",
"      <a class=\"local\" href=\"#H13312371\">",
"       'Introduction'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thoroughly clean the ear canal",
"     </li>",
"     <li>",
"      Treat inflammation and infection",
"     </li>",
"     <li>",
"      Control pain",
"     </li>",
"     <li>",
"      Avoid promoting factors",
"     </li>",
"     <li>",
"      Follow-up and culture of recalcitrant cases (as well as consider alternative diagnoses)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cleaning out the external canal is an essential first step in treatment. The removal of cerumen, desquamated skin, and purulent material from the ear canal greatly facilitates healing and enhances penetration of ear drops into the site of inflammation. (See",
"      <a class=\"local\" href=\"#H13312378\">",
"       'Cleaning the ear canal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For immunocompetent patients with external otitis who do not have infection of soft tissues outside the external auditory canal, we recommend topical therapy rather than oral therapy for initial treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Many topical preparations are available alone or in combination, which include antibiotics, antiseptics, glucocorticoids,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acidifying solutions (",
"      <a class=\"graphic graphic_table graphicRef67418 \" href=\"UTD.htm?8/45/8925\">",
"       table 1",
"      </a>",
"      ). The choice of topical therapy depends on the severity of external otitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H277540#H277540\">",
"       \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Clinical features'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mild disease is characterized by minor discomfort and pruritus (",
"      <a class=\"graphic graphic_picture graphicRef83227 \" href=\"UTD.htm?19/55/20337\">",
"       picture 2",
"      </a>",
"      ). There is minimal canal edema.",
"     </li>",
"     <li>",
"      Moderate disease is characterized by an intermediate degree of pain and pruritus. The canal is partially occluded (",
"      <a class=\"graphic graphic_picture graphicRef83228 \" href=\"UTD.htm?0/21/337\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Severe disease is characterized by intense pain, and the canal is completely occluded from edema. There is usually periauricular erythema, lymphadenopathy, and fever (",
"      <a class=\"graphic graphic_picture graphicRef55712 \" href=\"UTD.htm?43/29/44511\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with mild disease, we suggest a non-antibiotic topical preparation containing an acidifying agent and a glucocorticoid (eg,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"        acetic acid",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"        hydrocortisone",
"       </a>",
"       )",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with moderate and severe disease, we suggest an ototopical medication that is acidic and contains an antibiotic, an antiseptic, and a glucocorticoid (eg, Cipro HC, Cortisporin) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13312434\">",
"       'Choice of topical agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe external otitis will need placement of a wick, which allows topical medications to reach the medial aspect of the ear canal; they also facilitate longer retention of topical solutions in the affected areas. (See",
"      <a class=\"local\" href=\"#H279471\">",
"       'Wick placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest systemic, in addition to topical, antibiotics for patients with deeper tissue infection beyond the external auditory canal (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Combined systemic and topical antibiotics are also indicated in patients who are immunosuppressed (ie, post-transplant, receiving chemotherapy or radiation therapy). Antibiotic coverage should include the most common pathogens, P. aeruginosa and S. aureus. Quinolones (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"       ofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ) are a good first-line option that are effective and have few side effects. Patients with evidence of infection outside of the auditory canal may be at risk for malignant external otitis and should be referred to an otolaryngologist for further evaluation. (See",
"      <a class=\"local\" href=\"#H13312448\">",
"       'Oral antibiotics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20216?source=see_link\">",
"       \"Malignant (necrotizing) external otitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with severe ear pain can also be treated with oral nonsteroidal anti-inflammatory agents. Some patients with persistent, severe pain may require opioid analgesics. (See",
"      <a class=\"local\" href=\"#H13312455\">",
"       'Pain control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ear should be protected from water during recovery from external otitis. This can be accomplished by placing a cotton ball coated with petroleum jelly in the ear canal while bathing. Specific preventive measures for those who engage in water sports include use of ear plugs, shaking the ear dry after swimming, and blow drying the ear after water exposure (placing the blow dryer on a low setting 12 inches away from the ears). (See",
"      <a class=\"local\" href=\"#H13312462\">",
"       'Avoiding promoting factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients will generally experience some symptom improvement within 36 to 48 hours after treatment is initiated, with full symptom resolution by about six days. In patients who do not respond to treatment within three days, culture of the ear canal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      referral to an otolaryngologist should be considered. Patients who do not respond to initial treatment should also be evaluated for other conditions that may mimic or complicate external otitis. (See",
"      <a class=\"local\" href=\"#H13312469\">",
"       'Follow-up'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H20#H20\">",
"       \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/1\">",
"      Kaushik V, Malik T, Saeed SR. Interventions for acute otitis externa. Cochrane Database Syst Rev 2010; :CD004740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/2\">",
"      Rosenfeld RM, Singer M, Wasserman JM, Stinnett SS. Systematic review of topical antimicrobial therapy for acute otitis externa. Otolaryngol Head Neck Surg 2006; 134:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/3\">",
"      Rosenfeld RM, Brown L, Cannon CR, et al. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg 2006; 134:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/4\">",
"      Jones RN, Milazzo J, Seidlin M. Ofloxacin otic solution for treatment of otitis externa in children and adults. Arch Otolaryngol Head Neck Surg 1997; 123:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/5\">",
"      Schwartz RH. Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa. Curr Med Res Opin 2006; 22:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/6\">",
"      Roland PS, Younis R, Wall GM. A comparison of ciprofloxacin/dexamethasone with neomycin/polymyxin/hydrocortisone for otitis externa pain. Adv Ther 2007; 24:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/7\">",
"      Roland PS, Stewart MG, Hannley M, et al. Consensus panel on role of potentially ototoxic antibiotics for topical middle ear use: Introduction, methodology, and recommendations. Otolaryngol Head Neck Surg 2004; 130:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/8\">",
"      Van Ginkel CJ, Bruintjes TD, Huizing EH. Allergy due to topical medications in chronic otitis externa and chronic otitis media. Clin Otolaryngol Allied Sci 1995; 20:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/9\">",
"      Dohar JE, Kenna MA, Wadowsky RM. In vitro susceptibility of aural isolates of Pseudomonas aeruginosa to commonly used ototopical antibiotics. Am J Otol 1996; 17:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/10\">",
"      Kim JK, Cho JH. Change of external auditory canal pH in acute otitis externa. Ann Otol Rhinol Laryngol 2009; 118:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/11\">",
"      van Balen FA, Smit WM, Zuithoff NP, Verheij TJ. Clinical efficacy of three common treatments in acute otitis externa in primary care: randomised controlled trial. BMJ 2003; 327:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/12\">",
"      Yelland MJ. The efficacy of oral cotrimoxazole in the treatment of otitis externa in general practice. Med J Aust 1993; 158:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/13\">",
"      Rowlands S, Devalia H, Smith C, et al. Otitis externa in UK general practice: a survey using the UK General Practice Research Database. Br J Gen Pract 2001; 51:533.",
"     </a>",
"    </li>",
"    <li>",
"     Santos F, Selesnick SH, Gurnstein E. Diseases of the External Ear. In: Current Diagnosis and Treatment in Otolaryngology: Head and Neck Surgery, Lalwani AK (Ed), Lange Medical Books/McGraw-Hill, New York 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/15\">",
"      Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/16\">",
"      Osguthorpe JD, Nielsen DR. Otitis externa: Review and clinical update. Am Fam Physician 2006; 74:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/17\">",
"      Vennewald I, Klemm E. Otomycosis: Diagnosis and treatment. Clin Dermatol 2010; 28:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/18\">",
"      Munguia R, Daniel SJ. Ototopical antifungals and otomycosis: a review. Int J Pediatr Otorhinolaryngol 2008; 72:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/19\">",
"      Lawrence TL, Ayers LW, Saunders WH. Drug therapy in otomycosis: an in vitro study. Laryngoscope 1978; 88:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12456/abstract/20\">",
"      Stern JC, Shah MK, Lucente FE. In vitro effectiveness of 13 agents in otomycosis and review of the literature. Laryngoscope 1988; 98:1173.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16516 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-23D1513A50-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12456=[""].join("\n");
var outline_f12_10_12456=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H158769004\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13312371\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13312378\">",
"      CLEANING THE EAR CANAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13312385\">",
"      TREATMENT OF INFLAMMATION AND INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H279397\">",
"      Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13312392\">",
"      - Topical preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1295111\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13312406\">",
"      Antiseptics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13312413\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13312420\">",
"      Acidifying solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13312427\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13312434\">",
"      - Choice of topical agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13312441\">",
"      - Installation and duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H279471\">",
"      Wick placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13312448\">",
"      Oral antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13312455\">",
"      PAIN CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13312462\">",
"      AVOIDING PROMOTING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13312469\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H569884709\">",
"      TREATMENT OF ASSOCIATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H569884918\">",
"      Otomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H569884925\">",
"      Contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63949079\">",
"      Carcinoma of the ear canal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63949169\">",
"      Periauricular cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63949176\">",
"      Malignant external otitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H158769004\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16516\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16516|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/26/13732\" title=\"picture 1\">",
"      Fungal OE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/55/20337\" title=\"picture 2\">",
"      Mild OE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/21/337\" title=\"picture 3\">",
"      Moderate OE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/29/44511\" title=\"picture 4\">",
"      Severe otitis externa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16516|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/45/8925\" title=\"table 1\">",
"      Common drugs for external otitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/18/41261\" title=\"table 2A\">",
"      Antimicrob activity abx A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/28/2510\" title=\"table 2B\">",
"      Antimicrob activity abx B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/34/1581\" title=\"table 3\">",
"      Efficacy antifungal agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/16/29963\" title=\"table 4\">",
"      Antimicrobactivity antiseptics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/12/23756\" title=\"table 5\">",
"      Empiric antibiotics cellulitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=related_link\">",
"      Acute otitis media in adults (suppurative and serous)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5593?source=related_link\">",
"      Evaluation and management of middle ear trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13050?source=related_link\">",
"      Evaluation of earache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=related_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20216?source=related_link\">",
"      Malignant (necrotizing) external otitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/12/26816?source=related_link\">",
"      Patient information: External otitis (including swimmer's ear) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/2/15394?source=related_link\">",
"      Patient information: Outer ear infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/57/10130?source=related_link\">",
"      Patient information: Removing objects stuck in the ear (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_10_12457="Treatment of extranodal NK/T cell lymphoma, nasal type";
var content_f12_10_12457=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of extranodal NK/T cell lymphoma, nasal type",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12457/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12457/contributors\">",
"     Kensei Tobinai, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12457/contributors\">",
"     Motoko Yamaguchi, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12457/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12457/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12457/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12457/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/10/12457/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H62375632\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive lymphoid neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas (NHLs) in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among these, in decreasing frequency of occurrence, are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral T cell lymphoma, not otherwise specified (NOS)",
"     </li>",
"     <li>",
"      Anaplastic large cell lymphoma, primary systemic type",
"     </li>",
"     <li>",
"      Angioimmunoblastic T cell lymphoma",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type",
"     </li>",
"     <li>",
"      Subcutaneous panniculitis-like T cell lymphoma",
"     </li>",
"     <li>",
"      Enteropathy associated T cell lymphoma",
"     </li>",
"     <li>",
"      Hepatosplenic T cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extranodal natural",
"    <span class=\"nowrap\">",
"     killer/T",
"    </span>",
"    cell lymphoma, nasal type (formerly called angiocentric lymphoma), is the most common cause of the syndrome known as \"lethal midline granuloma.\" It is an extranodal lymphoma, usually with a natural killer (NK) cell phenotype and positivity for Epstein-Barr virus (EBV), with a broad morphologic spectrum, frequent necrosis, and angioinvasion. It is designated",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    because of uncertainty regarding its cellular lineage. Gene rearrangement studies support a natural killer cell origin in most cases, but a small minority has clonal T cell receptor gene rearrangements and appears to be derived from cytotoxic T cells.",
"   </p>",
"   <p>",
"    The treatment of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type will be discussed here. The clinical presentation, pathologic features, and diagnosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62376231\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of patients with NHL must establish the precise histologic subtype, the extent and sites of disease (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ), and the performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 graphicRef72901 \" href=\"UTD.htm?43/16/44300\">",
"     table 2A-B",
"    </a>",
"    ) of the patient. General approaches to the diagnostic work-up and staging of NHL are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis has been definitively established, the pretreatment evaluation determines both the bulk of disease and the individual's comorbidities that are likely to have an impact on treatment options. In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), hepatitis B virus, HIV, and uric acid. Measurement of a pretreatment plasma EBV DNA by quantitative polymerase chain reaction, if available, helps to predict prognosis and serves as a baseline value with which to compare during response assessment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\", section on 'Prognosis'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H62376560\">",
"       'Response assessment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Unilateral bone marrow aspiration and biopsy.",
"     </li>",
"     <li>",
"      Computed tomography (CT) and magnetic resonance imaging (MRI) are both typically performed and are complementary in evaluating disease extent and in distinguishing tumor from infection, retained secretions, and granulation of scar tissue. Due to the nature of tumor occurring in the nasal structures, CT offers superior bony definition and MRI gives superior soft tissue delineation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/8\">",
"       8",
"      </a>",
"      ]. As such, we perform CT and MRI of the head plus a CT of the neck, chest, abdomen and pelvis. These studies provide critical information on the measurement of disease prior to treatment and aids in staging [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/9\">",
"       9",
"      </a>",
"      ]. Most cases are FDG-avid [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/10\">",
"       10",
"      </a>",
"      ]. When available, we obtain a combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      scan at diagnosis to serve as a baseline for comparison after therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Routine imaging studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A pretreatment study of cardiac ejection fraction (eg, echocardiogram or MUGA) should be performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men and women of childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The speed with which induction chemotherapy and radiation should begin varies with the individual patient's condition and treatment options. Occasionally, it is more important to stabilize a patient's condition and correct or control co-morbidities, such as infection and bleeding, than it is to immediately start radiotherapy or chemotherapy. This interval of several days also allows for complete staging and pretreatment evaluation where the results will have an impact on the choice of treatment. However, treatment must be started as soon as possible for patients with a rapidly deteriorating clinical status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62377097\">",
"    <span class=\"h1\">",
"     INDUCTION THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194235122\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type is largely determined by the extent of disease. This approach is largely consistent with that described by the National Comprehensive Cancer Network (NCCN) and the British Committee for Standards in Hematology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Once the diagnosis of extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type has been established, subsequent therapy and prognosis are based upon the stage of the disease, as defined by a modified Ann Arbor staging system (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"     table 3",
"    </a>",
"    ) as follows: &nbsp;",
"   </p>",
"   <p>",
"    Localized disease includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I(E) &mdash; Single extranodal involvement (usually of the upper aerodigestive tract) with or without contiguous involvement extending to adjacent structures (eg, tumor with an extension to the nasal cavity, the maxillary antra, anterior or posterior ethmoid sinus, sphenoidal sinus, orbit, superior alveolar bone, cheeks, superior buccinator space, or hard palate).",
"     </li>",
"     <li>",
"      Stage II(E) &mdash; Stage I(E) disease (usually of the upper aerodigestive tract)",
"      <strong>",
"       plus",
"      </strong>",
"      one or more of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cervical lymph node involvement (contiguous stage IIE)",
"     </li>",
"     <li>",
"      Involvement of other supradiaphragmatic lymph node regions",
"     </li>",
"     <li>",
"      Isolated involvement of additional sites in the head and neck (eg, Waldeyer&rsquo;s ring, oropharynx, hypopharynx, etc.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advanced disease includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage III(E) (rare) &mdash; Stage I(E) disease (usually of the upper aerodigestive tract)",
"      <strong>",
"       with",
"      </strong>",
"      cervical lymph node involvement",
"      <strong>",
"       plus",
"      </strong>",
"      infradiaphragmatic lymph node involvement",
"      <span class=\"nowrap\">",
"       <strong>",
"        and/or",
"       </strong>",
"      </span>",
"      involvement of the spleen",
"     </li>",
"     <li>",
"      Stage IV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stage I(E) disease (usually of the upper aerodigestive tract)",
"      <strong>",
"       plus",
"      </strong>",
"      isolated distant involvement",
"     </li>",
"     <li>",
"      Any involvement of the liver or bone marrow",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More than two-thirds of patients with extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type occurring outside the upper aerodigestive tract have advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 70 to 80 percent of patients present with localized disease that initially responds well to radiation with or without chemotherapy (",
"    <a class=\"graphic graphic_figure graphicRef78792 \" href=\"UTD.htm?27/34/28205\">",
"     figure 1",
"    </a>",
"    ). Such patients have a median overall survival of three to five years. In comparison, patients with advanced disease at the time of diagnosis respond poorly to chemotherapy and have demonstrated a median survival with conventional chemotherapy of approximately four months.",
"   </p>",
"   <p>",
"    Of importance, a small percentage of cases are associated with EBV-related hemophagocytic syndrome, an often fatal complication, which may present with high fevers, maculopapular rash, failure to thrive, central nervous system symptoms, hepatosplenomegaly, lymphadenopathy, cytopenias, coagulopathy, abnormal liver function tests, or extremely high serum ferritin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Patients with this complication are typically treated urgently with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus glucocorticoids followed by combination chemotherapy plus glucocorticoids with or without radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62375639\">",
"    <span class=\"h2\">",
"     Localized disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with localized (stage I or II) extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type are treated with radiation therapy (RT) with or without consolidation chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Three-dimensional conformal radiation planning using computed tomography is recommended. The radiation field should encompass the entire nasal cavity, the nasopharynx, and the gross tumor volume with a sufficient margin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/16\">",
"     16",
"    </a>",
"    ]. Preferably,&nbsp;radiation should be given",
"    <strong>",
"     concurrently",
"    </strong>",
"    with&nbsp;chemotherapy, but if the patient's performance status and comorbidities do not allow concurrent therapy, radiation should be administered",
"    <strong>",
"     prior",
"    </strong>",
"    to chemotherapy. Patients with stage I or contiguous stage IIE disease are good candidates for concurrent chemotherapy plus radiotherapy to increase the antitumor efficacy.",
"   </p>",
"   <p>",
"    Studies that have evaluated RT and chemotherapy have been limited to retrospective analyses and single arm prospective trials. Data from these studies have demonstrated superior outcomes for patients whose therapy included RT, and suggested a benefit from the use of adjuvant combination chemotherapy after RT. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An international retrospective analysis of 136 patients with extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma treated with varying protocols largely consisting of anthracycline-based chemotherapy plus RT reported a median overall survival (OS) of approximately three years for patients with limited stage disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/13\">",
"       13",
"      </a>",
"      ]. When compared with those who received chemotherapy alone, patients with localized disease who received chemotherapy plus RT had a significantly longer median OS with 57 percent of patients alive at three years.",
"     </li>",
"     <li>",
"      Other retrospective analyses investigating RT with or without chemotherapy have had mixed results. Some demonstrate a small survival benefit with the addition of chemotherapy, while others do not [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]. However, all of these studies have demonstrated that, when compared with those receiving initial chemotherapy followed by RT, patients receiving initial treatment with RT have superior complete response rates and OS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been no randomized trials comparing treatment regimens for extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type. Data regarding the choice of combination chemotherapy regimen to add to RT come from small prospective trials. Acceptable treatment regimens include DeVIC (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ) alone and the combination of weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    followed by VIPD (etoposide, ifosfamide, cisplatin, and dexamethasone). In contrast, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (CHOP) used for other lymphomas is not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/20-24\">",
"     20-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial of concurrent localized RT (50 Gy, 2 cm to the gross tumor volume and the entire nasal cavity and nasopharynx) and three courses of DeVIC in 33 patients with newly diagnosed stage IE or contiguous IIE disease established a decreased (two-thirds) dose of DeVIC as the recommended dose [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/23\">",
"       23",
"      </a>",
"      ]. In this study, 27 patients treated with two-thirds dose DeVIC showed an overall response rate of 81 percent (77 percent complete) with a two-year overall survival rate of 78 percent. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      nonhematologic toxicity was radiation induced mucositis (30 percent). No treatment-related death was observed. A subsequent analysis with a median follow-up of 67 months reported progression-free and overall survival rates at five years of 63 and 70 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/25\">",
"       25",
"      </a>",
"      ]. Two patients recurred within the radiation field. Late toxicities were generally mild to moderate (grade",
"      <span class=\"nowrap\">",
"       1/2)",
"      </span>",
"      and localized to the mucous membranes and skin of the head and neck, salivary glands, and eye. &nbsp;",
"     </li>",
"     <li>",
"      A phase II trial of concurrent RT (median dose, 40 Gy; range, 40 to 52.8 Gy) and weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      followed by three cycles of VIPD chemotherapy in 30 patients with newly diagnosed stage IE to IIE disease demonstrated an overall response rate of 83 percent and estimated rates of three-year progression-free survival and overall survival of 85 and 86 percent, respectively. Two treatment-related deaths due to infection were observed during VIPD chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data regarding the ideal radiation dose are limited. A choice of radiation dose must balance efficacy with toxicity. Retrospective analyses have reported improved local control with radiation doses 50 Gy or more in cases of radiation therapy alone. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of 82 patients with localized extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type included 74 patients who received RT alone or in combination with chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/18\">",
"       18",
"      </a>",
"      ]. When compared with those who received less RT, patients receiving at least 54 Gy of RT had superior OS (75 versus 46 percent) and disease-free survival (60 versus 33 percent) at five years.",
"     </li>",
"     <li>",
"      A retrospective analysis that included 26 patients with extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type treated with RT with or without combination chemotherapy reported superior control of non-bulky disease among patients who received at least 54 Gy of RT [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/26\">",
"       26",
"      </a>",
"      ]. Local disease control was reported in all six patients treated with more than 54 Gy, but only three of the nine patients treated with 52 Gy or less.",
"     </li>",
"     <li>",
"      In a retrospective study of 35 patients with localized extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type treated with RT alone or RT followed by chemotherapy, the median radiation dose was 50 Gy (range, 22 to 60 Gy) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/17\">",
"       17",
"      </a>",
"      ]. At a median follow-up of 11.1 years, the local control rate at five years was significantly higher in patients who received extended-field RT than in those who received RT with small margin (72 versus 42 percent).",
"     </li>",
"     <li>",
"      In another study, 42 patients with localized extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type were treated with intensity-modulated RT (median radiation to primary tumor 50 Gy) with or without CHOP-like combination chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/27\">",
"       27",
"      </a>",
"      ]. At a median follow-up of 27 months, the estimated rate of locoregional control was 93 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with localized extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type, we suggest combined modality therapy. Preferably,&nbsp;radiation should be given",
"    <strong>",
"     concurrently",
"    </strong>",
"    with&nbsp;chemotherapy, but if the patient's performance status and comorbidities do not allow concurrent therapy, radiation should be administered prior to chemotherapy. We generally administer a radiation dose of 50 Gy and concurrent therapy with two-thirds dose DeVIC alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/23\">",
"     23",
"    </a>",
"    ] or RT of 40 Gy with weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    followed by VIPD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/24\">",
"     24",
"    </a>",
"    ]. Central nervous system prophylaxis should be considered for a subset of patients as described in more detail below. (See",
"    <a class=\"local\" href=\"#H197739\">",
"     'Central nervous system prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62375646\">",
"    <span class=\"h2\">",
"     Disseminated disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best treatment option for patients with disseminated (stage III or IV) extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type is unknown, and patients should be encouraged to participate in clinical trials whenever possible. Extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type occurring outside the upper aerodigestive tract should usually be treated as disseminated disease. Outside of a clinical trial, there are limited treatment options for patients with disseminated (stage III or IV) extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type. Only approximately 30 percent of such patients will achieve a complete remission with anthracycline-based chemotherapy, and the median survival with chemotherapy is approximately 4.3 months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/13\">",
"     13",
"    </a>",
"    ]. Several regimens incorporating L-asparaginase as salvage therapy have shown promising results [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Confirmatory trials are ongoing.",
"   </p>",
"   <p>",
"    The following studies have evaluated the use of L-asparaginase-based chemotherapy regimens in extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma in newly diagnosed disseminated disease or",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    cases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase I study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , L-asparaginase, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (SMILE) in six patients with disseminated extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma reported an overall response rate of 67 percent with 50 percent complete responses [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/30\">",
"       30",
"      </a>",
"      ]. Hematologic toxicity was significant and the protocol was revised to require prophylactic G-CSF after dose limiting toxicities were seen in the first three patients, including one death from sepsis in the setting of grade 4 neutropenia.",
"     </li>",
"     <li>",
"      A subsequent phase II study of SMILE in 38 patients, including 20 patients (53 percent) with newly-diagnosed stage IV disease, reported an overall response rate of 79 percent (45 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/31\">",
"       31",
"      </a>",
"      ]. Despite the mandated use of prophylactic G-CSF and suggested use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , all patients experienced severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia and the most common nonhematologic severe toxicity was infection (61 percent). At a median follow-up of 24 months, progression-free and overall survival rates at one year were 53 and 55 percent, respectively. Patients who proceeded with autologous hematopoietic cell transplantation had a trend towards increased survival that did not reach statistical significance.",
"     </li>",
"     <li>",
"      A retrospective analysis of 87 patients with newly diagnosed or",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma treated with up to six courses of SMILE (median three courses) reported toxicities including severe neutropenia in the majority of patients with five sepsis-related deaths; severe thrombocytopenia; and nephrotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/32\">",
"       32",
"      </a>",
"      ]. The disease was localized (stage",
"      <span class=\"nowrap\">",
"       I/II)",
"      </span>",
"      in 44 percent. The overall response rate was 81 percent (66 percent complete) and was similar for newly diagnosed and",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      disease. At a median follow-up of 31 months, estimated rates of overall and disease-free survival at five years were 50 and 64 percent, respectively. &nbsp;",
"     </li>",
"     <li>",
"      A retrospective analysis of 45 patients with relapsed (four patients) or refractory disease after initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (CHOP) chemotherapy treated with a combination of L-asparaginase, vincristine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (LVD) plus radiation therapy (if not previously given) reported a complete response rate of 56 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/28\">",
"       28",
"      </a>",
"      ]. At a median follow-up of 35 months, the three-year survival rate was 67 percent and there appeared to be a plateau after 16 months. Major toxicities included myelosuppression, liver dysfunction, hyperglycemia, and allergic reaction.",
"     </li>",
"     <li>",
"      A retrospective analysis of 15 patients with relapsed, refractory, or disseminated extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type treated with L-asparaginase-containing chemotherapy regimens reported an overall response rate of 87 percent (47 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multicenter phase II study of L-asparaginase,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (AspaMetDex) in 19 patients with relapsed or refractory extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type reported an overall response rate of 78 percent (61 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/34\">",
"       34",
"      </a>",
"      ]. At a median follow-up of 26 months, the median survival was one year, with a median duration of response of 12 months. The main toxicities were hepatitis, cytopenia, and allergy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with disseminated extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type not enrolled in a clinical trial, we suggest the use of a combination chemotherapy regimen incorporating L-asparaginase (eg, SMILE) rather than CHOP chemotherapy. Patients older than 69 years or those with low lymphocyte count (less than",
"    <span class=\"nowrap\">",
"     500/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    or severe organ dysfunction (eg, grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    cytopenias, liver or kidney dysfunction) will likely not tolerate SMILE [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/31\">",
"     31",
"    </a>",
"    ] and may be considered for a less intensive regimen, such as dose-reduced DeVIC. The role and timing of allogeneic and autologous hematopoietic cell transplantation remains to be defined but should be strongly considered in patients with disseminated disease that is responsive to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/35\">",
"     35",
"    </a>",
"    ]. Central nervous system prophylaxis may be considered for a subset of patients. (See",
"    <a class=\"local\" href=\"#H197739\">",
"     'Central nervous system prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197739\">",
"    <span class=\"h2\">",
"     Central nervous system prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing central nervous system (CNS) involvement may vary, at least in part, depending upon clinical factors at the time of diagnosis. To prevent the direct invasion of the brain, a sufficient margin of radiation therapy field to the side of the CNS should be established. One report suggested that the need for CNS prophylaxis is largely determined by the",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma prognostic index (NKPI) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The NKPI stratifies patients by four features (",
"    <a class=\"graphic graphic_table graphicRef67924 \" href=\"UTD.htm?22/12/22732\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of B symptoms",
"      <span class=\"nowrap\">",
"       (fever/chills,",
"      </span>",
"      drenching night sweats, weight loss)",
"     </li>",
"     <li>",
"      Stage III or IV disease (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Elevated lactate dehydrogenase",
"     </li>",
"     <li>",
"      Regional lymph node involvement (eg, cervical node involvement for patients with disease of the upper aerodigestive tract)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective study suggested that, without CNS prophylaxis, CNS recurrence will develop in 10 percent of patients with three or four features compared with less than 2 percent of those with one or two features [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/36\">",
"     36",
"    </a>",
"    ]. Prospective studies have not evaluated whether CNS prophylaxis can reduce the CNS recurrence rate, and the use of CNS prophylaxis is controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62377121\">",
"    <span class=\"h1\">",
"     CONSOLIDATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The poor outcomes in patients with extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type after conventional chemotherapy alone have generated interest in the use of autologous hematopoietic cell transplantation (HCT) as consolidation therapy. Although controversial, autologous or allogeneic HCT may be considered for patients in first partial response. (See",
"    <a class=\"local\" href=\"#H243760413\">",
"     'Treatment of relapsed or refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243760692\">",
"    <span class=\"h2\">",
"     Autologous hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no prospective trials evaluating the role of high dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) in patients with extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma, nasal type. Data come largely from retrospective analyses and case series that suggest better outcomes among patients who undergo autologous HCT in first complete or partial remission.",
"   </p>",
"   <p>",
"    The largest retrospective analysis compared 47 patients who underwent autologous HCT with 107 historical controls matched for NKPI and disease status at the time of HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/35\">",
"     35",
"    </a>",
"    ]. After a median follow-up of nine years, the median survival had not been reached for patients who had undergone HCT, but was 43.5 months for the historical controls. There appeared to be a survival benefit for HCT among the group as a whole. Among patients in complete remission, patients who underwent HCT had a higher disease-specific survival at five years (87 versus 68 percent). Among patients not in complete remission, there was a nonsignificant trend towards improved disease-specific survival at five years with HCT (67 versus 29 percent). Although this study was based on long-term follow-up data, no consideration was given to the heterogeneity of treatment, such as the chemotherapeutic regimen or the timing of the radiotherapy.",
"   </p>",
"   <p>",
"    Treatment-related morbidity and mortality with autologous HCT are relatively low (&le;3 percent); However, patients who undergo autologous HCT are at risk for bacterial, viral, and fungal infections, the time course of which varies in the post-transplant period, according to the degree of immune deficiency and cytopenia induced by the transplantation procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most patients who achieve a partial response after induction therapy, we suggest consolidation with an autologous HCT rather than observation. To evaluate the exact role of high dose chemotherapy followed by autologous HCT, however, prospective trials are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62376552\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62376560\">",
"    <span class=\"h2\">",
"     Response assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, flexible nasal endoscopic examination, and laboratory studies (complete blood count, lactate dehydrogenase, biochemical profile, and plasma EBV DNA by quantitative polymerase chain reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], if available). During the flexible nasal endoscopy, biopsies should be taken of any suspicious lesions and of random normal looking mucosa. The post-treatment imaging study of choice is the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, which provides information on the size and activity of residual masses and allows for the distinction between active disease and fibrosis.",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    should be obtained six to eight weeks after completion of chemotherapy and 12 weeks after the completion of radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using information gathered from the history, physical, and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, disease response is determined by the International Workshop Criteria (IWC) (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/9\">",
"     9",
"    </a>",
"    ]. A complete remission has been achieved if all of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence of disease or disease-related symptoms on history and physical examination.",
"     </li>",
"     <li>",
"      All post-treatment residual masses are negative on PET scan.",
"     </li>",
"     <li>",
"      The spleen and liver are non-palpable and without nodules.",
"     </li>",
"     <li>",
"      If a pretreatment bone marrow biopsy was positive, a repeat bone marrow biopsy must be negative. If morphologically indeterminate, immunohistochemistry should be negative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A discussion of the accuracy of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the follow-up of patients with lymphoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H17#H17\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Evaluating response to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a partial remission is obtained, further chemotherapy may be considered for patients with localized disease who are not candidates for transplantation. Otherwise, patients with a partial remission are frequently considered for autologous or allogeneic transplantation. (See",
"    <a class=\"local\" href=\"#H243760692\">",
"     'Autologous hematopoietic cell transplantation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243760434\">",
"    <span class=\"h2\">",
"     Reconstructive surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of treatment, patients should be evaluated for damage to the neighboring bony structures to assess whether reconstructive surgery is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/39\">",
"     39",
"    </a>",
"    ]. Examples of complications that may require reconstructive surgery include a collapsed orbital floor leading to visual impairment and a perforated hard palate resulting in difficulties eating. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=see_link\">",
"     \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62376567\">",
"    <span class=\"h2\">",
"     Surveillance for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach to patient surveillance is to schedule patient visits every three months during the first two years, then every six months starting two years after complete response. Starting at year five, patients are seen once per year.",
"   </p>",
"   <p>",
"    At these visits we perform a history and physical examination, complete blood count, chemistries, and LDH. Plasma EBV DNA by quantitative polymerase chain reaction may be useful. Flexible nasal endoscopic examination is recommended every six months for the first three years. We obtain an MRI and CT of the head every six months for the first three years then once a year at year four and year five. We only obtain additional",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scans to further evaluate any concerning findings noted on CT or MRI. We do not obtain routine MRI or CT scan after year five unless there are signs, symptoms, or exam findings to suggest relapse.",
"   </p>",
"   <p>",
"    Relapsed or progressive disease can present with systemic B symptoms (ie, fever, night sweats, weight loss), cytopenias, the development of an extranodal mass, or as the symptomatic or asymptomatic enlargement of the lymph nodes, liver, or spleen. By definition, relapsed or progressive disease reflects the appearance of any new lesion, a 50 percent increase in the longest diameter of a previously identified lesion, or",
"    <span class=\"nowrap\">",
"     new/recurrent",
"    </span>",
"    involvement of the bone marrow (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Relapsed disease can be suggested by changes on imaging studies but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243760413\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSED OR REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 percent of patients with localized disease and 80 percent of patients with disseminated disease will either not achieve remission or will relapse. There is a paucity of data regarding the treatment of these patients. The general approach has been to administer a second-line combination chemotherapy regimen with the hope of attaining a complete or partial remission. Patients who respond to these therapies should be offered autologous or allogeneic hematopoietic cell transplantation (HCT) given the potential for long-term disease-free survival after these procedures and the lack of long-term responders after chemotherapy alone.",
"   </p>",
"   <p>",
"    Data supporting the use of most agents are limited. Several regimens incorporating L-asparaginase as salvage therapy have shown promising results. They are described in more detail above, as is the use of autologous HCT. (See",
"    <a class=\"local\" href=\"#H62375646\">",
"     'Disseminated disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H243760692\">",
"     'Autologous hematopoietic cell transplantation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Retrospective analyses suggest that allogeneic HCT results in long-term survival in a subset of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of 12 patients with disseminated and refractory extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type treated with allogeneic HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/40\">",
"       40",
"      </a>",
"      ]: At a median follow-up of 13 months, all patients with disease progression at the time of transplant died of disease progression, whereas seven of the eight patients with a complete or partial response at the time of transplant were alive without disease recurrence.",
"     </li>",
"     <li>",
"      A case series of five patients with relapsed or refractory extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type who underwent L-asparaginase-based combination chemotherapy followed by myeloablative allogeneic HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12457/abstract/41\">",
"       41",
"      </a>",
"      ]: At the time of HCT, three patients had achieved a second complete response, one was in first relapse, and one was refractory to treatment. At a median follow-up of five years, all patients were alive without evidence of disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who attain a complete or partial remission with second line chemotherapy, we suggest consolidation with HCT. A choice between autologous and allogeneic HCT depends upon the patient&rsquo;s performance status and organ function and the availability of a donor. Treatment of patients who are not transplant candidates, who fail to respond to second line chemotherapy regimens, or who relapse after HCT is generally palliative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62376574\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\", section on 'Clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62376239\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of patients with extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type is largely determined by the extent of disease. Localized disease includes tumors confined to a primary extralymphatic organ with contiguous extension to surrounding tissues (stage I) or with supradiaphragmatic lymph node involvement (stage II) (",
"      <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H62377097\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with localized (stage I or II) extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type, we suggest combined modality therapy with radiation and chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Preferably,&nbsp;radiation should be given",
"      <strong>",
"       concurrently",
"      </strong>",
"      with&nbsp;chemotherapy, but if the patient's performance status and comorbidities do not allow concurrent therapy, radiation should be administered",
"      <strong>",
"       prior",
"      </strong>",
"      to chemotherapy. We do not routinely administer CNS prophylaxis. (See",
"      <a class=\"local\" href=\"#H62375639\">",
"       'Localized disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with disseminated (stage III or IV) extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, we suggest the use of a combination chemotherapy regimen incorporating L-asparaginase rather than CHOP chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with NKPI scores of 3 or 4 (",
"      <a class=\"graphic graphic_table graphicRef67924 \" href=\"UTD.htm?22/12/22732\">",
"       table 4",
"      </a>",
"      ), we suggest the addition of CNS prophylaxis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H62375646\">",
"       'Disseminated disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H197739\">",
"       'Central nervous system prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients who achieve a partial response after induction therapy, we suggest consolidation with high dose chemotherapy and an autologous hematopoietic cell transplantation (HCT) rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H243760692\">",
"       'Autologous hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 30 percent of patients with localized disease and 80 percent of patients with disseminated disease at the time of diagnosis will either not achieve remission or will relapse. The general approach has been to administer a second-line combination chemotherapy regimen with the hope of attaining a complete or partial remission. For patients who attain a complete or partial remission with second line chemotherapy, we suggest consolidation with HCT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A choice between autologous and allogeneic HCT depends upon the patient&rsquo;s performance status and organ function and the availability of a donor. (See",
"      <a class=\"local\" href=\"#H243760413\">",
"       'Treatment of relapsed or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/1\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/2\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/3\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/5\">",
"      Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma. Blood 2006; 107:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/6\">",
"      Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 2011; 118:6018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/7\">",
"      Wang ZY, Liu QF, Wang H, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood 2012; 120:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/8\">",
"      Ooi GC, Chim CS, Liang R, et al. Nasal T-cell/natural killer cell lymphoma: CT and MR imaging features of a new clinicopathologic entity. AJR Am J Roentgenol 2000; 174:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/9\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/10\">",
"      Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 2007; 18:1685.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf (Accessed on August 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/12\">",
"      Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011; 153:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/13\">",
"      Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113:3931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/14\">",
"      Falini B, Pileri S, De Solas I, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood 1990; 75:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/15\">",
"      Okuda T, Sakamoto S, Deguchi T, et al. Hemophagocytic syndrome associated with aggressive natural killer cell leukemia. Am J Hematol 1991; 38:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/16\">",
"      Isobe K, Uno T, Tamaru J, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 2006; 106:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/17\">",
"      Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/18\">",
"      Huang MJ, Jiang Y, Liu WP, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 2008; 70:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/19\">",
"      Avil&eacute;s A, D&iacute;az NR, Neri N, et al. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol 2000; 22:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/20\">",
"      Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/21\">",
"      Cheung MM, Chan JK, Lau WH, et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/22\">",
"      Ko YH, Ree HJ, Kim WS, et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 2000; 89:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/23\">",
"      Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009; 27:5594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/24\">",
"      Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009; 27:6027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/25\">",
"      Yamaguchi M, Tobinai K, Oguchi M, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol 2012; 30:4044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/26\">",
"      Sakata K, Fuwa N, Kodaira T, et al. Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol 2006; 79:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/27\">",
"      Wang H, Li YX, Wang WH, et al. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys 2012; 82:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/28\">",
"      Yong W, Zheng W, Zhu J, et al. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 2009; 88:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/29\">",
"      Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003; 78:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/30\">",
"      Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/31\">",
"      Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011; 29:4410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/32\">",
"      Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012; 120:2973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/33\">",
"      Jaccard A, Petit B, Girault S, et al. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2009; 20:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/34\">",
"      Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011; 117:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/35\">",
"      Lee J, Au WY, Park MJ, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008; 14:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/36\">",
"      Kim SJ, Oh SY, Hong JY, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol 2010; 21:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/37\">",
"      Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/38\">",
"      Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/39\">",
"      Liang R. Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type. Br J Haematol 2009; 147:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/40\">",
"      Ennishi D, Maeda Y, Fujii N, et al. Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type. Leuk Lymphoma 2011; 52:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12457/abstract/41\">",
"      Yokoyama H, Yamamoto J, Tohmiya Y, et al. Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type. Leuk Lymphoma 2010; 51:1509.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16591 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-9C20EB8C63-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12457=[""].join("\n");
var outline_f12_10_12457=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H62376239\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62375632\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62376231\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62377097\">",
"      INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194235122\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62375639\">",
"      Localized disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62375646\">",
"      Disseminated disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H197739\">",
"      Central nervous system prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62377121\">",
"      CONSOLIDATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H243760692\">",
"      Autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62376552\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62376560\">",
"      Response assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H243760434\">",
"      Reconstructive surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62376567\">",
"      Surveillance for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H243760413\">",
"      TREATMENT OF RELAPSED OR REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62376574\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62376239\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/16591\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16591|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/34/28205\" title=\"figure 1\">",
"      Kaplan-Meier analysis extranodal NK-T cell lymphoma nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/16591|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2A\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 2B\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/23/19836\" title=\"table 3\">",
"      Cotswolds system in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/12/22732\" title=\"table 4\">",
"      NKPI for extranodal NK-T cell lymphoma nasal type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/27/30140\" title=\"table 5\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=related_link\">",
"      Mandibular and palatal reconstruction in patients with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=related_link\">",
"      Treatment of relapsed or refractory peripheral T cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_10_12458="Clinical manifestations and diagnosis of bronchiectasis in adults";
var content_f12_10_12458=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of bronchiectasis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12458/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12458/contributors\">",
"     Alan F Barker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12458/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12458/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/10/12458/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/10/12458/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/10/12458/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchiectasis shares many clinical features with chronic obstructive pulmonary disease (COPD), including inflamed and easily collapsible airways, obstruction to airflow, and frequent office visits and hospitalizations. The diagnosis is usually established clinically on the basis of chronic daily cough with viscid sputum production, and radiographically by the presence of bronchial wall thickening and luminal dilatation on chest computed tomographic (CT) scans [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, major clinical manifestations, and diagnostic approach to bronchiectasis will be reviewed here. The clinical manifestations and treatment of cystic fibrosis lung disease and the treatment of bronchiectasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of bronchiectasis is unknown, but probably varies substantially among different countries. Helpful information is provided by independent analyses of ICD codes from two large and different United States databases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An estimated 110,000 individuals have bronchiectasis in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The prevalence of bronchiectasis increases with age",
"     </li>",
"     <li>",
"      Bronchiectasis is more common in women",
"     </li>",
"     <li>",
"      Patients with bronchiectasis use extensive healthcare resources (eg, frequent ambulatory visits, antibiotic usage, chest computed tomography, hospitalization), and bronchiectasis associated healthcare usage increased from 2000 to 2007 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction of bronchiectasis requires two factors (",
"    <a class=\"graphic graphic_table graphicRef56821 graphicRef69598 graphicRef81561 \" href=\"UTD.htm?14/5/14430\">",
"     table 1A-C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An infectious insult",
"     </li>",
"     <li>",
"      Impaired drainage, airway obstruction, or a defect in host defense",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ensuing host response, immune effector cells, neutrophilic proteases, reactive oxygen intermediates (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    [H",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    ]), and inflammatory cytokines, causes transmural inflammation, mucosal edema, cratering, ulceration, and neovascularization in the airways [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. The result is permanent abnormal dilatation and destruction of the major bronchi and bronchiole walls.",
"   </p>",
"   <p>",
"    Recurrent infection is common, which can lead to further scarring, obstruction, and distortion of the airways, as well as temporary or permanent damage to the lung parenchyma. One reason that recurrent infection may be so common is that bacterial pathogens have evolved a method of evading elimination by the immune system of patients with cystic fibrosis or bronchiectasis. As an example, interleukin-8 (IL-8) recruits neutrophils to inflammatory sites via its interaction with the chemokine receptor, CXCR1. Proteases from bacterial pathogens (eg, Pseudomonas) cleave and disable CXCR1, leading to reduced neutrophil recruitment and failure of bacterial killing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/9\">",
"     9",
"    </a>",
"    ]. Anti-proteases, such as alpha-1 antitrypsin, restore CXCR1 and enhance bacterial killing.",
"   </p>",
"   <p>",
"    Another explanation for recurrent infection, despite the presence of increased numbers of neutrophils in the airways of patients with bronchiectasis, is that the neutrophils are ineffective. In a study of stable patients with bronchiectasis, high sputum levels of human neutrophil peptides (HNP, also called alpha-defensins) were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/10\">",
"     10",
"    </a>",
"    ]. HNP normally have an antimicrobial effect by themselves, but impair neutrophil phagocytosis leading to loss of antimicrobicidal activity. Addition of alpha-1 antitrypsin to sputum neutrophil cell cultures attenuated of HNP activity and improved phagocytic activity.",
"   </p>",
"   <p>",
"    On the other hand, the progressive airway destruction in bronchiectasis may in part be related to unopposed activity of neutrophil elastase [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/8\">",
"     8",
"    </a>",
"    ]. In a study of sputum properties, neutrophil elastase complexed with syndecan-1, protecting it from inactivation by alpha-1 antitrypsin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/8\">",
"     8",
"    </a>",
"    ]. Unopposed neutrophil elastase activity has also been implicated in the tissue destruction leading to emphysema in patients with alpha-1-antitrypsin deficiency.",
"   </p>",
"   <p>",
"    Attention to the physical properties of sputum suggesting differences between CF and non-CF bronchiectasis may help explain different responses to bronchial hygiene measures. Physicochemical studies of sputum from native American children from Alaska (indigenous populations and populations from developing countries have a high prevalence of bronchiectasis) was less elastic and viscous and had higher transportability than banked sputum of patients with cystic fibrosis and chronic bronchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of bronchiectasis in adults\", section on 'Bronchial hygiene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with diffuse bronchiectasis and negative sweat chloride testing, a heterozygous mutation in the cystic fibrosis transmembrane regulator (CFTR) gene may contribute to development of bronchiectasis, through dysfunction of the airway sodium and chloride channels [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/12\">",
"     12",
"    </a>",
"    ]. This hypothesis was examined in a study that assessed nasal transepithelial potential difference in patients with diffuse bronchiectasis, a normal sweat chloride, and either a normal CFTR genotype, or one or two CFTR mutations (eg, a loss of function mutation on one chromosome and a mild mutation on the other), and compared the results with those in normal subjects and patients with known cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/12\">",
"     12",
"    </a>",
"    ]. The nasal potential difference test reflects the function of sodium and chloride channels in the airway epithelium. An abnormal nasal electrophysiologic phenotype, intermediate between normal and cystic fibrosis values, was identified in patients with diffuse bronchiectasis and one CFTR mutation, suggesting that the presence of a single CFTR mutation may play a role in the development of diffuse bronchiectasis.",
"   </p>",
"   <p>",
"    A potential role of vitamin D deficiency in the vicious cycle of recurrent exacerbations of bronchiectasis was examined in an observational study of 402 patients with noncystic fibrosis bronchiectasis, who were followed for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/13\">",
"     13",
"    </a>",
"    ]. At baseline, 50 percent were vitamin D deficient (25 hydroxy-vitamin D levels &lt;25",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and another 43 percent were insufficient (25 hydroxy-vitamin D &lt;75",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    The vitamin D deficient patients (compared to the insufficient and sufficient patients) were more likely to have sputum colonization with bacteria including pseudomonas, more frequent exacerbations including those needing hospitalization, worse respiratory symptoms as assessed by standard questionnaires, and increased sputum markers of neutrophil inflammation. It is not known whether this association reflects an effect of vitamin D on innate immunity or reduced outdoor physical activity due to more severe disease.",
"   </p>",
"   <p>",
"    Small airway changes have been described before the advanced and destructive manifestations of bronchiectasis become apparent in patients with common variable immunodeficiency (CVID). As an example, inspiratory and expiratory HRCT scans were performed on 54 children ages 6 to 18 with CVID in a stable state [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/14\">",
"     14",
"    </a>",
"    ]. The most common abnormality was expiratory air trapping (mosaic attenuation), which was seen in 71 to 80 percent and was the only abnormality in 9 to 15 percent. The presence of air trapping on expiratory but not inspiratory views suggests that airway inflammatory changes are the cause and raises the possibility that these changes are reversible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link&amp;anchor=H10572385#H10572385\">",
"     \"Common variable immunodeficiency in children\", section on 'Pulmonary manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link&amp;anchor=H1193479#H1193479\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\", section on 'Pulmonary disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous etiologies that can induce or contribute to the pathophysiologic processes that result in bronchiectasis (",
"    <a class=\"graphic graphic_table graphicRef56821 graphicRef69598 graphicRef81561 \" href=\"UTD.htm?14/5/14430\">",
"     table 1A-C",
"    </a>",
"    ). They include airway obstruction (eg, foreign body aspiration), defective host defenses, cystic fibrosis, Young's syndrome, rheumatic and systemic diseases, dyskinetic cilia, pulmonary infections, allergic bronchopulmonary aspergillosis (ABPA), and cigarette smoking. The frequency of the different etiologies varies with the geographic location and referral population, as shown in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a North American referral center population, a comprehensive evaluation of 112 patients with bronchiectasis confirmed on chest computed tomography identified a specific etiology in 93 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/15\">",
"       15",
"      </a>",
"      ]. The most common etiologies were rheumatic disease (rheumatoid arthritis, Sj&ouml;gren syndrome, Crohn&rsquo;s disease), allergic bronchopulmonary aspergillosis, immunodeficiency, hematologic malignancy, aspiration, and nontuberculous mycobacterial infection.",
"     </li>",
"     <li>",
"      A referral center in the United Kingdom identified an underlying cause in 74 percent of 240 patients with the most common etiologies being prior infection, primary ciliary dyskinesia, allergic bronchopulmonary aspergillosis, and immune deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An underlying etiology is often identified in children and adolescents. In a review of 136 patients with non-CF bronchiectasis ranging from age 3 to 18 years, an etiology was identified in 101 patients (74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/17\">",
"     17",
"    </a>",
"    ]. Of greater importance, 77 of these children had immunodeficiency, gastroesophageal reflux, or ciliary dyskinesia, conditions in which specific management strategies may improve outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway obstruction can be caused by foreign body aspiration, an intraluminal obstructing lesion such as a carcinoid tumor, or extraluminal compression from encroaching lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/18\">",
"     18",
"    </a>",
"    ]. It is important to identify the presence of airway obstruction because surgical resection is often curative.",
"   </p>",
"   <p>",
"    Bronchiectasis that results from foreign body aspiration generally occurs in the right lung and in the lower lobes or the posterior segments of the upper lobes. As an example, toddlers (ages one to three years) may aspirate seeds, popcorn, or unchewed food [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/19\">",
"     19",
"    </a>",
"    ]. An episode of choking, coughing, or unexplained wheezing or hemoptysis should raise the suspicion of a foreign body. A retrospective study found that among children with greater than one month of respiratory symptoms and middle lobe or lingula abnormalities on chest x-ray, an early and aggressive strategy of chest computed tomography (CT) and bronchoscopy with cultures led to interventions (eg, foreign body removal, infection treatment) that produced favorable outcomes, including reduced bronchiectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, particulate aspiration is typically associated with an altered state of consciousness (due to stroke, seizures, intoxication, or emergent general anesthesia). The foreign body is often unchewed food, or part of a tooth or crown. A post-obstructive pneumonia may follow the aspiration event, often resulting in incomplete resolution and predisposition to subsequent lung abscess. Delayed or ineffective therapy and poor nutrition may contribute to prolonged pneumonitis with resultant focal bronchiectasis (",
"    <a class=\"graphic graphic_figure graphicRef58341 \" href=\"UTD.htm?25/11/25776\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35399?source=see_link\">",
"     \"Airway foreign bodies in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal reflux contributes to asthma and interstitial lung disease. The same concern or association applies to bronchiectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/17,21\">",
"     17,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Defective host defenses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impairment in host defenses may be local, as with ciliary dyskinesia, or systemic, as with hypogammaglobulinemia, or prolonged immunosuppression (eg, in transplant patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. The mechanism of bronchiectasis is likely bronchial wall injury from repeated infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Primary ciliary dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with hypogammaglobulinemia usually present in childhood with repeated sinopulmonary infections; however, middle-aged adults have been identified with few or no recognized previous respiratory infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Immunoglobulin quantitation is included in the diagnostic evaluation of the patient with bronchiectasis, since gamma globulin replacement can diminish or prevent further respiratory tract infections and lung damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link&amp;anchor=H1196168#H1196168\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment and prognosis of common variable immunodeficiency\", section on 'Immunoglobulin replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolated IgG subclass deficiency (in the presence of normal or near normal levels of total IgG) as a cause of bronchiectasis is controversial due to variable ranges of values even in normal individuals. To help determine whether a low IgG subclass represents immunodeficiency, a challenge with common humoral bacterial antigens (eg, Haemophilus influenzae vaccine and pneumococcal vaccine), followed six weeks later by measurement of antibody titers, can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Milder cases of autosomal recessive chronic granulomatous disease may present in adulthood. Extrapulmonary infections such as cellulitis, cutaneous abscesses, lymphadenitis, and osteomyelitis are common in these patients. The majority of infections are due to",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    , Burkholderia (Pseudomonas) cepacia,",
"    <em>",
"     Serratia marcescens",
"    </em>",
"    , Nocardia, and Aspergillus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=see_link\">",
"     \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although generally considered a disease of childhood, up to 7 percent of patients with cystic fibrosis (CF) are diagnosed at age 18 years or older [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Sinusitis and bronchiectasis are the major respiratory manifestations of CF, and the latter may be the sole feature of CF in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clues suggesting the presence of this disorder include upper lobe radiographic involvement and sputum cultures showing mucoid",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/32\">",
"     32",
"    </a>",
"    ]. When CF is diagnosed after the age of 20 years, homozygosity at the delta F508 locus in the cystic fibrosis transmembrane conductance regulator (CFTR) gene is less common than in children and non-delta F508 mutations are more common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A positive sputum culture for mucoid",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    in the year of diagnosis is more common in adults than children with CF, while a positive culture for nonmucoid",
"    <em>",
"     P. aeruginosa",
"    </em>",
"    is more common in children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/32\">",
"     32",
"    </a>",
"    ]. Adults also have increased colonization with non-tuberculous mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/30,32-34\">",
"     30,32-34",
"    </a>",
"    ]. Pancreatic insufficiency and diabetes mellitus are less common when CF is discovered after age 20 than before.",
"   </p>",
"   <p>",
"    The diagnosis of CF can usually be established by demonstrating an elevated sweat chloride concentration (&gt;30",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    values of 30 to 60 require additional testing) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/30-32,35\">",
"     30-32,35",
"    </a>",
"    ]. Screening for mutations in the CFTR gene may be required to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Measurement of the potential difference across the nasal epithelium, available in specialized centers, is sometimes used to corroborate the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/12,30,32\">",
"     12,30,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H19#H19\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Sweat chloride'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H22#H22\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Molecular diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H23#H23\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Nasal potential difference measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Young's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Young's syndrome exhibit clinical features similar to individuals with cystic fibrosis, including bronchiectasis, sinusitis, and obstructive azoospermia. However, they do not have increased sweat chloride values, pancreatic insufficiency, abnormal nasal potential differences, or abnormal CF mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/36\">",
"     36",
"    </a>",
"    ]. Affected individuals are often middle-aged males identified during an evaluation for infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rheumatic and other systemic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two rheumatic diseases, rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/37,38\">",
"     37,38",
"    </a>",
"    ] and Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/39\">",
"     39",
"    </a>",
"    ], can be complicated by bronchiectasis. Arthropathy and sicca features are usually advanced when bronchiectasis becomes apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/37\">",
"     37",
"    </a>",
"    ]. In some cases, however, bronchiectasis occurs before the rheumatic disease. In a prospective series of 42 patients with autoantibody positivity for RA (positive anticyclic citrullinated peptide",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    two rheumatoid factor isotypes) but no inflammatory arthritis, HRCT demonstrated bronchiectasis in six patients, two of whom developed frank RA in a 13 month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/38\">",
"     38",
"    </a>",
"    ]. Similarly, bronchiectasis was present in 2 of 12 patients with recent-onset inflammatory rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism underlying bronchiectasis in patients with RA and Sj&ouml;gren&rsquo;s is not known. In a family-based association study, the frequency of an abnormal cystic fibrosis gene (CFTR) allele was increased in patients with bronchiectasis and RA relative to patients with RA but without bronchiectasis and normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Bronchiectasis is a rare complication of other rheumatic or connective tissue diseases, including systemic lupus erythematosus and Marfan syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/41\">",
"     41",
"    </a>",
"    ]. Bronchiectasis has been noted in association with other systemic diseases, such as inflammatory bowel disease, more frequently in ulcerative colitis than in Crohn's disease, and the yellow nail syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=see_link\">",
"     \"Pulmonary complications of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Primary ciliary dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although immotile cilia were originally described in the respiratory tract and sperm of patients with Kartagener's syndrome (dextrocardia, sinusitis, bronchiectasis), many other patients have been identified with dyskinetic cilia leading to poor mucociliary clearance, repeated sinopulmonary infections, and subsequent bronchiectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. An epithelial (nasal or bronchial) brush or biopsy will confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/44\">",
"     44",
"    </a>",
"    ]. The diagnosis and management of primary ciliary dyskinesia (PCD) are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=see_link\">",
"     \"Primary ciliary dyskinesia (immotile-cilia syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further evidence of the relationship between bronchiectasis and dyskinetic cilia comes from patients with autosomal dominant polycystic kidney disease (ADPKD), a disease in which renal cysts develop because of defective cilia and ciliary protein expression (polycystin-1 and polycystin-2). Immunostaining of lung tissue from non-ADPKD patients reveals that the motile cilia of airway epithelial cells express polycystin-1, suggesting that absent polycystin-1 in patients with ADPKD might be a risk factor for airway damage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/45\">",
"     45",
"    </a>",
"    ]. In a retrospective review of chest CT scans, 34 out of 92 patients with ADPKD had bronchiectasis (37 percent) compared to 12 out of 93 patients with non-ADPKD chronic renal disease (13 percent), a difference that was statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/45\">",
"     45",
"    </a>",
"    ]. In autopsy examinations, the lungs from one of five patients with ADPKD had histologic evidence of bronchiectasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Alpha-1 antitrypsin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emphysema is the main lung disease recognized in alpha-1 antitrypsin deficiency. However, a review of the clinical manifestations and chest CT scans of 74 patients with alpha-1 antitrypsin deficiency found that 70 had radiographic abnormalities suggestive of bronchiectasis (95 percent) and 20 had regular sputum production (27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/46\">",
"     46",
"    </a>",
"    ]. These observations support the",
"    <span class=\"nowrap\">",
"     ATS/ERS",
"    </span>",
"    guidelines that recommend alpha-1 testing in patients with bronchiectasis and no other evident etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of pulmonary infections have been associated with the development of bronchiectasis. As an example, some individuals with presumed viral or Mycoplasma infection develop repeated respiratory infections and bronchiectasis. In addition to direct tissue injury, a sequela of virulent infections (such as tuberculosis) may include enlarged and caseous lymph nodes around bronchi or damaged airways that predispose to bacterial colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/48\">",
"     48",
"    </a>",
"    ]. In a Korean study, 9 percent of 1409 individuals who underwent chest computed tomography (CT) screening for lung cancer had bronchiectasis; a previous history of tuberculosis was significantly associated with bronchiectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Childhood whooping cough (pertussis) is of historical interest in the pathogenesis of bronchiectasis. However, other childhood infections may play a role, as illustrated by an observational cohort study of 1392 individuals followed from birth in 1958 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/50\">",
"     50",
"    </a>",
"    ]. Pulmonary function was measured at ages 34 to 35 years, which demonstrated that individuals with pneumonia, but not whooping cough, before the age of seven years had reduced FEV1 and FVC, compared to members of the cohort without such histories. This suggests that early pneumonia may play a role in subsequent lower airway damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=see_link\">",
"     \"Clinical features and diagnosis of Bordetella pertussis infection in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-tuberculous mycobacteria (NTM) have traditionally been considered a secondary pathogen in an abnormal host (AIDS) or in a previously damaged lung (bullous emphysema). However, apparently normal hosts (primarily nonsmoking women over the age of 50 years) may develop bronchiectasis due to primary NTM infection. Similar to a sputum smear showing acid-fast bacilli and a culture confirming the presence of NTM, a CT scan of the chest is relatively specific, showing small irregular nodules, often in the middle lobe or lingula [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Patients with bronchiectasis and NTM infection are more likely to have aspergillus-related lung disease (including allergic bronchopulmonary aspergillosis) than patients with bronchiectasis who do not have NTM infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mycobacterium avium complex (MAC) are the most frequently identified NTMs. Evidence of the pathogenicity of MAC comes from a surgical series of nine patients with positive sputum cultures for MAC [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/54\">",
"     54",
"    </a>",
"    ]. Examination of resected lung tissues revealed MAC, bronchiectasis, and granulomata. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=see_link\">",
"     \"Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Allergic bronchopulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic bronchopulmonary aspergillosis (ABPA) should be suspected in patients with a long history of asthma that is resistant to bronchodilator therapy and associated with a cough. The cough is often productive of sputum that is mucopurulent or contains mucous plugs, suggesting infection. Sputum cultures may be positive for Aspergillus species. Chest CT scans show central airway bronchiectasis, which is unusual in patients with bronchiectasis caused by other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ABPA probably represents a hyperimmune reaction to the Aspergillus organism rather than a true infection and is characterized by an exaggerated T helper cell response. Immunologic features of ABPA include blood eosinophilia, very high plasma IgE levels, and precipitating and specific antibodies to Aspergillus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;A causal role for cigarette smoking in bronchiectasis has not been demonstrated conclusively. However, smoking and repeated infections may worsen pulmonary function and accelerate the progression of disease that is already present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5990869\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic clinical manifestations of bronchiectasis are cough and the daily production of mucopurulent and tenacious sputum lasting months to years. The older literature also described \"dry bronchiectasis\" with episodic hemoptysis and no sputum production, but this presentation is less common.",
"   </p>",
"   <p>",
"    Other, less specific complaints include dyspnea, wheezing, and pleuritic chest pain. Patients often report frequent bouts of \"bronchitis\" requiring therapy with repeated courses of antibiotics. There is generally a past history of repeated respiratory tract infections over several years, although a single episode of severe bacterial pneumonia, pertussis, tuberculosis, and Mycoplasma infection can also result in bronchiectasis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etiologies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a retrospective chart review of 103 patients with bronchiectasis who presented to a referral center, the following clinical findings were documented [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms &ndash; cough (98 percent of patients), daily sputum production (78 percent), dyspnea (62 percent), rhinosinusitis (73 percent), hemoptysis (27 percent), and recurrent pleurisy (20 percent)",
"     </li>",
"     <li>",
"      Physical findings &ndash; crackles (75 percent) and wheezing (22 percent) were common, with digital clubbing occurring in only 2 percent of patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although respiratory complaints are prominent, other symptoms can be annoying and distressing. Fatigue was noted in 43 percent of 117 bronchiectasis patients using a validated fatigue impact scale. The presence of fatigue correlated with lower forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) values, but not the presence of P. aeruginosa in sputum [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/59\">",
"     59",
"    </a>",
"    ]. Seventy-five women attending a respiratory clinic were evaluated for urinary incontinence and its effect on their quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/60\">",
"     60",
"    </a>",
"    ]. The prevalence of urinary incontinence in the patients with bronchiectasis was 47 percent, compared to an estimated prevalence of 10 to 12 percent in the general population. Many of these patients were reluctant to discuss such complaints.",
"   </p>",
"   <p>",
"    Among patients with bronchiectasis, a reduced sense of smell is common. In a study of 91 patients with bronchiectasis, a significant reduction in sense of smell was noted in patients with a history of chronic rhinosinusitis (with or without associated nasal polyps)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    primary humoral immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of a diagnostic evaluation is radiographic confirmation of the diagnosis, identification of potentially treatable causes, and functional assessment (",
"    <a class=\"graphic graphic_table graphicRef56821 graphicRef69598 graphicRef81561 \" href=\"UTD.htm?14/5/14430\">",
"     table 1A-C",
"    </a>",
"    ). The evaluation consists of laboratory testing, radiographic imaging, and pulmonary function testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following studies are typically part of the initial evaluation of a patient with bronchiectasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete blood count with differential",
"     </li>",
"     <li>",
"      Immunoglobulin quantitation to measure the levels of the immunoglobulins IgG, IgM, and IgA (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"       \"Primary humoral immune deficiencies: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"       \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      IgG subclass levels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=see_link&amp;anchor=H11#H11\">",
"       \"IgG subclass deficiency\", section on 'Evaluation and diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antibody titers to pneumococcal serotypes before and four weeks after vaccination with polysaccharide pneumococcal vaccine (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=see_link&amp;anchor=H20#H20\">",
"       \"Assessing the immunologic response to vaccination\", section on 'Assessing polysaccharide responses in adults and children over two years'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mutation analysis of the cystic fibrosis transmembrane conductance regulator (CFTR) gene (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Cystic fibrosis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Sputum culture and smear for bacteria, mycobacteria, and fungi",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific aspergillus IgE and IgG antibodies, total serum IgE level, alpha-1 antitrypsin level",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phenotype, dihydrorhodamine 123 (DHR) flow cytometric assay for chronic granulomatous disease, and rheumatoid factor measurements should be obtained in the appropriate clinical settings (",
"    <a class=\"graphic graphic_table graphicRef56821 graphicRef69598 graphicRef81561 \" href=\"UTD.htm?14/5/14430\">",
"     table 1A-C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etiologies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cell counts of induced sputum are being evaluated as a way to identify patients with bronchiectasis. In a retrospective series of patients with stable obstructive airways disease who had an HRCT available for analysis, sputum leukocytosis and neutrophilia were more common in those with radiographic bronchiectasis than those without (mean 48.2 X 10",
"    <sup>",
"     6",
"    </sup>",
"    versus 12.6 X 10",
"    <sup>",
"     6",
"     <span class=\"nowrap\">",
"     </span>",
"    </sup>",
"    cells/gram",
"    of sputum and 78.2 versus 64.4 percent neutrophils) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/62\">",
"     62",
"    </a>",
"    ]. Performing cell counts on induced sputum is labor intensive and would require more study prior to widespread implementation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph is abnormal in most patients with bronchiectasis and, in combination with the clinical findings, may be sufficient to establish the diagnosis. Suspicious, but nondiagnostic radiographic findings include linear atelectasis, dilated and thickened airways (ie, tram or parallel lines, ring shadows on cross section) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75583 graphicRef63795 \" href=\"UTD.htm?34/56/35721\">",
"     image 1A-B",
"    </a>",
"    ), and irregular peripheral opacities that may represent mucopurulent plugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;High resolution computed tomography (HRCT) of the chest has become the defining test for bronchiectasis. HRCT scans obtain images of 1 to 1.5 mm collimation slices every 10 mm and multidetector computed tomography (MDCT) scans obtain high resolution images using 1 to 1.5 mm contiguous slices and a high-spatial frequency reconstruction algorithm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/63\">",
"     63",
"    </a>",
"    ]. In a series of 61 patients with bronchiectasis diagnosed by MDCT, HRCT scans did not demonstrate bronchiectasis in seven [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/63\">",
"     63",
"    </a>",
"    ]. Among 479 lung lobes, 59 were positive for bronchiectasis by MDCT and negative by HRCT, while 19 lobes were positive by HRCT and not by MDCT. Images obtained during exhalation enhance visualization of air trapping due to obstructed airways.",
"   </p>",
"   <p>",
"    MDCT (or HRCT if MDCT is not available) is indicated in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are suspicious clinical findings but a relatively normal chest radiograph.",
"     </li>",
"     <li>",
"      The chest radiograph has abnormal findings (eg, a pneumonic infiltrate) and bronchiectasis is strongly suspected.",
"     </li>",
"     <li>",
"      Management decisions must be made that depend upon the extent of bronchiectasis. As an example, mapping of the chest is needed to define suspected abnormal areas and to demonstrate absent or minimal involvement in the rest of the lung if surgical resection is being contemplated.",
"     </li>",
"     <li>",
"      The presence (or absence) of confounding diseases needs to be defined, such as chronic obstructive lung disease, interstitial lung disease, or malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major features of bronchiectasis on HRCT and MDCT include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway dilatation, which can be detected as parallel (tram) lines or end-on ring shadows (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73028 \" href=\"UTD.htm?30/26/31137\">",
"       image 2",
"      </a>",
"      ). A luminal airway diameter 1.0 to 1.5 times the adjacent vessel is normal; a diameter more than 1.5 times the adjacent vessel is indicative of cylindrical bronchiectasis.",
"     </li>",
"     <li>",
"      Lack of tapering in combination with dilatation may be more specific than bronchial dilatation alone because some healthy individuals and patients with asthma may have areas of bronchial dilatation.",
"     </li>",
"     <li>",
"      Bronchial wall thickening observed in dilated airways may be the best correlate and predictor of functional decline.",
"     </li>",
"     <li>",
"      Airways affected by bronchiectasis may contain mucopurulent plugs or debris accompanied by post-obstructive air trapping. When small airways are affected, peripheral, irregular, short (2 to 4 mm) linear branching markings are noted and the term \"tree-in-bud pattern\" is applicable (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52831 \" href=\"UTD.htm?34/52/35649\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cysts off the bronchial wall are a feature of more destructive bronchiectasis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef60935 \" href=\"UTD.htm?30/46/31458\">",
"       image 4",
"      </a>",
"      ). In heavily involved areas, the cysts are clustered to appear like grapes (cystic bronchiectasis) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51957 \" href=\"UTD.htm?27/38/28258\">",
"       image 5",
"      </a>",
"      ). Blebs, seen in emphysema, are thinner walled and not accompanied by proximal airway changes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not characteristic of bronchiectasis, other abnormalities may exist on HRCT, none of which are diagnostic of bronchiectasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consolidation of a segment or lobe (from pneumonia).",
"     </li>",
"     <li>",
"      Enlarged lymph nodes, likely a reaction to infection.",
"     </li>",
"     <li>",
"      Areas of low attenuation and vascular disruption suggesting emphysema. This is probably due to the distorting effect of an inflammatory process in small airways.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distribution of bronchiectasis may be important diagnostically. A central (perihilar) distribution is suggestive of allergic bronchopulmonary aspergillosis; predominant upper lobe distribution is characteristic of cystic fibrosis or one of its variants; middle and lower lobe distribution is consistent with PCD; middle lobe and lingular segment of the LUL involvement is characteristic of nontuberculous mycobacteria (NTM); and lower lobe involvement is typical of idiopathic bronchiectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/52,64-66\">",
"     52,64-66",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64077 graphicRef53471 graphicRef78762 \" href=\"UTD.htm?15/59/16313\">",
"     image 6A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Another confounding diagnosis is the \"traction bronchiectasis\" seen in pulmonary fibrosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70396 \" href=\"UTD.htm?8/31/8688\">",
"     image 7",
"    </a>",
"    ). When the lung parenchyma is distorted by fibrosis, the airways can be dilated or pulled to simulate bronchiectasis; in this setting, however, the other features of bronchiectasis are absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various grading systems have been proposed to correlate the extent of bronchiectasis on HRCT with disease severity; however, none of these systems has been validated prospectively or with large patient populations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One group performed serial HRCTs and spirometry on 48 patients with bronchiectasis, with follow-up ranging from 6 to 74 months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/68\">",
"       68",
"      </a>",
"      ]. HRCT evidence of mucous plugging (potentially reversible) and bronchial wall thickening best correlated with decline in FEV1 and FVC.",
"     </li>",
"     <li>",
"      Among patients with COPD, coexisting MDCT evidence of bronchiectasis is associated with increased severity of COPD exacerbations. In a two-year follow-up study of 54 patients with stable COPD, 27 patients (50 percent) had coexisting lower lobe bronchiectasis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/69\">",
"       69",
"      </a>",
"      ]. Compared to patients without bronchiectasis, patients with bronchiectasis had a longer duration of symptoms during exacerbations, a greater burden of potentially pathogenic bacteria in the lower airway, and increased sputum inflammatory markers, including interleukin (IL)-8 and IL-6 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lung function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing is used for functional assessment of impairment due to bronchiectasis. Spirometry before and after the administration of a bronchodilator is satisfactory in most patients. Obstructive impairment (ie, reduced or normal forced vital capacity [FVC], low forced expiratory volume [FEV1], and low",
"    <span class=\"nowrap\">",
"     FEV1/FVC)",
"    </span>",
"    is the most frequent finding, but a very low FVC can also be seen in advanced disease in which much of the lung has been destroyed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The six-minute walk test may provide additional information to standard physiologic tests (eg, FVC, FEV1,",
"    <span class=\"nowrap\">",
"     FEV1/FVC).",
"    </span>",
"    In a study of 27 patients with bronchiectasis, the six-minute walk test distance correlated more closely with quality of life (St. George's Respiratory Questionnaire and Short Form 36) than the physiologic tests [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients suspected of having primary ciliary dysfunction (eg, family history, infertility, situs inversus), nasal brushing with a bronchoscopy brush is used to obtain ciliate epithelium to examine under high speed video microscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=see_link&amp;anchor=H26740088#H26740088\">",
"     \"Primary ciliary dyskinesia (immotile-cilia syndrome)\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    or interferon-gamma release assay (IGRA) is performed in patients from areas of high Mycobacteria tuberculosis endemicity.",
"   </p>",
"   <p>",
"    Sweat chloride testing for cystic fibrosis is performed at specialized centers. Depending on availability this test may be used to screen for CF in adults or may be used to confirm CF in patients with abnormal DNA analysis of the cystic fibrosis transmembrane conductance regulator (CFTR). Patients who present with CF as adults may have intermediate or normal sweat chloride results. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Cystic fibrosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H59100333#H59100333\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fiberoptic bronchoscopy may be performed when a focal obstructing lesion is suspected. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Airway obstruction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     BRONCHIECTASIS REGISTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bronchiectasis research consortium and registry has been established to gather key patient-related diagnostic and therapeutic features. The registry will be available for multi-center research studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/10/12458/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/31/41457?source=see_link\">",
"       \"Patient information: Allergic bronchopulmonary aspergillosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=see_link\">",
"       \"Patient information: Coughing up blood (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/25/39314?source=see_link\">",
"       \"Patient information: Bronchiectasis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic clinical manifestations of bronchiectasis are cough and the daily production of mucopurulent and tenacious sputum lasting months to years. Less specific complaints include dyspnea, hemoptysis, wheezing, and pleuritic chest pain. (See",
"      <a class=\"local\" href=\"#H5990869\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bronchiectasis is an acquired disorder of the major bronchi and bronchioles that is characterized by permanent abnormal dilatation and destruction of bronchial walls. The induction of bronchiectasis requires an infectious insult plus impairment of drainage, airway obstruction,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a defect in host defense. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are numerous etiologies that can induce or contribute to the pathophysiologic processes that result in bronchiectasis. They include airway obstruction (eg, foreign body aspiration), defective host defenses, cystic fibrosis, Young's syndrome, rheumatic and systemic diseases, dyskinetic cilia, pulmonary infections, allergic bronchopulmonary aspergillosis (ABPA), and cigarette smoking. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The purpose of the diagnostic evaluation is radiographic confirmation of the diagnosis, identification of potentially treatable causes, and functional assessment. The evaluation consists of laboratory testing, radiographic imaging, and pulmonary function testing (",
"      <a class=\"graphic graphic_table graphicRef56821 graphicRef69598 graphicRef81561 \" href=\"UTD.htm?14/5/14430\">",
"       table 1A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of a patient with bronchiectasis should include a complete blood count with differential, immunoglobulin quantitation (IgG, IgM, and IgA), and sputum culture and smear for bacteria, mycobacteria, and fungi. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chest radiograph is abnormal in most patients with bronchiectasis. However, high resolution computed tomography (HRCT) and multidetector computed tomography (MDCT) of the chest have become the defining tests of bronchiectasis. Characteristic features of bronchiectasis on HRCT and MDCT include airway dilatation, lack of airway tapering, bronchial thickening, and cysts. In addition, mucopurulent plugs or debris accompanied by post-obstructive air trapping may be observed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Chest radiograph'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Computed tomography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary function testing is used for functional assessment of impairment due to bronchiectasis. Obstructive impairment (ie, reduced or normal FVC, low FEV1, and low",
"      <span class=\"nowrap\">",
"       FEV1/FVC)",
"      </span>",
"      is the most frequent finding. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Lung function tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A bronchiectasis research consortium and registry has been established to gather key patient-related diagnostic and therapeutic features. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Bronchiectasis registry'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/1\">",
"      Barker AF. Bronchiectasis. N Engl J Med 2002; 346:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/2\">",
"      Weycker, D, Edelsberg, J, Oster, G, Tino, G. Prevalence and economic burden of bronchiectasis [obstructive airways disease]. Clin Pulm Med 2005; 12:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/3\">",
"      Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012; 142:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/4\">",
"      Loukides S, Bouros D, Papatheodorou G, et al. Exhaled H(2)O(2) in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease. Chest 2002; 121:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/5\">",
"      Silva JR, Jones JA, Cole PJ, Poulter LW. The immunological component of the cellular inflammatory infiltrate in bronchiectasis. Thorax 1989; 44:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/6\">",
"      Tsang KW, Chan K, Ho P, et al. Sputum elastase in steady-state bronchiectasis. Chest 2000; 117:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/7\">",
"      Gaga M, Bentley AM, Humbert M, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998; 53:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/8\">",
"      Chan SC, Leung VO, Ip MS, Shum DK. Shed syndecan-1 restricts neutrophil elastase from alpha1-antitrypsin in neutrophilic airway inflammation. Am J Respir Cell Mol Biol 2009; 41:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/9\">",
"      Hartl D, Latzin P, Hordijk P, et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007; 13:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/10\">",
"      Voglis S, Quinn K, Tullis E, et al. Human neutrophil peptides and phagocytic deficiency in bronchiectatic lungs. Am J Respir Crit Care Med 2009; 180:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/11\">",
"      Redding GJ, Kishioka C, Martinez P, Rubin BK. Physical and transport properties of sputum from children with idiopathic bronchiectasis. Chest 2008; 134:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/12\">",
"      Bienvenu T, Sermet-Gaudelus I, Burgel PR, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010; 181:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/13\">",
"      Chalmers JD, McHugh BJ, Docherty C, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013; 68:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/14\">",
"      van de Ven AA, van Montfrans JM, Terheggen-Lagro SW, et al. A CT scan score for the assessment of lung disease in children with common variable immunodeficiency disorders. Chest 2010; 138:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/15\">",
"      McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest 2012; 142:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/16\">",
"      Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007; 101:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/17\">",
"      Li AM, Sonnappa S, Lex C, et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur Respir J 2005; 26:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/18\">",
"      Kwon KY, Myers JL, Swensen SJ, Colby TV. Middle lobe syndrome: a clinicopathological study of 21 patients. Hum Pathol 1995; 26:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/19\">",
"      Limper AH, Prakash UB. Tracheobronchial foreign bodies in adults. Ann Intern Med 1990; 112:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/20\">",
"      Priftis KN, Mermiri D, Papadopoulou A, et al. The role of timely intervention in middle lobe syndrome in children. Chest 2005; 128:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/21\">",
"      Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/22\">",
"      Barbato A, Frischer T, Kuehni CE, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur Respir J 2009; 34:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/23\">",
"      Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004; 169:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/24\">",
"      Rook M, Postma DS, van der Jagt EJ, et al. Mycophenolate mofetil and bronchiectasis in kidney transplant patients: a possible relationship. Transplantation 2006; 81:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/25\">",
"      Rentenaar RJ, van Diepen FN, Meijer RT, et al. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int 2002; 62:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/26\">",
"      Thickett KM, Kumararatne DS, Banerjee AK, et al. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. QJM 2002; 95:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/27\">",
"      Tarzi MD, Grigoriadou S, Carr SB, et al. Clinical immunology review series: An approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol 2009; 155:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/28\">",
"      Vendrell M, de Gracia J, Rodrigo MJ, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest 2005; 127:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/29\">",
"      van Kessel DA, van Velzen-Blad H, van den Bosch JM, Rijkers GT. Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. Eur Respir J 2005; 25:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/30\">",
"      Gilljam M, Ellis L, Corey M, et al. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest 2004; 126:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/31\">",
"      Gonska T, Choi P, Stephenson A, et al. Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease. Chest 2012; 142:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/32\">",
"      Keating CL, Liu X, Dimango EA. Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis. Chest 2010; 137:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/33\">",
"      Rodman DM, Polis JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005; 171:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/34\">",
"      Ziedalski TM, Kao PN, Henig NR, et al. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 2006; 130:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/35\">",
"      Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/36\">",
"      Friedman KJ, Teichtahl H, De Kretser DM, et al. Screening Young syndrome patients for CFTR mutations. Am J Respir Crit Care Med 1995; 152:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/37\">",
"      Shadick NA, Fanta CH, Weinblatt ME, et al. Bronchiectasis. A late feature of severe rheumatoid arthritis. Medicine (Baltimore) 1994; 73:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/38\">",
"      Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum 2012; 64:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/39\">",
"      Soto-Cardenas MJ, Perez-De-Lis M, Bove A, et al. Bronchiectasis in primary Sj&ouml;gren's syndrome: prevalence and clinical significance. Clin Exp Rheumatol 2010; 28:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/40\">",
"      Pu&eacute;chal X, Bienvenu T, G&eacute;nin E, et al. Mutations of the cystic fibrosis gene in patients with bronchiectasis associated with rheumatoid arthritis. Ann Rheum Dis 2011; 70:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/41\">",
"      Cohen M, Sahn SA. Bronchiectasis in systemic diseases. Chest 1999; 116:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/42\">",
"      Mahadeva R, Walsh G, Flower CD, Shneerson JM. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J 2000; 15:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/43\">",
"      Maldonado F, Tazelaar HD, Wang CW, Ryu JH. Yellow nail syndrome: analysis of 41 consecutive patients. Chest 2008; 134:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/44\">",
"      Stannard WA, Chilvers MA, Rutman AR, et al. Diagnostic testing of patients suspected of primary ciliary dyskinesia. Am J Respir Crit Care Med 2010; 181:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/45\">",
"      Driscoll JA, Bhalla S, Liapis H, et al. Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis. Chest 2008; 133:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/46\">",
"      Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/47\">",
"      American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/48\">",
"      Nikolaizik WH, Warner JO. Aetiology of chronic suppurative lung disease. Arch Dis Child 1994; 70:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/49\">",
"      Kwak HJ, Moon JY, Choi YW, et al. High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. Tohoku J Exp Med 2010; 222:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/50\">",
"      Johnston ID, Strachan DP, Anderson HR. Effect of pneumonia and whooping cough in childhood on adult lung function. N Engl J Med 1998; 338:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/51\">",
"      Glassroth J. Pulmonary disease due to nontuberculous mycobacteria. Chest 2008; 133:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/52\">",
"      Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/53\">",
"      Kunst H, Wickremasinghe M, Wells A, Wilson R. Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur Respir J 2006; 28:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/54\">",
"      Fujita J, Ohtsuki Y, Shigeto E, et al. Pathological findings of bronchiectases caused by Mycobacterium avium intracellulare complex. Respir Med 2003; 97:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/55\">",
"      Ward S, Heyneman L, Lee MJ, et al. Accuracy of CT in the diagnosis of allergic bronchopulmonary aspergillosis in asthmatic patients. AJR Am J Roentgenol 1999; 173:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/56\">",
"      Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/57\">",
"      Popa V. Airway obstruction in adults with recurrent respiratory infections and IgG deficiency. Chest 1994; 105:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/58\">",
"      King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006; 100:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/59\">",
"      Hester KL, Macfarlane JG, Tedd H, et al. Fatigue in bronchiectasis. QJM 2012; 105:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/60\">",
"      Prys-Picard CO, Niven R. Urinary incontinence in patients with bronchiectasis. Eur Respir J 2006; 27:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/61\">",
"      Guilemany JM, Mari&ntilde;o-S&aacute;nchez FS, Angrill J, et al. The importance of smell in patients with bronchiectasis. Respir Med 2011; 105:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/62\">",
"      Drost N, D'silva L, Rebello R, et al. Persistent sputum cellularity and neutrophils may predict bronchiectasis. Can Respir J 2011; 18:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/63\">",
"      Dodd JD, Souza CA, M&uuml;ller NL. Conventional high-resolution CT versus helical high-resolution MDCT in the detection of bronchiectasis. AJR Am J Roentgenol 2006; 187:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/64\">",
"      Kennedy MP, Noone PG, Leigh MW, et al. High-resolution CT of patients with primary ciliary dyskinesia. AJR Am J Roentgenol 2007; 188:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/65\">",
"      Santamaria F, Montella S, Tiddens HA, et al. Structural and functional lung disease in primary ciliary dyskinesia. Chest 2008; 134:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/66\">",
"      Cartier Y, Kavanagh PV, Johkoh T, et al. Bronchiectasis: accuracy of high-resolution CT in the differentiation of specific diseases. AJR Am J Roentgenol 1999; 173:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/67\">",
"      Lynch DA, Newell J, Hale V, et al. Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis. AJR Am J Roentgenol 1999; 173:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/68\">",
"      Sheehan RE, Wells AU, Copley SJ, et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002; 20:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/69\">",
"      Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/70\">",
"      Lee AL, Button BM, Ellis S, et al. Clinical determinants of the 6-Minute Walk Test in bronchiectasis. Respir Med 2009; 103:780.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cscc.unc.edu/bron/ (Accessed on December 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/10/12458/abstract/72\">",
"      LaVange, L, Stewart, MS, Thomashow, B, et al. The Bronchiectasis Research Registry: A resource for collaborative research in non-CF Bronchiectasis. Am J Resp Crit Care Med 2010; 181:A3173.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1444 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12458=[""].join("\n");
var outline_f12_10_12458=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Defective host defenses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Young's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rheumatic and other systemic diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Primary ciliary dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5990869\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Distribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lung function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      BRONCHIECTASIS REGISTRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1444\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1444|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/15/16630\" title=\"diagnostic image 1A\">",
"      Bronchiectasis PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/46/16100\" title=\"diagnostic image 1B\">",
"      Bronchiectasis Lateral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/26/31137\" title=\"diagnostic image 2\">",
"      Bronchiectasis CT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/52/35649\" title=\"diagnostic image 3\">",
"      Tree-in-bud CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/46/31458\" title=\"diagnostic image 4\">",
"      Cystic bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/38/28258\" title=\"diagnostic image 5\">",
"      Bronchiectasis CT II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/38/3682\" title=\"diagnostic image 6A\">",
"      Central bronchiectasis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/43/10930\" title=\"diagnostic image 6B\">",
"      Bronchiectasis CF CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/0/23552\" title=\"diagnostic image 6C\">",
"      Cylindrical bronchiectasis RML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/31/8688\" title=\"diagnostic image 7\">",
"      Traction bronchiectasis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1444|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/11/25776\" title=\"figure 1\">",
"      FBA complicated by pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1444|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/60/20428\" title=\"table 1A\">",
"      Evaluation bronchiectasis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/8/4237\" title=\"table 1B\">",
"      Evaluation bronchiectasis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/8/8331\" title=\"table 1C\">",
"      Evaluation bronchiectasis 3",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35399?source=related_link\">",
"      Airway foreign bodies in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16248?source=related_link\">",
"      Clinical features and diagnosis of Bordetella pertussis infection in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13911?source=related_link\">",
"      Clinical manifestations and diagnosis of Bordetella pertussis infections in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39095?source=related_link\">",
"      Cystic fibrosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=related_link\">",
"      Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/60/13258?source=related_link\">",
"      IgG subclass deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/31/41457?source=related_link\">",
"      Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/25/39314?source=related_link\">",
"      Patient information: Bronchiectasis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=related_link\">",
"      Patient information: Coughing up blood (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9817?source=related_link\">",
"      Primary ciliary dyskinesia (immotile-cilia syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=related_link\">",
"      Pulmonary complications of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30457?source=related_link\">",
"      Treatment and prognosis of common variable immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_10_12459="Clinical progression of transtentorial herniation";
var content_f12_10_12459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical progression of transtentorial herniation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Altered level of consciousness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilation of ipsilateral pupil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cranial nerve III palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ptosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Loss of medial gaze",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decerebrate posturing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemiparesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilation of opposite pupil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alteration of respiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bradycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory arrest",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12459=[""].join("\n");
var outline_f12_10_12459=null;
var title_f12_10_12460="Clinical features OSA";
var content_f12_10_12460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of obstructive sleep apnea (OSA)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Daytime sleepiness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nonrestorative sleep",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Witnessed apneas by bed partner",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Awakening with choking",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nocturnal restlessness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Insomnia with frequent awakenings",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lack of concentration",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cognitive deficits",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Changes in mood",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Morning headaches",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vivid, strange, or threatening dreams",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroesophageal reflux",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Obesity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Large neck circumference",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypercapnia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiovascular disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cerebrovascular disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiac dysrhythmias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Narrow or \"crowded\" airway",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cor pulmonale",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polycythemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Floppy eyelid syndrome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12460=[""].join("\n");
var outline_f12_10_12460=null;
var title_f12_10_12461="Pyogenic granuloma treatments and recurrence rates";
var content_f12_10_12461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatments utilized for pyogenic granuloma and recurrence rates",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        PG",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recurrences (recurrence rate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Surgical management",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        753",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        38 (5.05%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Surgical excision",
"       </td>",
"       <td>",
"        510",
"       </td>",
"       <td>",
"        15 (2.94%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Curettage/shave excision +/- cautery/cautery alone",
"       </td>",
"       <td>",
"        199",
"       </td>",
"       <td>",
"        19 (9.55%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Shave excision + laser photocoagulation",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        2 (7.14%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blunt removal + cauterization with silver nitrate",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        2 (15.38%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Punch excision/biopsy",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0 (0%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Applying a suture around the base",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0 (0%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Non-surgical management",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        409",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        15 (3.67%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryotherapy with liquid nitrogen",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        3 (1.62%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CO",
"        <sub>",
"         2",
"        </sub>",
"        laser ablation",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        5 (4.85%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flashlamp pulsed dye laser",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        3 (4.35%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nd-YAG laser",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0 (0%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1064 nm laser + glycerin sclerotherapy",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0 (0%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sclerotherapy with monoethanolamine oleate",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        0 (0%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sclerotherapy with monoethanolamine oleate",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2 (13.33%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Topical imiquimod 5% cream",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        0 (0%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systemic steroids",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0 (0%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diathermy",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0 (0%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Radiation treatment",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0 (0%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intralesional bleomycin injection",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0 (0%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Observation",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0 (0%)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1162",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         53 (4.56%)",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     From: Lee J, Sinno H, Tahiri Y, Gilardino MS. Treatment options for cutaneous pyogenic granulomas: A review. J Plast Reconstr Aesthet Surg 2011; 64:1216. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12461=[""].join("\n");
var outline_f12_10_12461=null;
var title_f12_10_12462="Differential Dx Chorea";
var content_f12_10_12462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of Chorea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hereditary causes of Chorea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Autosomal dominant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Benign hereditary chorea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dentatorubral pallidoluysian atrophy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Familial paroxysmal dystonic choreoathetosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Familial paroxysmal kinesigenic choreoathetosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Huntington disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Huntington disease-like syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neuroferritinopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pseudohypoparathyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pseudopseudohypoparathyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Autosomal recessive",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Friedreich ataxia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neuronal lipofuscinosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Niemann-Pick disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pantothenate kinase-associated neurodegeneration",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pelizaeus-Merzbacher disease (late onset)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Wilson disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            X-linked recessive",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            &nbsp;Lesch-Nyhan disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Maternal inheritance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mitochondrial cytopathy",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Acquired causes of Chorea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Autoimmune",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">",
"             Beh&ccedil;et",
"            </span>",
"            disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chorea gravidarum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Multiple sclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Periarteritis nodosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sydenham chorea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Amphetamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anticonvulsants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Antiparkinsonian medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Digoxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Glucocorticoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neuroleptics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Opiates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tricyclic antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Toxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Manganese",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mercury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Cerebrovascular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Arteriovenous malformation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            AIDS",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Creutzfeldt-Jakob disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diphtheria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Encephalitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Legionnaire's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lyme disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neurosyphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hepatocerebral degeneration",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hyperthyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypo/hyperglycemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypo/hypernatremia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypocalcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypoparathyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Niacin deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Polycythemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Renal failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thiamine deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Neoplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Basal ganglia involvement",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Paraneoplastic syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Degenerative",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Alzheimer disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pick disease (Frontotemporal lobe dementia)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12462=[""].join("\n");
var outline_f12_10_12462=null;
var title_f12_10_12463="Balanoposthitis";
var content_f12_10_12463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Balanoposthitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 271px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEPANgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyC2usxkHqo4NdF4Km88zKeSrA/hXDJcbIiDxmu28Bsr20sqLiSOQbseh/pXC46M7qUveR6AmQnTJH8vX6Vbt5WBGw4/DrVW3UyoQOT2qa2DrJuGQynkEdD71lY9SCujQlUIVMbHgbh64pybSFYcMT8wHQ/SnsFV0cqDG3K+mPTNP8tUuuPmj6j1//AF+tapWYpO6I2XfKcDp39PetbTX8pQqkEn+Bv89DVGRQs5CHKdVPtVmBud2M4/Oqi0mZP3kWltmcFyMgdR3HtT1h8psEZXpyP0oguvLDEg4NOW8Vn2SEbSMZIrS6IcWVr2BFXKuOeaz7lGgiVT82eQR3rUureMg4cZHOOwrNuFIwc8D9KciYIyLqY+YCp6daEuZGTvip5Y8sMIOf1qKHdGJMKpU9j/npWaRpUtYqXBJbDdR0rIuMuxGMn+daV3I3m4k+U4wM1RfOS4OHAz9ai2pMZW3KBIRyccHn6VT1MRtKTGuFYZ2+h71em+eJ2Ubl7EdR7Gs6Xc7RqVO4ZwfUelQ0zW/UyriPYMkcGsa8UbjjvXRTk+WUfGBx+FY93FnIPPv6UiXruc7dHb1rGvSSDkCulmtjPOIsZbkgZ5bHYe9c/qKDOA2QM4I4zW8Dkqow5VIJqA9aszKwPNVj1rqRwSWooFTxr39utRIM4xV6BCoDAZHXH8xSkwirli2jDHA44BBxRVm3j8uUA/ccZjb1Hp/n0orBvU6EtB9tdxzYDHafevQ/horyyXscYDcoRXlYt26qDx6V6X8FpDFfap5rZPlLwfT/APXTaVmFO/Mj1kIqWwdQfoeo9/5ir1tJ5pMr7WDqEfjkHsT6/XrVCKV5JWRjlCSR7H0/SrFv8rkFMg9R/MVz3PWhD3dTUuER7CMFNsisUcjpnsT6VViV0VWf7yjHP8qe+GiBR2DcKQejAf15pI9zbRjgnkVb1JtyphB85wQE5yM9KmlUwv8Auznsynt7VObXlFXIVxnJ7VCbd1YZBDg49QfalyiTTZLE6pCN5wucZ7ik82PawYgHse1OW3EisMbWx07Go5oSsa/Icj5c9ePSnZlpJkCMSgYEDBwwzSLKDJkZK9x7U37NIicjIJwfUVE6tCcE9euKbbG4pk8kSAbQw9qpvGvnbJWwCeT6imTSZJGD6f4GkIOUeRtwz3/X8aalqZSjZFLVbZ97AN5iR8bvbt+lZZRgdqnr610Gqn7PIUySNn1O0/z/AKVjFTIN0fzADOVPaiS1M1rHUzvIKuByAT1qjdr5bY6AcZ961NYuEXYsJZNwyeMjPsay2bzcA4V8Dg9/oaiaNIttXZTuFWRC7jDHjPY/4Gs6Qh+GGCOPr71rXr+Vp6qvEm/5gfSslLg+ZtkiV42/h6fkfWlpci+lzH1GHYUeIFmHzbRXP6xaGLD8tbygmKT174+o7iuuuUSOZgjGSJgSrdDg9Poc1jXzLJplxBtDKzhiBxhscOB+hrWCOeo2cXJDI5ZVIYgFgM9R3xVDvWjKdrFiOQOMVn/xGuiOxwz3JYvvDtzW1ZxBio9eh9PWsaPqM9K3bFg8Iz99OvuP8/zqJlQLkESI/lYzG2QyHqjeoPp3oq2my5hJxi4GNrjsR6+uRRWLb6G6ITZBTiuw+F8ITUr2MDLNGOvcd6otZjb0/StvwCotvE8QPCyoU5qhU3aSZ6VBGqyFueFGasqpkGV60OjRSSI4HsexB6fpT4VCyKc4B61i13PTg7lqxCo4MobaeMr1X3H0q2rAy+aYlRm7oDtb3x7+lRxhceoBxWjFAdvpng4q12Jnq7kCSO52gDYpyg9M9QKRkcTMWB2yc46H8PcVd8tYiygctyOODUsS/aCEP1Ge59qpdhR022M+VJQVeM7j346+9W1uBDaF3iDYHPFbEVttZVCbsnj2NXNR0xHtZJI4xkrlkx19x6GrcXa4lUjdJowpIYbqBJ4lCEjlTWHdW53sAgJ7A1s6TC5tH2bmjU4H+z7VUvoGWTLdxkGovcprlk4oyZ4tqbZkAK98c4/rWeI1Erx7wqk8N6ZrVnM5ZST0+Xnn8KoXWwtkRhSBgj1HpSbE07GXqqonlpDOXITkddo7g+nNU7GzlR3nj2/uxnBPBHf8KuXEKlmOMZOagvxItiI43yG6H+Yqb9WTyu3Lcw5FjvZmt3YxMoJBI49cnvWBMzqcHgAnH1+tdMkYRhLznHJ7/WsG/jA3jHHXjv70map2dkIskCwFrosZcYAHceo/rWLqF20ybdqqA24EDkH/AOvWpFJDsaO537CvySKMmJh0JHcdiPfNY8hUnDjYe47D8aXkYcrTbMySaTAjDHOcD8etUru3lZcMpD7gOO+e/wCdbbeWJW82MMHXHHGD6iq97FujhxKfNIwre4PpWkUZVrnF6tb+UGeNgwIG4d1P/wCusbo1dFfxPO00kiYZn288YbrXOsMMQeOe9dMdjgnuTREd+/FXLaVlyRyBjIHX6is9TjmpkkwQc4PrSkrhGVjahuyGVg3bOfUUVmbskFSA3UjsaKycEbKR6NZapDcAAkA1u6GV/te0kiIJDjpXmW1kbKEg+1dF4FubqfxRp9sWO3fuZuu0DvWcXdjSsz6AGZDxxkflVyG2JHPTFOktvLlVRgsOoq3GG3AN6fnU9bHpRfYdbW+HAPetExFQuTjjiqsb5cLzuqee4RIzvJwefx9aq6Q1FyZJEHkJB+9n8Ku2sbBnVombB5wOfp9apWEiu2QeehU9xW/pyHly5YHjPfI/hP8AStacebUJvlRZtQJFyxBRvlJxxU9/tiVbWa4EckoKxmToW7Antkd6dAo86RRH5nGWjXguvt/hVK7ml1KWG3tdssEREmZUzx/st244I5xWrWlmYxSlLyJLXT7ex03c7mO453Z5EgJ549agm0lJ4RsYE5zyc1tXEEE5Tysk9GjboKrPpqxRcSusgOApPP0oUNdjOVS/vX1OOu9JxuGMc4+hrEurBlyGHTiuuuyYi+SW+b5iev1rOunDhkx83Ucc/hWUoq5qpM42e0zlMnH8PtWPNbvslUDBTDZ7V2d3AsqMUx7joRWPcWZALRsdw4yOtZuKGpdTlJfliZWG1s8g1hXCgNjPtXWX0AeRt6444x296xbu1AOQoORzUuJd76nLPJKh3Kgz0+tUnt7hQZWQqgQOWI4IPf8ADvW+1qWyqL3+tRajJdQ6S0SlfL5Taw5HPSkl1Jbd7I5SaUDKqcBT0znFUbybMS7gDzuBB6Veu7VorQORhhgY9Qa5+/dtpUVUbmVUpajqMplyGBHfI++O2awsZb3NXJQWfHvxmquOTXVHY86puNwR1pRUqDPDd6e9syjKcj0p3IsRqx6UU3kdqKVh3Oqlj+XPFbnw6gkfxppzQsQ8RZz9OmD+dZEgO3pXX/CSCOTxaPMJVhEdp/HmuKD1OyKu0e7xun3ickHBFWYjl8jOOnPaqBXyU2nk+oqxFNhNrHGOhFC1PQhDS5dUkNuZeV7juKZeM0beZGw3ZzgjIIPUEehHGKZFdBW2MRnqDSTK1xIERScnCqOST2A+tW1dGsItPUn0WSJp3t5od3nLmJEbGMZIVT29M+3NdXY3KG5jKhpo5EAlwuHDL3K+vY4ridOs7y5vJI7JDM0MbT7VOCcccd854x1yK6fwpcTXLR3EpjniaQo0ikCSA5+TcO4ataLewYmMbOSOosU26i0QONw822k6q395QfrWTZwJL4uuJYpJYLgjd5JQqgPRgO2cjOe+a3T59tdLL5XmW6PmRcZKZH309RnqOvJq/fzXUVzaPbwxTWxYrO2TvQHoy+oz1roa2PM9s4t26qxEtiAg+Xa/QMB+hFNurTbAXkZi3YHn8K1FfLFT1HT3FEr7ACQSPanc5PaSucdqVrtBY8BxlSehPpntXP3y74RghWU9xzXVazeoZD5eHiYEY9a5K5nQShmB8s8fQ1lNnfS5mrmc2w5Mi5yMHHBFZjOASGPIOCf61pXjLHkoQQeDWXMoYgLyCMkVgaJJoy7+HIY9hx9P/rViybSrBgMjpn1rdcqoIDhxyOvSsm9jV13Iw+lRsy7dDOtYUe5kVE3ebGwAzgqcZBH0I6d6zfG9qsMUCFjmeJZACMc/4/41bd5LeUMhw6kMpHqO9QeK5fP0uy8v5kjkxg8mLJzt+mT+tXzJxaM7WqRZx+rxuLVUJA9QfXHUVyepRggkjBAxx3NdvryMiorg7tnQ/pXI30WRu25GM1MdHYicbps5S6yrK3bFU15Oa2dYhCWsbKvI4J9fSsZa6o7HnS1ZKgyfpVuF9ox1qqjY71JvwKTAmmjhkyfumioGcYzRQFjrnjNd18IrEyaxLOM/KNgGOv09+a5R4cjgV6T8JrfZY3MuP+WlcFPVndTXvI9DnQrt3dD/ADpsLqTtIPPFTkmWJiTkN61WKoMqW+cVaPThtZkV4rRzDHKjpVmyugrKW3YyM7ThvwPY01nDELkEMO/rUMyiGQKwwcZUinexvF8yszYutffTNasdQtZY3u4yEmUoVE8JHJBHAOQMqckNyCQTVGzvYYdVlu4m2RyTuTFu2sisxKkdmxnHtWVqEkWyMy7lwcq69B9RUBmjzGw2kA8nHI+vt/KpdR33N4YePLdLyPUIvESGBQZnjfG193O054b3U9DjpUFxrOoafrZW7u1+yuhKJvAWVD1Mcnsex5HTuK423u9hVhyO4PNK17by6gsF3CfK2l4sMcA9wP61s6r0ORYSKk9NP62PWItQUW0c32hZBJyuxsMp9Oe1UrnV5trNHceYE5YY/mPT6dK42BY0VGaV0twcB+pX64qSeWYMY1eNsfdkU5B//XWrqtnGsNBMv3OoCWd5A23dzjORmql5NHJACp4PBB9ayJg4XePl7MvUD3FMa4BAjJIyPmB5x7+9RzXNZUktUF+5+zkxjnpkcjNYs9xwGGR3I9PWrF8zRgtDJgjhgD1FYk1w4bee36ipk0twhT6kV/K8c/mwklD98D+dDFJIVcHOeT7UizxtJiQDa3HpVaSQW84jJPlSfdbuD71NkxVL2sNuo1K4YfKf0rOicJOkE+0wO4Vi3QA8c1dmnDJlSO+R6Gsq5w7tjjj8/rS2dznfvKzDW4kvLlomgeKVUfK9RlTzgemSScdBg1wF2ud6pywJPHJxXWak8xt4/JkYyK5kjKn5kdR09wR0P4ViatJ/pFlqMGFZz+82jA3Dvj3H65q21LUhJxRxetuG0xfkxh+D6ev4VzwNdb4n8y30swMI3ieUlOMNGeCPwIPH41x+a6IrQ82W5MGxSl6h3UhJNOwrkjvRUVFOwrnrezI6Zr0z4bFI9Fyq/NuIYevvXnaKemK734fsRpkoBxskP4V5VJ6npUviR3SSLtKjlW5ArPkJ+0EZyOvPWnRzbhtwcg9R2qMqxfevSt46npR7llZGSRTjIPc85+tSzmKW2J5WQcgf4UlnbtP8oNPmspEDA02m0NNJ7mMJEd3t36OuQT/OoYbRpZGjVjvU7XTuMc/y5q2seJNjJ8rHBBGQrdiD1H9c1VImt7lJNh3gbdynkjtn6HofTisJx2bPUpTUtIm1BbxmIIrfMBxiqmpW0nk7S3Kncjehq1p8FxO/mbCXJySOhzWjLC4H7yMsO4PcVpy8y1OWU+SW5jQXbTJHndlRhtprVW4YwYbB9xxmoYraGG4Y7fkP4GpbuNVQCMNu7Y71cU0tWc1WabskNedTGPmHP+eaz5n+cHcQw4ph2B8OSAf51FcERq205PoTRzdyHoV72TfIfMkH1Axn/PeqcgXyT8wyO1FxcK52kYPpVc8q3UH1FF7jd7FG7Ijz3Q1RM7SxtE3J+8jdwamvS2NmM9+KzWZlIYdVPI7ikgWqJDMXG5l2yKMOP5GoZuAD2HTB6U4kNK208n1HSoGPBQ9PWlLUwqQtqhkQiMoaRwIg3zHunv8ASuc1QPBFdWu7csEwdWx0Dcj881rF0W4/eqzKoJO04IPqP8KpatFNbGbzmUB7ZQoxgshORwehGRx2rSOqOXms2mcZ4huFm05YpI282OTdFLn+AjlT9D0rmQme1dZqdqk1hO4fa8ahgh6EZ5x781gQxBsDvXRF6HDUj7xSKH0p8EBlfbW1HZbmHTcf1qWPTnjcyIuPahyI5Spa6VllLZwetFb0EbvBxwRzRWTmzRRO48n0rr/AXyQ3MbcEtke9YDQEdq2NA/dxzEHGCDXBSfvHXD4js1j+YBRzUj7oi25CrD7wNMsLqOSIFgMjv1rScpM2xQG46A9vp2+ldsbWZ2qTVrkFlPCQPnCMDkHNT3Vw0bZUgq3X2NU59MRuV4z0ZTioxYXO3MU+5V4KuOlTrc1ajvc2NHmP2jzZIElCDDADkgeo7itOCPSv7QWSe3lW0cZV052Z7kd8HOfUHpXLiS7swHaIuF/jiOSPqP61Zi1hANrsYi3OHGAa0c7JCVNt3X4HpieG7C5fz7K5jUuoLeXwpPZgM8Z7/pUF/wCErlgHt7pXburjH5H/ABrj7TVgsICN8nsc4rStvGF9aoRHKsyZ4Eg+77VSqQlucsqNaLvGV/Uz9X026sTtvLVoy2QGHIb6GsRpmVNgY5HSu1l8YwalbvBqNr+6YA/J/C3tmsDU5NPuxH9mASVeN4GNw+nrWUoreLN6c52tUiYEk+5TuA5/KqE+7zPmX5cYrZvtPVWAjPzkbjjoffHastw0TESKSuM5xkVNmaXi9imLcSzbDwW7ev0qtcQlHITPFaMoBPyE5HODUDtuB56+tLToTqZEsQmcZhbcOCVqlrOnvbFJG27XHB/xrrdGtjJM7KpZk5OPT/Gue8UO0t28JDIqn5cjj8PatOX3bs53NqpynO+VEY9zyHK8EAdv/rVEZADgHd2JHcU94284KDtJ49jVV4TGWVuJUbG31HqKncqctNTO1MryAcg8j3rH1DULi7VYppGl2KEjL87VznFaOpkcgHkcrnv61lSxiNFmU7gedtEV0MJWtcy7tfkKMONjHGayrGKMsockZ6GtW+Uli245Vf51WtYtqKCowT8rDoK2iraHHPV3LC2iZIWUhwcg1ejuXSRY5hkdnA60RRojhSoPHJq5tQERqo2nkZpNiUWRLKmSzDAU9u9FaMcISPmDcPUUUhpI7woMVb0nYHlRjjcMg9s1EUJWtfTLCMokvmqrDrXDSV5HTTTciSNkt4o2Dg54I7N7j0IrX0m8hebZIc7h8jg4Ib0qCLTIJnYuyDb8x29x647ipn0a353AbDzuRuD711Ja3R3xcWuVlpLv94x8zac4J960rS6jYbZCFP8AeX+dYn9h7cvFcS/NyQTuz706DS7wEGObcvutOKaLcYSW519t9iliKyFAwP314P5VZbw8t4qiF7WaJztIZsYPoRXMRRXML4kUEEc/408TTK4CxsrDupzke1a8y2aMHTd7xZrTeA54tzJDPDjg+U24fXFZd14evrZyocE+kq7T+fQ1di8SX1pjNzcLjgFiTj860h48lZ1W6gt5ABhgwxn6UuWn6CcsQlfc4yW31C1YmSzm2g4bb82KjjukSRi+9PXcpGK9Bg8SaPMS/kyQhhtkiPIHuv8AhVK5/sW5tWmt7gRzR/fhk/jU91zUygt4sIV53alE5C4vvNiRo3BZOmDVcXayhSxORxkdR7//AFq3brSNPlT5dgJ/Dj1BHWsibREgmMfmOoJyJEYMCp71n7yZoqkGrWKvlysHLLl4hkqOuPUetZs8i/eVuDz9a1L3SdQjjfyblZAvQjjjtXPXVpepGzeSzof4ozmnOxNN33ZMt3PbOZLaQxsRglT1/CqU00joyvI0gbnDjI/+tRDJIiHz4nAx121FO6OQ6soI+9Qn2Ina+pnyRK8bZ4I/SoEvFhMwnRGJTBBHUVbmI83AGCTVO5ti5BG36j+VJNrYhpNWZRtLa0vryJrk7IwSZSO49a5RkQXMzQsWg3kIf7y54NdabZQjLuK8ENkYyKxNYs5bJVTZ8r/MGHIOO4P06itE7q5zy0bRhXkCG8fyckMgOP58VnWcbMSq8qT3rrJII49NedplSZwGjjZOcj0PuP5Vy/nNAzDyjtJzvFaWOdvQ1IJVjKK0ZzjHNTo++E7RtYHjPaoYArgFpAQcE+1av2GB41cSYA9D1qWNSuNjluIrZ1xuRRk47UU+PajA2u6QH7y0UguemxW7SsQi5NW4NMfeGkZtg6hG5FV1LxtujbY3rThrv2a5MN9byRzYzkLkMPUEdRXLSUd2ehho3em5aexUswt76ROOCRkUW66raNhJYpUzwehq/YajZXabVBV/dcVNcWGxcxMULc4U5B/Ct1BPVHa5yi7S/EfHJcGDcwEbDnA6H39quWl1MgwWIDc5zkVlzC9igDACRRxnGPwqGLVWhHl3Fu8ZBypxkZqmrMpO6sdGdVuofkAV07Bh90+1T22sxTxgXWlwSOhwWjYoSvv/AI1zJ1qB2w7YwO/FWba4guRvhkCyL3BxSW+jE6aS95HeWGm6JrkWLC7lsronBgmYOD9M9fwNSf8ACCXJYq91ZsAcBSp5H9K4iGby2SYIjspyVb7rexruNK8cWD26QXtlJtQhSSQ5VfXnlgD+OK6Icr3OGtTqw1pO6Mm68B3gd1jtcBs4KS8ceh7fjWHqHhTVbOOOSSOdewJUNg+nHSvT7vV5NUtJovDwE2xclyccjnaAec479O1c9qPiG9tbX7DOqZkXcspzuHrleuQe5/CnKjFrUyp162x51It3GvytuCnO05BFNWedInx16gZra1G+u5j5syCSQDBcLy3ufWsWa/jaGR2SPHRl6fj7GsJR5dDvg3JFWHXJImKTiRAOMsDjFQSatEGbY4A74NWbW9gdSCCR9cile3tJWL+TFheoK/pWajdbmzik9YkVnqQV9uVZG7HtVu7jjSEb4YvNJzgKDx6EelUrnTrQyLJbxLHjkFGOD7EUwRMl4ks80rxLxsPVfoe9XFOOjOWdKM3dIydQ022LM1pJLCevlsNyj1AzzisaX7RArHZ5kajJeLnA9x1rsNVit5rsTWskiQMuGWRclT6ZHUe9ZcVv5QkkdkJQkLjkOD1H/wBak4NSMuS8bnPx3EdynykZbjHoaju2t1sZorkFsDdFgfcYe1XrnTFaSN3VXjmzskVsYPpnsfrXOaxFeWDH7SrzWoP+sx8yDtuH9elNXjqc84X0K+okS2kJ2jYIiFA4298Vz2TGoJ5j3YYY9elb0TrPbuI2DxqRnB6qado+irqNxeWLziJmiZomYZG9eRn69KpS5mrGEoqMWmYsEcc8gUptUcVZ8iRJvKMuI8cEmsuKRnOMMjqcMPQ960IYjj59zDPB9KbM0aNpBmQpFPtbZkt70VVE7QBmhAz/ABCihNLcGm+p7HLHk8dahuZLvT4186FpLXOVONwTPpVxhk1Ct9c2TkSQtJbnhivzDHqRXHSaT3O2ja+pjP4rtLeTY+N3QcU8+Kprhl8m3uHUdlXrXRRWel6kCBFFubnBXrU/9hiEbrD5SOcDv+FdEYSfU9J1IRtaOvmZMXiV9gzFcxtjB3IeR71fsfEsODHOiSRt/DIuCPp6VLJME2rdxiOXpn+E0+KC0ueJFQN/tDIP+FP3k7Jj92cbuJZgn0efBu7SOeJuMqdrJ/TNW4ND8M31xF5F9JYscqyuvzDPQgjhh655FUG0S03KLfYN3BG7AH41NL4Yu7WcxyW1wT1UKdwYHoVI6itVfqkzJxVvdk0zSl8C6l5cp0bVLe9EeSUVw/Q9MdQa52+stdsHzc6bOAON8YyDWnYifTbwXFnLNBPG2MOOh7g10I8T62Z/NiuIZVIAMUijB+vv71XJCXkZ89em+kl56HG6T4lltC6LcNbyEYIbKmukTxVb6pbww+I4GuY0Py3UB2zIPr3HtUl/rGi3sEn9saJAL9WyVUbUkz1z6cdxXLXXh7Tbiec+HtXl05W+ZbS8+ZD64btR70VZO4Xp1HecXHz/AOCjduJbKwvgmnaz9ptmGVZozlf9lh6/SodQsYtVty6wRzSAfOYOCR6kVwlxba5p7HEcd7H/AHoGyfyp+neKVt7lTK0ltcDswKEGsvbW92aOj6qmualK7Nyfw1DvWHdNayH7pDfK341Sl0Wa3Mga6mBAx9Pw7inR69JcSIVkLsOMHnitp7tpbVHZQz4+pFCUZaoalVp2Umc/BZ6gIyIZUkcDOwDn8PUVUu31FThrc5A5Cn+lav2zy5xIAA6kEemRWpqmpWmrXCzGAWjsoVwp3KT/AHh6fSptFrc0bnGV7XRxf9oyxwbpo5Fx6r2pj6lA0KkNgsNrA8fQity4tgJGinYBgTgjuKpFFjjdcJMB0yBkikkwl72qRlNcL5XDDaSGIHTPrVK5lAZ4x0YZXPbPVfpWs1vpzgE2oRh/EmVP6cVz+pWRkmdrW6V8DhZB2+optNLQwklfVWMTUrZY2aex2RSE/OnRGb19iag0a9lFzyCpJP3uoPoah1GWe1f/AEmEoJMhTnKOfY+vt1qpZXuZC23OzG72HvU3adzhrUktYjNYZtPvEliTck3X2bvUS3s2d7rtQ8Vuaxppu7ESRkhV+cY7+ornUiTZtLEjqCTWi1RwzTi9DVW7t4sq7jewzRWU6IZUPl9BRVcvYj1PogJirlmlqzGO4YDcMq684+oqPaKxWiaW7khjJ87Pyn+7XFStc76MVJ6m5e6WrNyQpH3ZYzjcPrUFgL+2l8u4ufPj/hlK4bHv2J9+KSG/msWW21VNjD+Mcqf8DWzbmGYgRspz+VdSeuh6cZe5Z7DJnW4QxXyDJGAxHDD1rO1Dw5eWkK3OmXSzxtz5TkkqfQHrj61sSWxUlVcY67G5FOjuJIIyFQbe+Dn8qvli/iM05xd6ZziahJFFi+glglHG4jMbf8C7fjV6z1sxbRHdyIEGAu8/L9PSrS3ByxY/e4II4PsRVeTTrKYhordFYdhRyvozX2nScTYtvFjGZmuDDdl1CMJVBDAdPxHrWtpV7o92SLu2lgkYfft2yD9VPesFNItvsjE2alsdjg/UHtVK2sp4m3QO4x/C3P61aU1vqZ2pTTtodpceG7PVI3jtLq3uZsblhceW7L/RhXE6t4VvNPcRslxbs3KbhuBH8jWxHDfz2bzhBKkXLIrfvFHqB3H0praxqyW/2bFxJEv3UkXIHuDTmo77EQUk7KSf9f10OXhs7y3RnkkXzFOdvIJHqPWpPKh1JLlb1FkBTlZIty5Hr3B9CK6Wzhm1COVpLWR9oyWQDK/8BqCOJonDAlGPt1pLTQpq9+5i6F8N21CSUo91pTogZGYZBPuD296oX2g+INJuvLa9tZk6q45DD1BHautmvrmJEVJ51SLom88D29qqrMJXCqVO48huDS5aeyHF17uUndHIaot5akP/AGdKLgcsUcPE/uO4rPj1Jw2LiKW3DdyuVFekXlokdrMJ0dZAMxuOVYd1Ydj7islbD7TFscpHkcHqAfeplRu9y4Yj3dUcPd6zCkgV5w5XgEH/ADxUiaraz2DyCRFePt3Nbk2hwxzSJPHBvHPTKt+PasnUtB026UeZCEZeQ0Z2kfiKjkkmaSqRaWhzt7d3k8TvZyRgdCDWKbnU7INNJa/aIRw7RHOAfUdfxrrINC08HdG0nmL2LHn6itS6ms47RjHDslZCsgHR/wDaHo3r2oVO+rZz1Kslolc89h1CC8spEbEkUgwyMMg/hXP2tnfM08cMDBHzGsrdx2zW3ZeHm1G9nltrkwhmJPGVz649K7PRtLm0+FUkIkUDDBuQfp6irhTb3OOtJPbcp6ZaGGxijmcSHbgkD7p96811xW03Vbqzm42tuQjoVPSvXb6EKpMKmMdhnO0+n0rz/wCIFkZ7WC9Me2WE+VIe+D0z/jVOCi9Dkqxbjc5hbs4Hy8Dg80VS56LyKKWxy3PqEuRyKs6THGb1rgkK4UDP8jVJ8ioyWDKUcqR3FcNJ8srnbF66m3qVolzn7Suc9xWD/ZWo2UhktLlXjHKrIO3pkVYsdfKSm11GGSFgcI7L8kg9j0rUa6gdAEkUK3TmuqykehCUoR93YqWWt4kjTUImhfOGB6N9DXR2L2d5O1uZ44g4/dyN0J9Ce31rnLgwShopgrDrg1lTxzWLeZZN5sHeNjyPoaL8vmbK0t9GegweF726LfZfs8u0/Mm/n6j1FQy6bdWkqxz27wkkLuxlfzrlNG8SkSjypHiuBwVJwwrtNO8WzTCT7fPMrgDDoAeR3IPWtoOD2MqntYvXVC3ljfWzhDHIwxjKKWUj6iq9ppN9LdeWsYRuvzvtBB9+9dLpPxCsfI8vULdoZAMb4hlW98dq5fxZrFnf3cc+kTTxvyGXPyfUDtVSate5nRdVy5JRt59DcXwxcQSFLnULW2LcpvOQ3rzmoX0a7jBj/tSxKr0USZ49q5kaRc3YVmv1AK5QsSwB9PauX1FLq1kdY7tSynlWH8jUSk1rZm1OCm7c6v6HpN3oF9b2rXtpf21wifM3lyYdB3//AFVzgebc3mncp6Z7V5++s6lDL8qpcD0UkGp5vE9xaRxtfWtzbLJyrOhKt7g1lKq91c6Y0GtHJN/cdjezPJFtJzj1HI/GqshR0AYkMOg9PxrmYPF1o+T9pTPcHjFPPieycMzXUSkdj3qOe5sqTgjsRNPd2K75cqnClu/tmoriEWtqswlQluCFPT8K4lvFLEMLeOeZSc/IpwarS6pq984W3snjB7ucVoqjfRtmUqSju0kdfLdpJgvtPHXNc3rGr29ux3SquOlQf2ZfTRAy3Dxy5+ZVOQRWtD4QsEtzcKn2mPjcXJ3xt2J9RV+yqSMHiKUPM5GPVZZSxs7aRmbuw+U/jU39hazqiqftEIjYbzCuQ59Rz3Fdf9hhhVNi49QBVq2TCqQMMp4I4OauNBL4mYVMRKWsVYw9K0gacETy8heQrfqM+9X7lIxMVi3JG2Cu7naann6OR1z0quJl2lZACvX6e9aXtoYKL3ZQ1N1VSNpC/wASZzj6e1cfrTK0M9tMN6SqU5/8dNdDrD7VKqQcDdwa43WH320mCQ4IIrGUtSpU/dODOEYg8EcHiipL5GS4fd1PPFFZczPN5EfTLMDTAPm3AcDk1ESaazvsOw4bHFcsbKSbNbmkixznY4V0cdO1ZNzoWwuba7mgRjnaDlQfoelUdK1gLeeVNxk7SD1U1vPeo6AEncD+des1GS1NYuUH7rMgeHr24dfN1acgdMKAauWnhvY5WXUbuVO/zdK0YrpCFUcZ4zU6SYkB5pwpU+xrKtVta5j3Xg2wkZXWSbeOVkD4ZfxqrfaL4itov9FvVuIh93zB8wH1FdIszrIw6MDg5H86sJeGM4wMHqPWqdGDXYlVqsWmnc4mx0jxhdpO1vHYyomCVMhDY9R64qWPQvFhnMQSzRiMxsZsrJ9D2Psa7nTtQtowVkjPmdM9M1IbkRTLtP7rOVJP6Gs/qlPuavHYhO1l9xX8NeC/EeqxYudatrRQPl8lCxb1Bz0xWla/Ci1lMwv9RvZbhDglW+VvwrTsdX2TKYH2bsZHXBroY/E1vZxCPVcBj9yUfxfj61s6MUtNTgnicQ5aO1+xy+jfDyCOzeSxkAniY4LD7xH8qludFe/Rra8SNsjeqbPl3jrx2NdLpHiO2eGUi3crIxIYdCfelS8T7VFMSoRyd3qp96tR3VtDJzne8tzgdT8GWy2RdbOHzF6qUGfwNYh0GySA+ZaxZXkYQZFegeI9dt2upIzgqAMr2auP1jV7RrgmzR4Y2XBV23YPfB9PrUuMVrY6qTqTVjMuLWPTpVa1AHHKFMFfYioI9jyFsAZ5wO3tU00nmw48xmZRgfT0qtEpLjJ4zUXs9DrjBW13J3iDsNyFQR8rdiRTYLkoSh4GCp9/Y1PJJKLaRY2LQjBYZyAfWs2W7MUWCFIznpyP/rUNijFPQs+bGMoQAxOQaqeYPNZdxUdsdPxqlJfbxkD3HNUri4JJdDwvJHpWMpmihqaVxMrRuGOCOd1Y95cgIFUgHGM+tNmnLIWHU/kaypvMwCR8vT6Gs5TuWodQvpiYsMSm4HnrXP3kSyxnJ2kYOe1bFyT5W0c8dKyrxcxMoGcis2TPVHH60mZ9+MYO0+1FTeIeLkjOQUXBxzx/WiplueZPSR78fpTGHBx6VMVBqNwcVzWFcxNQ05Li5E8ZCy9GU8B/8DSO19bROwia5twMlo+XT/eXrx6itKRDmliYowIJDA5BBwR9D2renV5dGO8lqjOs9UWRVf7ynglex961/tjRsrIx2kZyO1MMNlLL5k4SKZzgsg2hz/tL0z7inS2JjIaLbKvp0OPoP5j8q7Iydrj+sxbs1Zk6aoxmP2jbKjDhhxT3uvMIKc9sHrWatq/ls8OHAOSpHzLQrKkW8uOO47fX/GqU2axqweqNASlZAx79QakmuAw+VmAHY1lmd3ALkMB36frTJ7ggfJlSOtUpGqmmaljqzx3PzZCj0rUvNYW4iKMx2HkA8jNcWtxvBTPPapYZyYirlty9D1zTVTSw5wi3zHa6fqskSBYjweq9jVjUtRmktWk2bJQc7g38xXEx6kI4sbsN/Op7nWjNaqkr5UfnTU9CHT1TSJk1BpZW3OSxP8RpCwuiwL7SnOSKyXuoQNyt8wpGu0RlkhlbLDkVnfudF+2hsW8rcfN1HXrUMl6MvkEsPTrVK3v1J+ZkUHjd71mXN6POIVs89R0pOWhUE29TfgmEyuwkK8VSkmJVgxyQfSqqXUaDbGwlLD5gwxRePyg2kHb0zU3BuzLtpc21ukj3CsSUwqkZ5rOhVpV3dAO3SoLhyyKFzgcZpyymOBUkc4zkCob6E8rWq6hKcRnDZUHpnn/9VVZyvkEqTlexqSVlZ8nABqOYgx45z7VF+pd9CgrmVx0OeMelUdSHl3Hl56jIJq/EACeAwqhq0ivPGQDu+63FSTJ6nKeJAhl3JnAIU+v0oo10BVkBOeRn35ootc8+rpI+gQ2aMZpgHpTh1rmM7kckfHSoTHVpqjIpDuUpEzkEcVftr0MojuAobPDngH6+h96hkUHNQulXCo4O6FOCmtTRlieG6XLN83KMeCR7MOM+x/Wq2o2p3+aEKs3cD5X/APr0y2uZIE8tgZID1jJ6fT0rUtJBOrGNkdMYJbgf7si/yYV206kam25ySjKm7nPbQoI6DpnHA+oqGRScjBjPoDkVt6naLG6t5ckeeoBzj3B7isphJAQJCHhJ+VwOlWawqPdGNLHIhJ4JXqy9quad82TMWGfTpTNXRpDFJE4Ug4Z19PcVUDz2LoEbKv8AwnkfgaSdmdam5InvLd4m5cHJyOarHoVIIb0BqxGzXL/8e5VweSOhFVr2CVGzGo98Gm+6No1HsyqrMA5GcZ6GmQyhnwzECnm4KgxFNjHrkZzUKS7WCyrgE43kVDOmMmX28sL8nJ7/AEqJ1XOV2kHriomZ4myeF7MOlTSk7VbYB2JB60MLvoODyFkTggdMClml/fKQ7E4wc9qgDLsOeG61CzEHcxOfWk3YtLqy3GWJILDHpRLIm4jBJHSmwPnnG6l375PlH1FSS5aiAgkbvvnqDU0iKBkjA9KRVAkBPpQxBU5ORn1pGUpalR1VFkKkEHnB61g3MmLhGkUEBuh7itm8fA479vWsHUmY7cnocZpNCcrnO+Jpk83ZEW2u3AbqPY0Vm6pIJ9SG1shB+tFDOGpL3j6VOUYhhgilzmt7WtKGS6YDCufIKkhuo61jODi7Myp1FJXHE0w0ufWgkVFixnekIpWGMUZ9KVi0MZBjNQjfFKJImKOO4qZmqIuM0K6d0O1zVsr37SoiwEk7xZwH/wBpD2b26Gorq1ikYqwYO3dOj+5X+99Ky34wRkEdCD0q9BfRzoYbxck9JB1z6muynXU/dluck6Lg+aJk3lobY5P3DnB7H/A/WqU0f+jgBiozlT1FdFLKSfKmILHjcRkOPX2NYN/C9u8hjUBd3zIT8pPp7H0I/GtWjSnUvoVXvJYdmXx8uM4yG/wrHuLtPNLSTt5h6he9al1hFSSME2x+8D95D/Wsy8so4ZlYnKN90ik2zrptEHnqoO4MwPQnqPpVizimvEk2lm2+vesi5LRSkbm2jse30qWCZyPkJz7HFSnrY6NbaF8SmBgCMqOqsMinXT71DRFBHjPy54qlJcMcF8l+nXINSWN2qT5O7Yw2kDvQXeyuSrIHO5gcevWmXEg3Y/hPpUUxt/IOzzFkzwexHoRVKSccc9Ooqdik76mjHcGM5U/Ue1SxXqxlt2cdj6VkM5xlWqu8jEZz9aLi3Z0I1CEn7x9+KT+0I/Kc8Belc+C2wsDx3FSW5iYEzE7R2HcU1qZTsXftazHeoIjTr9a5rX7/AMlW2sC7nI9qvXlwhkZYDshx0x1rj9WmMkzHqc0WMZzsivb53Su/UmihR5Vv+GaKlq7OO5//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD, MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_10_12463=[""].join("\n");
var outline_f12_10_12463=null;
